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The Myt1l gene, which encodes a neuron-specific transcription factor, is highly 
expressed in the developing brain, suggesting a crucial role in the processes of 
neurodevelopment. Although the expression of this gene decreases after birth, it 
continues to have a good level of expression throughout adulthood in localized 
areas. Nevertheless, the role of this gene in neural development and resultant 
behaviours has not been firmly established yet. In an effort to elucidate its function, 
lentiviral vectors containing synthetic microRNA-adapted short hairpin (shRNAmir) 
targeting Myt1l were produced to significantly decrease its expression. The 
knockdown efficiency of these vectors was corroborated in-vitro in the human 
neural stem cell line (SPC04) and the mouse cell line Neuro-2A. The effects of 
downregulating MYT1L at gene expression level during differentiation of SPC04 
were assessed at two time points: pre-differentiation and day 7 differentiation. The 
results from this experiment identified five genes being co-expressed with MYT1L 
during stem cell differentiation: BCL11B, MYT1, SYN1, SNAP25 and JPH3. Further 
in-silico analysis localized a MYT1L binding site in the promoter region of each one 
of those genes, suggesting that they might be direct targets of MYT1L. In order to 
expand our understanding of the possible behavioural effects of this gene, an in-
vivo study was also performed in which adult mice received microinjections of 
lentiviruses expressing Myt1l shRNAmir in the dorsal hippocampus. These mice 
manifested a very subtle and transient increase in anxiety-like behaviour, which 
normalised with time. Even though the dorsal hippocampus has been only weakly 
linked to anxiety, our results seem to support this association when the expression 
of Myt1l is reduced. The findings of this thesis have laid the foundations of 
understanding the function of MYT1L pathway and the impact it has on behaviour.  
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Explaining the structure and function of the brain represents one of the greatest 
challenges to science; even more convoluted is determining the role that the 
genomic mechanisms behind this powerful organ play. The brain, considered 
one of the most complex systems in the body, is composed of 100 billion nerve 
cells that are precisely interconnected through trillions of synapses, giving rise 
to highly specialized structures which shape the characteristics of our species 
(Colón-Ramos and Shen 2008, Johnson, Kawasawa et al. 2009). The proper 
development of the mammalian brain is essential to creating a well-integrated 
and functional system capable of cognitive functions. Therefore, the 
programmes that regulate its development are extremely complex and must be 
tightly controlled to guarantee a functional outcome; these processes are largely 
driven by genetic factors (Stiles 2008). Failure to adequately execute these 
programmes can lead to a wide variety of phenotypes such as brain 
malformation, body growth deficiency and tumour susceptibility among others 
that can, in extreme cases, be fatal (Latchman 1996, Semenza 1998).  
 
In recent years, scientific advances have enhanced our understanding of the 
mechanisms relating to brain development. Remarkable milestones have been 
the sequencing, in their totality, of the mouse and human genome in the early 
2000s (Venter, Adams et al. 2001, Mouse-Genome-Sequencing-Consortium 
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2002). It was widely expected that knowing the full nucleotide sequence would 
help with the task of identifying the relationship between genes and 
environment, and the role these two play in disease (Venter, Adams et al. 
2001); however, these goals are far from being completed but it is certain that 
knowledge in the field is building every day.  
 
1.2 How the brain develops 
 
1.2.1 Prenatal brain development 
 
Neurons begin to differentiate and consequently form networks during the early 
stages of life in embryogenesis but the process will continue throughout the life 
of an individual. The differentiation of all the embryonic cells is conducted by a 
series of well-orchestrated signalling cascades (Stiles and Jernigan 2010). 
Specifically, the event that marks the emergence of the brain is the derivation of 
the ectoderm during gastrulation (Tam and Beddington 1987). During this 
period of development, the blastula reorganizes itself to form three layers: the 
endoderm, the mesoderm and the ectoderm (Lumsden and Chris 2003). Each 
one of these layers contains specific progenitor cells capable of producing the 
different structures of the embryo. For instance, the ectoderm will differentiate 
into different cell populations such as neural progenitor cells, progenitor cells for 
the neural crest, and the epidermal ectoderm (Tam and Beddington 1987).  
 
A key aspect not only involved in deciding which cells will become part of the 
Chapter 1 
18 
future nervous system, but also important in defining the location of organs in 
the embryo is patterning. The establishment of the rostral-caudal axis through 
signalling molecules is a crucial step for this regional patterning (Yamaguchi 
2001). In addition, further cues, varying in time and location, influence the 
release of signalling molecules to assist in delimitating this axis and guide cell 
differentiation (Stiles 2008). Special signalling tissues like the organizer node 
are also involved in patterning (Gritsman, Talbot et al. 2000, Mareschal, 
Johnson et al. 2007, Stiles and Jernigan 2010). In addition, the products of the 
genes expressed in this site help to establish the dorsal ventral axis (Anderson, 
Lawrence et al. 2002), as well as the asymmetry seen in the left and right axis. 
This third spatial patterning is important for organogenesis (Ohuchi, Kimura et 
al. 2000).  
 
This process in which the foundations of the central nervous systems are 
properly established is called neurulation, which culminates in the formation of 
the neural tube. The development of the neural tube begins when a specialized 
dorsal region of the ectoderm enlarges and its edges are brought together to 
form the neural tube. It is largely dependent on the presence of morphogenes 
(Copp, Greene et al. 2003, Mareschal, Johnson et al. 2007, Brodal 2010), which 
code for diffusible proteins whose effects during development vary according to 
their concentration (Brodal 2010).  
 
After its closure, the morphology of the neural tube evolves rapidly. The rostral 
part of the tube forms the primary vesicles which will generate the embryonic 
precursor of the forebrain (proencephalon), mid brain structures 
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(mesencephalon), and the hind brain (rhomboencephalon) and spinal cord 
(posterior neural tube) (Gilbert 2010). The proencephalon and the 
rhomboencephalon will further divide as shown in Figure 1.1.  
 
 
Figure 1.1 This figure illustrates how the neural tube develops into different parts of the 
central nervous system.  
The rostral part of the neural tube forms 3 vesicles, which through development are subdivided 
into 5 secondary vesicles. On the right side of the figure, there is a list of the mature derivatives 
of those vesicles and their functions. The image was taken from Gilbert (Gilbert 2010). 
 
All the pouches shown in Figure 1.1 are organized along the rostral-caudal axis 
of the embryo and will enlarge and bend to further accommodate the developing 
structures (Gilbert 2010). The cells that will develop into neural progenitor cells 
are not selected randomly, but rather by genetic signalling emanating from the 
organizer node. This node is responsible for guiding ectodermal cells into 
becoming neural progenitor cells (Stiles 2008). For example, one of the most 
important groups of genes involved in patterning and inducting neural 
phenotypes is composed of antagonists of bone morphogenic protein 4 (BMP4) 
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(Wilson, Lagna et al. 1997). Their importance was demonstrated when knockout 
mice lacking noggin and chordin, both BMP4 antagonists, were seen to have a 
reduced neural plate. As a consequence, the brain was smaller and more 
importantly, the forebrain was absent (Anderson, Lawrence et al. 2002). Hence, 
the importance of establishing a dorso-ventral gradient of BMP4 is necessary to 
aid the development of the brain and other organs (Lumsden and Chris 2003). 
Other morphogens like Wingless (Wnt), Sonic Hedgehog (Shh), epidermal 
growth factor (EGF), and fibroblast growth factor (FGF), which establish their 
effects in a concentration-dependent manner, are also required for brain 
patterning and help cells elicit their final lineage (Stiles 2011). 
 
1.2.1.1 The creation of a circuit: neurogenesis and cell differentiation and 
synapse formation 
 
When neurulation is complete, the gross morphology of the central nervous 
system has been established. As illustrated in Figure 1.2, further stages are 
dedicated to the proliferation, migration and differentiation of neurons, as well 
as axonal and dendritic outgrowth leading to synaptogenesis and the creation of 
neural networks and circuits (Paczkowski and Chun 2009). A neural network is 
simply defined as interconnected neurons that activate a linear pathway. In 
contrast, a circuit is a cluster of interconnected neurons that receives, modifies 
and transmits information through electrochemical signals to other circuits with 





Figure 1.2 Timeline of the major events occurring during brain development.  
This figure shows the major events involved in brain development across time. The image was 
taken from Tau et al. (Tau and Peterson 2009). 
 
After the neural tube has formed, an increase in neurogenesis is observed 
(Figure 1.2). The lumen of the neural tube encloses an area of neural stem cells 
which expands in number before differentiating into neurons and glial cells that 
eventually migrate to other regions of the brain (Farkas and Huttner 2008). This 
process of expanding the neural stem cell pool follows both symmetrical and 
asymmetrical division: vertical cleavage of the neural stem cells increases 
division in a symmetrical manner, meaning daughter cells are the same as the 
parent cell; on the other hand, horizontal cleavage results in asymmetrical 
division, meaning each parent cell gives rise to one neural stem cell and one 
neural progenitor cell. These cells then differentiate into a neuron or a glial cell, 
with the former continuing to divide in the proliferative zone while the latter 
migrates into its final location. The proportion of cells undergoing symmetrical 
and asymmetrical division changes with time, increasing drastically when 
cortical neurogenesis begins (Chenn and McConnell 1995).  
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The cortex is formed from neurons generated in the ventricular zone (Meyer, 
Schaaps et al. 2000). These neurons require radial and tangential migration to 
reach their final location (Meyer, Schaaps et al. 2000). Cell migration in this 
case is performed in an “inside-out” fashion (from layer 6 to layer 1), meaning 
that the newly formed neurons populate the deeper layers of the cortex, while 
those formed just after migrate to the more external layers (Francis, Koulakoff et 
al. 1999). Disturbances in the genes required to regulate these complex 
processes of cell differentiation, neuron migration, and connectivity, can lead to 
cortical malformations resulting in disorders such as mental retardation and 
epilepsy (Francis, Koulakoff et al. 1999, Meyer, Schaaps et al. 2000). 
 
Continuing with the development of the cortex, transplantation experiments 
have shown the importance of time-controlled expression of environmental cues 
when establishing the six morphological and functional distinctive layers of the 
cortex (Fukuchi-Shimogori and Grove 2001). For example, when cortex 
progenitor cells were transplanted from a younger donor, which were building 
cortex layer 4, into an older donor, whose progenitor cells were already building 
layers 2 and 3, the newly added cells followed the older cells’ differentiation and 
built the appropriate layers (layers 2 and 3). This demonstrated that cells in 
layer 4 are still multipotent. To the contrary, when progenitor cells belonging to 
an older donor (building layer 4) were transplanted into a much younger donor 
(layer 6), the cells were unable to acquire the characteristics of layer 6 and they 
migrated to layer 4. These results were interpreted as evidence that the 
environmental cues change along development and their presence is 
determinant of the progression towards an irreversible cell lineage (Desai and 
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McConnell 2000). However, recent studies have refuted the idea of permanent 
cell commitment after skin cells were able to be converted into functional 
neurons using transcription factors involved in brain development (Vierbuchen, 
Ostermeier et al. 2010). 
 
Further research on the impact of migration and time-specific environmental 
cues have shown that once the cells have reached their final destination, cell to 
cell recognition and adhesive interactions among neurons, glia and the 
surrounding tissue possibly trigger additional signalling cues for neuron 
differentiation (Ghashghaei, Lai et al. 2007). This interaction of proximal neural 
cells is important for the establishment of neural networks and circuits 
(Dermietzel and Spray 1993). These circuits are seen as the primary mediators 
of the functional capacities of the brain (Tau and Peterson 2009). 
 
The establishment of neural networks and circuits is tightly coupled to neuron 
differentiation and the development of special junctions called synapses (Li and 
Sheng 2003, Tau and Peterson 2009). Synapses between neurons occur 
through electrochemical signalling and their formation requires the neurites 
(axons and dendrites) of the neuron to elongate and come into proximity (Tau 
and Peterson 2009). For instance, the process of guiding axons towards their 
target dendrites depends on cell-related cues, chemical gradients and some 
extracellular signals (Palka, Whitlock et al. 1992). Axons travelling long distance 
depend on intermediate targets consisting of guidepost cells, which can be 
neurons, immature neurons (Sanes and Yamagata 1999) or glial cells (Pfrieger 
2010). The chemical gradient provides additional guidance, just like in brain 
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patterning, by attracting or repelling the axon within a considerable distance 
(Chédotal and Richards 2010).  
 
While a neuron can only have one axon, it can possess more than one dendrite. 
The dendrites emanate from the neuron and ramify in the proximity during 
development (Hof, Trapp et al. 2003). Since these ramifications vary in size and 
can define the properties of a neuron, the development of dendritic branching 
has to be well regulated at the molecular level and guided by intrinsic 
mechanisms (Perycz, Urbanska et al. 2011). It has been hypothesized that 
cytoskeleton dynamics and synthesis of proteins within the dendrites contribute 
to correct spine formation and neuronal connection (Crino, Khodakhah et al. 
1998). 
 
Shortly after the neuron has extended its neurites, genes coding for proteins 
involved in formation, accumulation and trafficking of synaptic vesicles begin to 
be expressed. These synaptic vesicles contain neurotransmitters that are cell-
specific, determining the phenotype and function of a neuron. The specificity of 
neurotransmitters is largely regulated by transcription factors (Goridis and 
Brunet 1999). For example, transcription factors Forkhead box A1 (FOXA1) 
and A2 (FOXA2) were found to be necessary to regulate and maintain the 





1.2.1.2 Morphological changes and cell pruning 
 
After all the effort and resource spent on the generation of neurons and their 
synapses during the early prenatal stages, it is surprising that the latter stages 
of central nervous system development involve the death of at least half of the 
cells and connections created in the process (Mareschal, Johnson et al. 2007, 
Stiles, Reilly et al. 2012). This programmed cell death or apoptosis is not a 
fortuitous event, but a well-regulated process controlled by several intrinsic and 
extrinsic factors (Mareschal, Johnson et al. 2007). Even though the purpose of 
apoptosis during differentiation is not yet fully understood, there are some 
hypotheses as to why it may occur. After an extensive literature review, 
Oppenheim (Oppenheim 1991) suggested that different functions for apoptosis 
may depend on the embryonic stage in which they took place. In the early 
embryonic stages, it could be useful to eliminate defective cells. Later on, other 
cells that were created to perform a transient task may die after having fulfilled 
it, such as that of guiding axonal projections to their final destination. Right 
before birth, the massive pruning of cells might be the answer to adjusting the 
final number of neurons and synaptic connections.  
 
1.2.2 Postnatal brain development 
 
After birth, the brain does not develop in a continuous fashion, but it follows a 
non-linear pattern consisting of distinct age-dependant stages. These are 
roughly outlined below. 
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1.2.2.1 Infant brain development  
 
Although a massive wave of apoptosis occurs before birth, the brain continues 
to grow in a linear and rapid manner right before the individual is born (Hüppi, 
Warfield et al. 1998). This linear growth of the brain continues throughout early 
childhood, reaching about 95% of its final size by age six (Dekaban and 
Sadowsky 1978, Lenroot and Giedd 2006). In order to assess the development 
of the brain, parameters such as intracranial space, cerebrospinal fluid, and 
grey and white matter volumes have been investigated through magnetic 
resonance imaging (MRI) (Courchesne, Chisum et al. 2000). For instance, white 
matter volume (myelinated axons and myelinating oligodendrocytes) normally 
follows a linear increase from birth to adolescence, when it reaches its peak 
(Giedd, Blumenthal et al. 1999, Matsuzawa, Matsui et al. 2001). The white 
matter volume augments due to differentiation and oligondedrocytes wrapping 
around the axons. These cells are in charge of enhancing connectivity by 
insulating the axons and upregulating the myelin protein (McTigue and Tripathi 
2008).  
 
By contrast, grey matter volume (neuronal cell bodies and glial cells) increases 
rapidly and continuously during foetal development, with it accounting for 50% 
of the total brain volume at the time of birth (Hüppi, Warfield et al. 1998, Lenroot 
and Giedd 2006). After birth, a non-continuous increase of grey matter volume 
is observed in a region-specific manner, peaking in late childhood and 
adolescence. For instance, the parietal lobe reaches its maximum volume by 
the age of 10, while the temporal lobe does not peak till around 16 years of age 
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(Courchesne, Chisum et al. 2000). The increase in grey matter volume is 
thought to be due to cell differentiation more than cell proliferation, as well as 
synaptogenesis. The functional implications of the augmentation of white and 
grey matter volume will be reviewed further below.  
 
1.2.2.2 Brain development during adolescent and adulthood 
 
Although adolescence is a period of development difficult to precisely define, it 
is usually described as the time between the start of sexual maturation to 
adulthood (Dahl 2004). It is characterized by an increase in gonadal steroid 
hormones (testosterone and estradiol), which are known to have an 
organizational effect on neural circuitry during foetal development and early 
childhood. Besides these effects in earlier development, these hormones induce 
sex-specific changes during adolescence, especially in brain areas that have 
gender dimorphisms like the amygdala and the hypothalamus (Jernigan, Baaré 
et al. 2011).  
 
A neuronal event characteristic of adolescence involves a second wave of 
massive pruning, similar to the one observed before birth (Pfefferbaum A 1994, 
Andersen 2003, Crews, He et al. 2007). It is hypothesised that it shapes the 
brain and prepares its neural circuitry for mature adult behaviour (Crews, He et 




MRI studies have quantified the effects pruning has on brain volume during 
adolescence. In regards to white matter volume, it does not seem to be 
affected, which is logical considering it increases linearly until it reaches a 
plateau around the age of 40 (Courchesne, Chisum et al. 2000). On the 
contrary, there is a volume reduction observed in grey matter that could be 
associated with synaptic and axonal pruning (Pfefferbaum A 1994). After the 
volume of grey matter in the different regions peaks in late childhood, it 
proceeds to decrease (Giedd, Blumenthal et al. 1999, Lenroot and Giedd 2006) 
at a rate of approximately 5% per decade (Courchesne, Chisum et al. 2000), 
with the exemption of the volume of the temporal lobe that peaks during 
adolescence (as noted above), which then also beings to decrease (Giedd, 
Blumenthal et al. 1999).  
 
The variations in white and grey matter volume along development seem to be 
part of the ongoing maturation and remodelling of the brain. Abnormal changes 
could have consequences for the development of adult cognition. A study by 
Reiss (Reiss, Abrams et al. 1996) showed a positive correlation between  
intelligence, as measured by an intelligence quotient (IQ), and the total brain 
volume, particularly the grey matter volume in the prefrontal cortex. Other 
studies have supported this statement and have correlated IQ with the grey and 
white matter volumes of other specific brain regions in the different lobes (Haier, 
Jung et al. 2004). Social cognition, which represents the interplay between 
emotion-related processes and cognition, has also been correlated to changes 
in brain volume, especially white matter in the occipito-temporal lobe. The 
appropriate development of social cognition during adolescence is crucial in 
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interpreting verbal and non-verbal cues related to human interaction and 
communication (Paus 2005). 
 
Brain function can be measured by using functional MRI (fMRI) to detect 
changes in blood flow and then associating these changes with neuronal activity 
in the grey matter when a particular task is being performed (Brown, Joanisse et 
al. 2013). Other imaging techniques such as diffusion tensor studies are 
capable of measuring the magnitude and direction of the water molecule 
diffusion inside the brain, allowing for measurements of the level of myelination 
and axon thickness (Gössl, Fahrmeir et al. 2002, Olesen, Nagy et al. 2003). 
When subjects are investigated using both techniques while performing a task, 
a correlation of the activation sites in each study can unravel the networks 
connecting grey and white matter (Werring, Clark et al. 1999, Olesen, Nagy et 
al. 2003). These techniques have been applied to children and adolescents in 
an effort to study neuropsychological traits such as working memory (Olesen, 
Nagy et al. 2003) and speech and motor functions (Paus, Zijdenbos et al. 
1999).  
 
Both MRI and functional MRI (fMRI) studies have, in combination with genetic 
studies, been used to determine the role genes play in structure and function of 
the brain (Bartley, Jones et al. 1997, Posthuma, De Geus et al. 2002, Toga and 
Thompson 2005), specifically in regards to the genetic influence on the frontal 
grey matter volume and its correlation to cognition (Thompson, Cannon et al. 
2001, Posthuma, De Geus et al. 2002).  
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In addition to genetic factors, environmental factors could also impact on the 
size and function of the brain (Thompson, Cannon et al. 2001, Toga and 
Thompson 2005). Throughout the lifetime of an individual, the brain can 
respond to those factors by activating brain plasticity, which is characterized by 
changes in synapses and neural networks (Kolb, Gibb et al. 2003). One 
hypothesis about the purpose of plasticity is to adjust the neural networks 
according to the environment in which the organism lives (Bavelier, Levi et al. 
2010). Brain plasticity cannot only be influenced by changes in the environment 
but also by factors like cognitive maturation (Lledo, Alonso et al. 2006), 
experience (Draganski, Gaser et al. 2004), learning (Poldrack 2000), memory 
(Bailey and Kandel 1993) and pathologies (Keyvani and Schallert 2002). For 
instance, one study observed that extensive navigational experience in taxi 
drivers was correlated with a larger grey matter density in the posterior 
hippocampus (the area of the brain is suggested to store spatial memory) in 
comparison to the general population (Maguire, Gadian et al. 2000).  
 
More recently, neurogenesis in the adult brain has been proposed to contribute 
to brain plasticity. Although neurogenesis decreases markedly before birth, 
there are still two areas in the adult brain that serve as areas for the remaining 
neural stem cells. The neurons that differentiate from the subgranular layer in 
the dentate gyrus are thought to play a role hippocampal-related memory and 
learning, whilst the neurons generated in the subventricular zone are associated 




1.3 The importance of transcription factors  
 
Changes in gene expression drive the structural alterations in the brain 
described in the previous chapter. Human post-mortem studies have suggested 
that these changes occur throughout the life of an individual in a spatio-
temporal manner (Erraji-Benchekroun, Underwood et al. 2005). Transcription 
factors have a particular role in this gene expression because by binding to the 
promoters of their target gene and working closely with chromatin-remodelling 
factors, they regulate the transcription of the target genes (Maniatis, Goodbourn 
et al. 1987). In this manner, transcription factors create transcriptional networks 
that regulate brain patterning, cell proliferation, cell differentiation, cell migration, 
synaptogenesis and programmed cell death (Southall and Brand 2009, Studer 
2011). Not surprisingly, neurons are one of the most transcriptionally active 
cells in the body, which enables them to obtain and maintain their phenotype 
throughout development (Nelson, Hempel et al. 2006).  
 
Transcription factors are characterized by a DNA-binding domain that facilitates 
specific recognition of target genomic regions. It has been estimated that about 
8% of the human genome (∼2000-3000 genes) encode for putative transcription 
factors, as judged by the presence of a DNA-binding site in their amino acid 
sequence (Brivanlou and Darnell 2002, Babu, Luscombe et al. 2004). Out of 
those, zinc finger accounted for about 3% of the genome (Klug 2010). Similar 
results were obtained in mouse studies, which showed that over 7% of the 
genome, encode for putative transcriptions factors (∼1445 genes). These 
results further concluded that more than 20% of those (~349 genes) were 
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restricted to the central nervous system and presented different patterns of 
expression during development. Moreover, the largest group of transcription 
factors were the zinc fingers (∼678 genes). Around 10% of them were restricted 
to the central nervous system, highlighting the importance of zinc fingers in the 
brain (Gray, Fu et al. 2004).  
 
It is thought that the zinc fingers are so widely used because the zinc ions offer 
structural stability to the folded domains that do not possess a stable 
hydrophobic core due to its length (Coleman 1992, Kim, Armstrong et al. 1997). 
The structure of zinc fingers normally comprises two small antiparallel beta-
strands followed by an alpha helix [Figure 1.3(c)]. The DNA binding properties 
are created from the tertiary structure established between the tetrahedral 
complex (either four cysteines or two histidines and 2 cysteines) and a zinc ion 
(Pabo and Sauer 1992, Semenza 1998, Klug 2010). Further stabilization of the 
zinc fingers is given by the hydrophobic core, usually composed of three 
conserved amino acids: tyrosine, phenylalanine and leucine (Klug 2010).  
 
In terms of their binding efficiency, the proteins require at least two zinc finger 
subunits to attach around the DNA (Coleman 1992). A classic proportion 
between a finger motif and DNA is one to one. This means that individual amino 
acids from the alpha helix typically recognize and interact with a specific 
adjacent three-base pairs site on the coding strand of the major groove of DNA. 
In addition, they have a fourth-amino acid docking a base overlapped with the 
previous finger; it is referred to as position ‘minus one’ and is situated before the 
alpha helix. One manner in which they are linked is a cross-strand interaction: 
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positions minus one, three and six are linked to the coding strand while position 
two binds to the non coding one [Figure 1.3(b)] (McBryant, Gedulin et al. 1996, 
Luscombe, Austin et al. 2000). Although this binding arrangement is common, 
some alterations in the way it is presented in the different families of zinc fingers 
have been noted (Klug 2005, Klug 2010).  
 
In most cases, the specificity of the DNA binding protein increases with the 
number of finger units in it; this is because each finger functions as an individual 
unit recognizing a DNA base. Therefore, a protein with two fingers is less 
specific and can target more genes because it binds to fewer DNA bases, while 
one with six fingers can bind to a longer part of the coding strand, making it 
more selective (Luscombe, Austin et al. 2000, Klug 2010). 
 
 
Figure 1.3 Structure and binding sites of a zinc finger protein.  
(a) The protein structure of Transcription factor IIIA (TFIIIA). This transcription factor is composed of nine 
CCHH zinc fingers and was the first to be discovered. (b) Schematic diagram of the DNA recognition 
model by sequence specific amino acids in the alpha helix. This model particularly illustrates the case of 
three amino acids being cross-strand linked with three adjacent base pairs in the coding (positions -1, 3 
and 6) and non-coding strand (position 2) of DNA. (c) Nuclear magnetic resonance of a two-finger protein 
study showed the structure of an individual finger CCHH motif. In this particular example, Tyr42, Phe53 




1.3.1 Transcription factors and psychiatric diseases 
 
The dysregulation and dysfunction of transcription factors is regarded as a 
cause of disease. More specifically, at least one third of disorders originating 
during development have been linked to their disruption (Vaquerizas, 
Kummerfeld et al. 2009). For instance, psychiatric disorders like autism, 
schizophrenia and mental retardation, among others, have linked their aetiology 
to disruptions in the sequence or the expression of transcriptions factors during 
brain development (Van Loo and Martens 2007). For example, in autism, 
genetic alterations of transcription factor Engrailed 2 (EN2) during cerebellar 
development were suggested to contribute to the observed pathology (Gharani, 
Benayed et al. 2004); in the case of schizophrenia, the expression of 
transcription factor SRY-related HMG-box 10 (SOX10), involved in developing 
and maturing glial cells like oligodendrocyte (Kuhlbrodt, Herbarth et al. 1998), 
was found to be decreased in a patient cohort (Tkachev, Mimmack et al. 2003); 
lastly, a candidate gene for X-linked mental retardation is Zinc finger protein 41 
(ZFP41), which is suggested to be important for cognitive development 
(Shoichet, Hoffmann et al. 2003). These examples illustrate the importance of 
transcription factors. When disturbed, they can impact the correct development 
of the brain and ultimately affect the behavioural output (Vaquerizas, 
Kummerfeld et al. 2009).  
 
1.3.2 Myelin transcription factor 1 like (MYT1L) 
 
MYT1L, which is also called neural zinc finger 1, is a zinc finger transcription 
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factor that has been related to the operation and development of the brain (Kim, 
Armstrong et al. 1997). It was discovered while searching for proteins capable 
of binding beta-retinoic acid. In the mouse, they observed that Myt1l could not 
only recognize the promoter in the beta-retinoic acid receptor, but also the 
promoters of the other two POU Class 1 Homeobox 1 (Pit-1) genes (Jiang, Yu 
et al. 1996).  
 
MYT1L belongs to the myelin transcription factor 1 family. This cluster of DNA-
binding proteins, commonly referred as CCHHC domains, stands for its peculiar 
motif of five, instead of four, conserved residues arranged as follows: Cys-X4-
Cys-X4-His-X7-His-X5-Cys (Jiang, Yu et al. 1996, Blasie and Berg 1999, 
Berkovits-Cymet, Amann et al. 2004). The involvement of the fifth metal ligand 
causes a spatial re-organization to the motif, which changes the potential 
binding of the zinc ion, modifying its folding domains and ultimately the 
structure. Specifically, MYT1L zinc finger is known to coordinate zinc in a 
tetrahedral manner by using one histidine and three cysteines (Berkovits-
Cymet, Amann et al. 2004). The additional histidine residue is hypothesised to 
stabilize an internal loop by interacting with a tyrosine (Figure 1.4); however, 






Figure 1.4 Schematic structure of a single Myt1l zinc-binding domain.  
This figure represents the solution structure of a zinc finger. Three cysteine residues and a 
histidine are interacting with the zinc ion, along with the additional histidine and a 
semiconserved tyrosine. The image was taken from Besold et al. (Besold, Lee et al. 2010). 
 
In the human genome, there are three members of this family: myelin 
transcription factor 1 (MYT1), myelin transcription factor 1 like (MYT1L) and 
suppression of tumorigenicity 18 (ST18) (Figue 1.5) (Wang, Zeng et al. 2010, 
Stevens, van Ravenswaaij-Arts et al. 2011). The MYT1L gene in humans is 
located in chromosome 2 (2p25.3) and is formed by 540,081 base pairs and 25 
exons. From those, only exons 6 to 24 and the proximal part of exon 25 are 
coding regions (Wang, Zeng et al. 2010), resulting in a protein composed of 
1186 amino acids (Meyer, Zweig et al. 2013). Interestingly, human MYT1L 
protein is similar to Myt1l rodent protein, being 95% equal to the mouse and 
92% to the rat, showing its high conservation through evolution (Stevens, van 
Ravenswaaij-Arts et al. 2011). It is formed by six zinc finger domains internally 
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organized in groups of two and three, leaving the remaining finger in the N-
terminus. An independent DNA binding domain is created by each one of the 
clustered zinc fingers. The cluster composed of three zinc fingers has a higher 
biding affinity (Jiang, Yu et al. 1996). Furthermore, a high degree of homology 
between the zinc fingers in MYT1L has been observed as both two and three-
finger clusters can bind the same DNA sequence. Although this allows any of 
those domain clusters to activate the promoter, the ability to decide which set of 
fingers docks the target gene might be part of the mechanism regulating 
transcription (Besold, Lee et al. 2010).  
 
Figure 1.5 Schematic representation of the clusters made by zinc finger in the MYT1 family.  
The black rectangles represent each one of the zinc fingers. The image was obtained from Besold et al. 
(Besold, Lee et al. 2010). 
 
Normally, when the structure of a DNA-binding protein is known, inferences can 
be made about the docking to the target gene. However, this is not the case for 
MYT1L. It was demonstrated that the MYT1L zinc fingers lack alpha helix and 
beta sheets, the former structure being widely used by other zinc fingers to 
interact with the DNA (Berkovits-Cymet, Amann et al. 2004, Besold, Lee et al. 
2010). Research performed on family member MYT1 revealed no other clear 
contact areas and it was suggested that the whole MYT1 zinc finger binds to the 
major groove of DNA, producing specific electrostatic and hydrophobic contacts 
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(Gamsjaeger, Swanton et al. 2008). This could also be the case for MYT1L. 
 
As for its expression, this DNA-binding protein is brain specific, specifically 
restricted to neurons (Berkovits-Cymet, Amann et al. 2004). The microarray 
data obtained online from the quantitative atlas BioGPS (available at 
http://biogps.org/#goto=welcome) has helped to provide evidence of the 
restricted expression of MYT1L in human and mouse brain (Figure 1.6) (Wu, 
Orozco et al. 2009). In particular, this protein is predominantly expressed in the 
developing central nervous system (Kim, Armstrong et al. 1997). A second in-
silico analysis using the Allen Developing Mouse Brain Atlas (available online at 
http://developingmouse.brain-map.org) has further corroborated this hypothesis 
by showing that the expression of Myt1l in the mouse appears to start around 
E13.5, reaching a peak around birth and lowering, but to still detectable levels, 
in adulthood (Figure 1.7). Previous in-situ hybridization experiments in rats 
found similar expression patterns, with Myt1l expression starting around days 
13-15 and reaching its maximum expression right before birth (Kim, Armstrong 





Figure 1.6 MYT1L mRNA expression in different tissues in (a) human and (b) mouse.  
The tissue-specific patterns of mRNA levels in these graphs were obtained from BioGPS. The expression 
levels correspond to the results obtained in microarray experiments conducted with Affymetrix chips (Wu, 
Orozco et al. 2009). (a) For analysing human mRNA levels, the probe 210016_at on the Human Genome 
U133 array was used (Su, Wiltshire et al. 2004); while for the mouse, the probe 1421175_at on the mouse 
genome 430 array was used (Lattin, Schroder et al. 2008). All microarray data was normalized using Gene 




Figure 1.7 Expression of Myt1l through different stages from embryonic (E) to postnatal (P) 
development in the mouse strain C57BL/6J.  
All images were obtained from the Allen Developing Mouse Brain Atlas. In the first column, in-situ 
hybridization (ISH) was used in sagittal brain sections to detect Myt1l mRNA. Images from the second 
column are another method of representing the gene expression obtained by ISH. Each ISH image 
undergoes a detection algorithm to create a high-resolution greyscale image to identify pixels that 
correspond to gene expression. The intensity of the signal is colour-coded, with blue representing the 
lowest gene expression and red the highest. Images in the third column are a 3D illustration of the gene 
expression (Lein, Hawrylycz et al. 2007). 
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1.3.2.1 The importance of MYT1L for neuronal induction in-vitro 
 
The fact that Myt1l is expressed only in neurons and that its expression is 
higher before birth suggests its crucial role in neurodevelopment (Jiang, Yu et 
al. 1996, Kim, Armstrong et al. 1997). Moreover, its presence in later stages of 
life denotes its possible importance for brain function. The first evidence 
supporting these conjectures was reported by early findings that Myt1l, along 
with Achaete-scute homolog 1 (Ascl1) and POU class 3 homeobox 2 (Brn2), is 
capable of not only reversing cell lineage in mouse fibroblast but also 
reprogramming them as neurons. Although, fibroblasts acquire an immature 
neuronal phenotype when the expression of Ascl1 is activated, the addition of 
Myt1l and Brn2 is fundamental to obtaining a mature neuron capable of 
synapse connections and action potentials (Vierbuchen, Ostermeier et al. 
2010). Characterization of the newly converted neurons indicate they are 
excitatory cells showing cortical neurons markers (Vierbuchen, Ostermeier et al. 
2010), suggesting their involvement in cognitive functions (Stevens, van 
Ravenswaaij-Arts et al. 2011). When the other genes were tested individually, 
none of them were sufficient to induce neuronal cell fate (Vierbuchen, 
Ostermeier et al. 2010).  
 
Similar to the previous experiment, a second study achieved the differentiation 
of human pluripotent stem cells into mature neurons through the addition of 
ASCL1, BRN2 and MYT1L. By including Neuronal differentiation 1 (NEUROD1) 
in the previous pool of genes, the same outcome was yielded when converting 
human foetal and postnatal fibroblasts. NEUROD1 aided these types of cells to 
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obtain the morphology and electrophysiological properties of a mature neuron. 
These studies were further corroborated when the newly transformed neurons 
were put in culture along with mouse cortical neurons to assess the integration 
into pre-existing neuronal networks. Further whole cell recording demonstrated 
the formation of neurotransmitter receptors and functional synapses. Moreover, 
the cell phenotype was maintained once these genes were no longer 
overexpressed (Pang, Yang et al. 2011).  
 
An alternative set up used microRNA-124 (miR-124) instead of ASCL1 plus 
BRN2 and MYT1L to transform human postnatal and adult fibroblasts into 
functionally mature neurons. When either BRN2 or MYT1L were tested 
separately in combination with mir-124, only MYT1L demonstrated the ability to 
promote a more elongated morphology. However, proper maturation and fully 
functional synapses still required all three factors (Ambasudhan, Talantova et 
al. 2011). Comparable results were obtained in an experiment using microRNA 
9/9 (mir-9/9), mir-124, Neuronal differentiation 2 (NEUROD2), ASCL1 and 
MYT1L (Yoo, Sun et al. 2011). Once again, MYT1L was necessary to enhance 
the level of maturation. These studies highlighted the possible role of microRNA 
in neurogenesis and phenotype determination (Ambasudhan, Talantova et al. 
2011, Yoo, Sun et al. 2011). 
 
In order to intentionally convert human embryonic fibroblasts and postnatal 
fibroblasts into functional dopamine neurons, the overexpression of ASCL1, 
BRN2, and MYT1L, supplemented by LIM homeobox transcription factor 1, 
alpha (LMX1A) and FOXA2 (genes related to dopaminergic differentiation) was 
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necessary. Out of the resulting neurons, one out of ten exhibited morphological 
and electrophysiological characteristics of midbrain dopamine neurons 
(Pfisterer, Kirkeby et al. 2011). Son and colleagues (Son, Ichida et al. 2011) 
further corroborated the possibility of inducing different neuronal phenotypes by 
reverting mouse fibroblasts into motor neurons. This experiment required the 
addition of LIM Homeobox 3 (Lhx3), Motor neuron and pancreas homeobox 1 
(Hb9), ISL LIM homeobox 1 (Isl1), and Neurogenin 2 (Ngn2) to the now well-
known protocol (Ascl1, Brn2 and Myt1l) to induce functional motor neurons. The 
addition of NEUROD1 to the previous mix was enough to replicate the effect in 
human embryonic fibroblasts.  
 
All of the experiments mentioned above relied on lentiviral vectors to increase 
expression of the genes in order to revert cell fate and obtain mature neurons. 
The use of this particular technique represents a challenge for further clinical 
application. A recent study in mouse embryonic fibroblasts proposed the use of 
plasmids Ascl1, Brn2 and Myt1l to recreate the same effect observed with 
lentiviral vectors. Surprisingly, results showed high transfection efficiency and 
low toxicity in addition to providing comparable results to the lentiviral 
technique. These experiments not only provide insight into the putative 
importance of MYT1L for cell differentiation and cell identity, but could also play 






1.3.2.2 The association of MYT1L and disease 
 
Considering the importance of MYT1L in neuronal development, it is logical that 
alteration in its sequence or expression could have an impact on psychiatric 
disorders. The development of new technologies like fluorescence in-situ 
hybridization and microarrays has helped the mapping of genomes of both the 
healthy and pathological populations (Rio, Royer et al. 2012). Both techniques 
have been able to extend the number of genes that can be analysed in a single 
experiment, providing a good approach to unravelling the genes that could be 
affected in a specific disease (Lee, Mattai et al. 2012).  
 
Clinical studies, which rely on such techniques, have positioned MYT1L as a 
candidate gene for psychiatric disorders (Table 1.1). The first link was reported 
in a genomic study aiming to identify rare copy number variants (CNV) in 
schizophrenic patients. In two patients it was observed that the breakpoint of 
CNV duplication was located on the terminal part of MYT1L, which could impact 
on both the dosage variation and its expression (Vrijenhoek, Buizer-Voskamp et 
al. 2008). Additional evidence of CNV affecting MYT1L came from an analysis 
of childhood onset of Schizophrenia, in which two patients presented 
duplications which disrupted MYT1L (Addington and Rapoport 2009). 
Independently, these studies only displayed a trend of association between 
duplications in MYT1L and schizophrenia. However, the results of four 
published studies were combined together in a meta-analysis to provide 
stronger evidence of how variable size MYT1L duplications might be involved in 
this disease. The overall rate of disruption in MYT1L found in this study was 
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comparable to other CNVs that have been classified as high risk for 
schizophrenia (Lee, Mattai et al. 2012). 
 
Table 1.1 Mutations in MYT1L and their linkage to disease  
N/A: Not applicable; PANSS: Positive and Negative Syndrome Scale. 
 Patient Mutation Diseases and other behavioural problems associated  
P1 Duplication of 1014 kb 
partially affecting MYT1L 
Schizophrenia (Severe delusions/ hallucinations 










P2 Duplication of 3134 kb 
afecting the whole MYT1L 
Schizophrenia (Bizarre delusions/ hallucinations; 
aggressive behavior; anhedonia) 
P1 Duplication of unknown 
size affecting MYT1L 











P2 Duplication of unknown 
size affecting MYT1L 
Childhood onset of schizophrenia  
N/A 
SNP mutation             
rs17039584 in MYT1L 
gene 
Schizophrenia in the Han Chinese population 
(females associated with positive syndrome 







SNP mutation             
rs10190125 in MYT1L 
gene 
Schizophrenia in the Han Chinese population 










SNP mutation             
rs3748989 in MYT1L 
gene 
Major Depressive Disorder in the Chinese Han 
Population 
P1 Duplication of 281 kb 
partially affecting MYT1L   








P2 Duplication of 281 kb 
partially affecting MYT1L   
Autistic patient with stereotypical autistic 
language 
P1 Deletion that partially 
affects MYT1L  
Developmental delay, absence of speech, 








Somatic mosaicism with 3 
cell population affecting 
MYT1L: 1/3 duplication, 
1/3 deletion and 1/3 
normal  











P1 Inverted duplication of 28 
Mb affecting MYT1L 
Severe psychomotor and mental retardation  
P1 
 Inverted duplication of 
10Mb affecting the whole 
MYT1L 
Moderate mental retardation with motor and 
speech delay 
P2 
 Inverted duplication of 
10Mb affecting the whole 
MYT1L 
Severe mental retardation with motor delay, and 










 Inverted duplication of 
10Mb affecting the whole 
MYT1L 
Moderate mental retardation 
P1 Deletion of 2.77 Mb that 
affected MYT1L 
Moderate mental retardation, hyperactivity, mood 
changes and obesity 
P2 Deletion of 2.77 Mb that 
affected MYT1L 
Moderate mental retardation, hyperactivity, mood 
changes and obesity 
P3 Deletion of 2.77 Mb that 
affected MYT1L 
Moderate mental retardation, hyperactivity, mood 
changes and obesity 
P4 Deletion of 3.13 Mb that 
affected MYT1L 
Moderate mental retardation and obesity 
P5 Deletion of 1.33 Mb that 
affected MYT1L 
Moderate mental retardation, psychomotor and 










P6 Deletion of 0.37 Mb that 
affected MYT1L 
Moderate to severe mental retardation, autism 
and obesity 
 
The association of a MYT1L polymorphism and schizophrenia was also 
explored in the Han Chinese population. In this study, six single-nucleotide 
polymorphisms (SNPs) were analyzed. The results showed that SNP 
rs17039584 and rs10190125 had a significant association with schizophrenic 
patients in comparison to the controls. The latter SNP was still significant after 




The first study to look for an association between MYT1L and major depressive 
disorder was also in the Han Chinese population. A set of eight SNPs was 
tested in a large population containing both affected and general population. It 
was found that SNP rs3748989 was significantly associated, indicating MYT1L 
might be a potential risk gene for major depressive disorder among the Han 
Chinese (Wang, Zeng et al. 2010). 
 
Garbett and collaborators (Garbett, Ebert et al. 2008) first suggested an 
association between transcription factor MYT1L and autism after encountering a 
reduced expression of this gene in the temporal gyrus of autistic patients. A 
more recent clinical report, in which two male half-siblings were found to have 
de novo duplication in chromosome 2p25.3, further supported the role of 
MYT1L as a possible candidate gene for autism. The breakpoints included a full 
copy of peroxidasin homolog (Drosophila; PXDN) and seven exons of the 
terminal part of MYT1L. Their psychiatrically healthy mother was analysed and 
it was revealed that the transmission was due to germline mosaicism (Meyer, 
Axelsen et al. 2012).  
 
In a case study of monozygotic twins, one twin was found to exhibit an autistic 
phenotype whilst her twin sister’s phenotype included absence of speech, 
developmental retardation, hyperactivity and obesity. The former twin suffered 
from somatic mosaicism in which the chromosomal imbalance included deletion 
of 2p25.3 in one third of the cells; duplication in the same location in another 
third; and the remaining third was normal. The other sister presented only a 
deletion but in the same region. While the deletions and the duplication seen in 
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both twins were of different sizes, MYT1L and syntrophin gamma 2 (SNTG2) 
appeared to be affected in both cases (Rio, Royer et al. 2012). Considering the 
associations of this gene with neuronal maturation and synapse formation, it is 
not unexpected that MYT1L could contribute to the induction of this disorder,  
 
Another psychiatric disease that has been linked to chromosome 2p25.3 is 
mental retardation. Inverted duplications with terminal deletions affecting this 
chromosomic region, hence MYT1L, were initially noted in a study involving four 
patients: two siblings (a boy and a girl), their father and a non-related girl. 
Although the deletions were different in size and specific location, the patients 
shared the following phenotypes: scoliosis, particular ear shape and mental 
retardation, the latter being more severe in the females (Gruchy, Jacquemont et 
al. 2007, Bonaglia, Giorda et al. 2008).  
 
A more compelling study linking intellectual disability and MYT1L combined 
phenotypic and genotypic data from six patients, three siblings and three non-
related. All patients shared moderate intellectual disability and were overweight. 
Five out of six had a square-shaped complexion and half of them suffered from 
hyperactivity. Microarray results identified a deletion in 2pq25.3 ranging from 
0.37 to 3.13 Mb. The only gene which overlapped and which was disturbed in 
all cases was MYT1L. Along with MYT1L, the following genes were affected by 
the deletion in four of the patients (including all the siblings): Family with 
sequence similarity 110 member C (FAM110C), Family with sequence similarity 
150 member B (FAM150B), Sh3 domain YSC-like 1 (SH3YL1), Acid 
phosphatase 1 (ACP1), TMEM18, Chromosome 2 open reading frame 90 
Chapter 1 
49 
(C2ORF90), Syntrophin, gamma 2 (SNTG2), Thyroid peroxidase (TPO) and 
PXDN. In contrast, one patient with a shorter deletion only had the following 
genes compromised: MYT1L, SNTG2, TPO and PXDN. For the remaining 
patient, only MYT1L and PXDN were disturbed in the deleted region. Taking 
these results into consideration, it was suggested that the cause of intellectual 
disability was due to MYT1L haploinsufficiency (Stevens, van Ravenswaaij-Arts 
et al. 2011). 
 
In the light of the genome variations affecting the previously mentioned 
psychiatric disorders, it is not unexpected that MYT1L could play a role in 
causing them when disrupted (Wang, Zeng et al. 2010).  
 
1.4 Underlying the function of genes 
 
The large amount of genetic information generated by the distinctive types 
microarrays has increased the number of candidate genes for most psychiatric 
disorders (Thakker, Natt et al. 2004). Although these studies have been a 
remarkable achievement in delimitating the genes involved in a particular 
disease, further research is required to establish the contribution of each gene 
to the psychopathology. A logical method to establish the function of individual 
genes is by significantly increasing or reducing their expression and observing 
the changes produced in an organism (Vallier, Rugg-Gunn et al. 2004, Weber, 
Bartsch et al. 2008). Both in-vitro and in-vivo models have used this technique 
to screen for phenotypic and genotypic consequences of gene modification 
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(Paddison, Caudy et al. 2002). The phenotypic products resulting from the loss 
of gene expression represents one way to unravel how the gene works by 
identifying its pathways, biological function and connections (Silva, Li et al. 
2005). 
 
1.4.1 Gene Silencing 
 
The knockout mouse model was one of the first approaches used to investigate 
gene function (Brunstein 2010). As 99% of genes between the mouse and the 
human are homologous, as revealed by the full sequencing of the mouse 
genome (Ahmad-Annuar, Tabrizi et al. 2003, Austin, Battey et al. 2004), this 
model provides an opportunity to study the possible consequences of blocking a 
particular gene from being expressed and observing the consequential effects 
on other genes, behaviour and physical characteristics. However, there are 
many disadvantages to this technique. First and foremost, it requires breeding 
mice injected with the modified sequence at least three times before a 
homozygous animal is obtained, making it time consuming and expensive 
(Rubinson, Dillon et al. 2003, Brunstein 2010). Furthermore, since the organism 
has to be genetically modified before birth, it is unsuitable for translation to 
human gene therapy (Rubinson, Dillon et al. 2003). It is inefficient at 
investigating the role of a gene in a very localized region, for example, a specific 
brain region (Hommel, Sears et al. 2003). In addition, because the gene 
modification starts early in development, there is a chance that some other 
genes will compensate for the deleted gene and the resulting animal will not be 
a clear representation of the gene deletion (Crawley 1999). Lastly, if the gene is 
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involved in vital functions or plays an essential part in development, it is highly 
possible that the knockout mouse will be incompatible with life (Blanchard, 
Iizuka et al. 1997, Sanford, Ormsby et al. 1997). 
 
1.4.2 The RNA interference (RNAi) pathway and lentiviral mediated gene 
transfer 
 
An alternative mechanism to silencing gene expression came after the 
discovery of the RNA interference (RNAi) pathway in 1998 (Tabara, Sarkissian 
et al. 1999, Hommel, Sears et al. 2003, Zamore and Haley 2005). This pathway 
occurs naturally in most eukaryotes and functions as surveillance machinery 
controlling gene expression in response to double-stranded RNA (dsRNA) 
(Tuschl, Zamore et al. 1999, Meister and Tuschl 2004, Thakker, Natt et al. 
2004). Characterisation of the dsRNA has shown that it is formed by two 
strands of 21 to 23 nucleotides with symmetric overhangs of two or three 
nucleotides in the 3’. The size of dsRNA is restricted to 30 nucleotides; any 
sequences longer that that can provoke an adverse reaction leading to cell 
death (Thakker, Natt et al. 2004). Additional features of dsRNA include a 
phosphate group located at the beginning of 5’ and a hydroxyl group at the start 
of 3’ (Dykxhoorn, Novina et al. 2003).  
 
Endogenously, the RNAi pathway is triggered either by precursory primary-
microRNA (pri-microRNA) or a long dsRNA. The process is initiated with either 
RNase III enzymes Drosha and/or Dicer to further activate the RNA-induced 
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silencing complex (RISC) to accomplish gene silencing (Hammond 2005). 
Specifically referring to the pri-microRNAs, they are transcribed from the 
genome by RNA polymerase II (Figure 1.8). This sequence typically folds its 33 
complementary nucleotides that end in a terminal loop (Carthew and 
Sontheimer 2009). Before leaving the nucleus, the pri-microRNAs encounter 
Drosha, presumably by recognizing the size of its loop (Hammond 2005). 
Subsequently, the RNase domains of Drosha form a pseudo-dimer that cleaves 
the pri-microRNA and produce a pre-microRNA (Hammond 2005, Carthew and 
Sontheimer 2009). After the cleaveage, the pre-microRNA is left with a PAZ 
domain consisting of 2-nucleotide overhanging in the 3’ (required for Dicer 
recognition) and ready for Exportin-5 to transport it outside the nucleus for 
further processing. Once in the cytoplasm, pre-microRNA is ready to undergo 
additional modifications by Dicer (Hammond 2005).  
 
In the case of the long dsRNAs, they are incorporated into the RNAi pathway as 
well as the pre-microRNAs when they are recognized and cleaved by Dicer 
(Paddison, Caudy et al. 2002, Caplen 2004, Hammond 2005, Carthew and 
Sontheimer 2009). Dicer, an RNase III enzyme, is characterised for having a 
dsRNA-binding domain (dsRBD), a PAZ domain and two tandem RNase III 
domains (Carthew and Sontheimer 2009). Structural, genetic and biochemical 
models agree that the way Dicer interacts with both premicro-RNA and dsRNA, 
is due to the overhang nucleotides in the 3’. These nucleotides bind to the PAZ 
domain, while the RNAase III domains engage in a pseudo-dimer, each domain 
hydrolysing one strand (Hammond 2005, Carthew and Sontheimer 2009). The 
resultant product has a new 2-nucleotide overhang on 3’ and a monophosphate 
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group at 5’, required for further silence processing (Carthew and Sontheimer 
2009). 
 
The small interfering RNAs (siRNAs) and the microRNA produced by the Dicer 
cleavage are integrated into a multi-component nuclease complex called RNA-
induced silencing complex (RISC), which identifies the substrate mRNA for 
destruction (Paddison, Caudy et al. 2002, Tiscornia, Singer et al. 2003, Caplen 
2004). It is important to note that when the double-stranded siRNA and 
microRNA enter RISC, the strands get separated and only one strand is 
required to guide the recognition of the mRNA (guide strand); the other strand 
gets dismissed (passenger strand) (Carthew and Sontheimer 2009).  
 
Exogenously, this pathway can be modified by the introduction of synthetic 
silencing sequences (McIntyre and Fanning 2006). The study and consequently 
the understanding of the RNAi pathway brought the evolution of synthetic ways 
of silencing genes through it (Hannon and Rossi 2004). Scientists have been 
able to generate synthetic dsRNA such as siRNA, short hairpin RNA (shRNA) 
and microRNA-adapted short hairpin (shRNAmir) capable of being integrated 
into the RNAi pathway (Fewell and Schmitt 2006). The siRNA are small 
molecules consisting of 21 to 25 bp that are cleaved directly by Dicer enzymes. 
Their effect is dose-dependent and transient since they do not incorporate into 
the genome of the host cell (Rao, Vorhies et al. 2009). On the contrary, shRNA 
are encoded in a DNA plasmid that integrates into the genome of the cells and 
presumably is incorporated into the RNAi pathway as endogenous dsRNA (Wu, 
Wu et al. 2005, Rao, Vorhies et al. 2009). The sequence is modelled after a 
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premicroRNA (Figure 1.8) and is composed of around 70 nucleotides that form 
a sense, a loop and an antisense sequence (Paddison, Caudy et al. 2002, 
Fewell and Schmitt 2006). The shRNAmir, also known as second-generation 
shRNAs, includes the same structure as shRNA in addition to a microRNA-30 
(miR30) sequence (Chang, Elledge et al. 2006). This extra sequence allows it to 
enter the pathway as a pri-microRNA, a precursor of premicroRNA (Figure 1.8) 
(Fewell and Schmitt 2006). This second generation of shRNA enters the 
pathway at an earlier stage, making it a more natural route capable of more 
effective silencing of the target gene (Chang, Elledge et al. 2006). 
 
Figure 1.8 The figure illustrates the RNAi pathway activated by lentiviral vectors 
containing shRNAmir to knockdown gene expression.  
The virus binds to the cell and delivers its engineered genome containing the shRNAmir specific 
to the target gene for knockdown. Once in the cytoplasm, it is reverse-transcribed and imported 
into the nucleus. Further integration into the cell genome takes place and pri-microRNAs are 
transcribed by the RNA polymerase II. Before leaving the nucleus, they are trimmed by Drosha 
complex to generate pre-microRNA. Pre-microRNA is then transported into the cytoplasm by 
exportin 5 proteins. The Dicer complex performs a second cutting, involving the removal of the 
loop and production of microRNA. The microRNA binds and activates RISC, which uses it as a 
guiding strand to identify target mRNAs. After recognition, the mRNAs are destroyed; hence 




Previously, the synthetic sequences had been restricted to being delivered 
directly through microinjections into worms and flies, as these organisms 
possess an effective endogenous machinery capable of uptaking dsRNA (Fire, 
Xu et al. 1998, Misquitta and Paterson 1999, Tuschl, Zamore et al. 1999, 
Elbashir, Harborth et al. 2001). In the case of mammalian cell culture, their lack 
of this machinery requires a more sophisticated delivery method to effectively 
downregulate the target gene (Rozema and Lewis 2003). One such mechanism 
is the use of DNA vectors to deliver synthetic silencing sequences into the cells, 
with comes with the additional advantage of integration into the endogenous 
genome of the host cell (Shi 2003). This technique allows the transfected cell to 
synthesize siRNAs, shRNAs and shRNAmir in order to achieve a longer 
silencing effect (Brummelkamp, Bernards et al. 2002, Pebernard and Iggo 
2004).  
 
Even though the use of DNA vectors is useful to increase the gene knockdown 
effect, this is often insufficient, especially for in-vivo purposes (van den Haute, 
Eggermont et al. 2003). To circumvent this problem, the use of viral vectors 
such as lentiviruses (van den Haute, Eggermont et al. 2003, Weber, Bartsch et 
al. 2008), adenoviruses (Shen, Buck et al. 2003) and adeno-associated viruses 
(Tomar, Matta et al. 2003) came to be used and appear to be well suited to 
ensuring the stable long-term expression of the siRNA.  
 
Although all of these viral vectors are capable of infecting dividing and non-
dividing cells, there are certain characteristics, which made lentiviral vectors a 
better approach for this project. Firstly, although they reach their transgene 
Chapter 1 
56 
expression peak at around day 7, their effects can last for years, allowing for 
long-term experiments (Doherty, Schaack et al. 2011). Moreover, lentiviruses 
have a greater capacity to carry large fragments of foreign DNA such as 
transgenes (around 10 kb) in comparison to other viral vectors (Doherty, 
Schaack et al. 2011). Additionally, the integration of the transgene into the host 
genome allows for continuous expression: in case the transduced cell is still 
dividing, their progeny will carry on the transgene (Manjunath, Wu et al. 2009). 
Lastly, lentiviruses produce a minimal immune response from the cell after 
transduction (Howarth, Lee et al. 2010). All of these factors contribute to the 
extensive use of lentviruses to create research models in-vitro and in-vivo.  
 
1.4.3 The peculiarities of pGPIZ vector 
 
The Myt1l shRNAmir, which was cloned into a lentiviral vector in this project, 
belonged to the library developed by Dr Greg Hannon and Dr Steve Elledge 
(Thermo Scientific Open Biosystems pGIPZ shRNAmir). This gene silencing 
system distinguishes itself by its ability to highly activate the RNAi pathway with 
its unique short hairpin design. The silencing sequence is expressed as human 
microRNA-30 (miR30) primary transcripts. The full hairpin includes 22 
nucleotides of dsRNA and the miR30 loop is composed of 19 nucleotides. The 
dsRNA sequence is made of two strands of 21 complementary nucleotides and 
one mismatch, located upstream towards the Drosha cut site. A Drosha 
processing site was added to the hairpin, which means greater numbers of pre-
microRNA were released for further processing and increased efficiency for 
silencing genes (Figure 1.8). Also, the miR30 design enables the use of rule 
Chapter 1 
57 
based design such as destabilizing the 5’ end of the antisense strand to 
incorporate strand specific microRNAs into the RISC machinery. All these 
peculiarities in the structure need to be maintained for proper incorporation into 
the RNAi pathway (Boudreau, Garwick-Coppens et al. 2011).  
 
Furthermore, the success rate of the system also relies on the characteristics of 
the vector delivering the shRNAmir into the cell. pGIPZ lentiviral vector has 
proven to be a good candidate, as it is capable of infecting, with low toxicity 
rates, most types of cell, whether they are dividing or fully differentiated.  
 
pGIPZ is a high copy plasmid composed of 11,774 base pairs containing 
different expression cassettes conferring its properties. For plasmid preparation, 
the pUC origin replication site in the plasmid allows high copy replication and 
maintenance when cloned in Escherichia coli. Additionally, the ampicillin-
resistance element is useful for selecting only the bacteria that was 
transformed. The presence of the reverse response element allows the plasmid 
to be reverse transcribed inside the cytoplasm. Once it is integrated into the 
host genome, the RNA Polymerase II promoter CMV-EI (cytomegalovirus-
immediate early promoter) is responsible for high transgene expression levels. 
The puromycin-resistance gene, encoded in the pGIPZ vector, permits further 
selection of infected cells. The visualization of transduced cells is granted by the 
expression of the turbo-Green Florescent Protein (GFP) site (Figure 1.9). 
 
pGIPZ plasmid requires special packaging plasmids (pTLA1-Pak, pTALA1-Enz, 
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pTLA1-Rev and pTLA1-TOFF) coding for genes essential for lentivirus 
production. For safety reasons, these lentiviruses are composed of less than 
30% of the human immunodeficiency virus type 1 (HIV-1) and they are 
replication-incompetent. This means that all the necessary genes and 
accessory genes necessary to produce viral progeny have been removed. 
However, all the cis-acting sequences essential for proper packaging, reverse 
transcription and integration are present but this lentivirus lacks HIV-1 pNL4-3 
provirus (all information about pGIPZ was obtained from Thermo Scientific 
Open Biosystems).  
 
Figure 1.9 The figure shows a graphical representation of pGIPZ vector (b) and an 
example of the shRNAmir cloned inside of it (a).  
The pGIPZ vector (b) is composed of a variety of cassette enclosing genes important for 
plasmid replication (pUC Ori); bacterial selection [ampicillin (Ampr) and zeocin (Zeo) resistance]; 
transgene expression (CMV); visualization (tGFP) and selection of cell expressing shRNAmir 
(IRES.Puror); and the shRNAmir. The shRNAmir (a) is composed of 22 nucleotides (red) that 
have a complementary strand (black) forming a dsRNA and a miR30 loop (green). It was 
designed to have a Drosha and a Dice processing site to adequately integrate into the RNAi 
pathway. All images were obtained from the Thermo Scientific Open Biosystems protocol. 
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1.5 Aims of this project 
 
As described above, early stages of neural development are characterized by 
neurogenesis, migration, differentiation of neurons into synaptically active 
phenotypes and pruning by programmed cell death (Andersen 2003, Toro and 
Deakin 2007). During adolescence, a new wave of neuronal rearrangement 
takes place, eliminating synapses and pruning more neurons (Andersen 2003). 
During adulthood, the brain can still modify its organization and function; this 
process is normally referred to as plasticity. These physical changes are 
normally associated with behavioural changes like learning, memory, 
maturation, recovery or addiction (Kolb, Gibb et al. 2003). In summary, brain 
development is a never-ending process and it is important to understand the 
role of genes throughout the different stages.  
 
The candidate gene MYT1L has not been fully studied either in early or late 
development. The literature available strongly suggests a role in cell 
differentiation, maturation and possible synapse development. Given the 
tendency of MYT1L to influence neurons and its restricted expression in the 
brain, we hypothesise that disruption of this gene will have detrimental 
consequences on gene expression that ultimately will affect the behavioural 
outcome, in particular in relation to memory, learning and possibly anxiety. To 
address this hypothesis and further unravel the function of MYT1L in gene 
expression and behaviour, we decided to use shRNAmir to reduce its 
expression in a number of models. To delineate the scope of this project, we 
have subdivided the objectives as follows: 
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1. Chapter 2: In-vitro screening of possible candidate shRNAmir sequences 
designed to knockdown Myt1l in the rat, mouse and human.  
 
2. Chapter 3: Infection of human neural stem cell line (SPC04) with MYT1L 
shRNAmir lentiviruses to identify possible downstream targets of MYT1L 
during cell differentiation. 
 
3. Chapter 4: Microinjection of Myt1l shRNA lentiviruses into the dorsal 
hippocampus of the adult mouse brain to evaluate changes in behaviour 










As discussed in Chapter one, the increasing research on Myt1l has started to 
give a better perspective on the possible function of this gene. From the cellular 
point of view, it is known that this neuron-specific transcription factor is required 
along with Ascl1, Brn2 and NeuroD1 to reverse cell lineage and induce a 
functional neuronal phenotype (Vierbuchen, Ostermeier et al. 2010, 
Ambasudhan, Talantova et al. 2011, Pfisterer, Kirkeby et al. 2011, Yoo, Sun et 
al. 2011, Adler, Grigsby et al. 2012). Combining this finding with the observation 
that there is a high expression of Myt1l during development (Kim, Armstrong et 
al. 1997), it is possible to hypothesise that it has a role in cell differentiation 
during brain development. From the genetic perspective, the detection of 
variations in the genome sequence and the differences in gene expression of a 
large number of genes in a single experiment have helped scientists to infer 
candidate genes for most psychiatric disorders (Pongrac, Middleton et al. 2002, 
Stankiewicz and Lupski 2010). MYT1L is not an exception and in recent years it 
has been linked to disorders such as schizophrenia (Lodge and Grace 2007), 
mental retardation (Huttenlocher 1991), autism (Raymond, Bauman et al. 1995) 
and major depression disorder (Belmaker and Agam 2008). The specific role 
played by MYT1L in each one of those diseases is not clear yet. Currently there 
is no information regarding the phenotypic outcome of cells or organisms when 
only this gene is disrupted or its expression is compromised.  
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2.1.1 Gene silencing and validation in a cell model 
 
One method used to investigate the effects of a gene in an organism is to either 
increase or decrease its expression (Vallier, Rugg-Gunn et al. 2004). The latter 
approach, where gene expression is inhibited, will be used in this model.  This 
technique has proven to be especially effective since the discovery of the RNAi 
pathway as an endogenous silencing machinery in the Caenorhabditis elegans 
(Fire, Xu et al. 1998); it has revolutionized the development of techniques to 
investigate gene function (Hannon and Rossi 2004). This pathway allows the 
post-transcriptional downregulation of genes by recognizing dsRNA and using it 
as a template to identify mRNA of target genes in order to eliminate them; it 
essentially works as genetic surveillance machinery (Tabara, Sarkissian et al. 
1999).  
 
The biochemical understanding of this singular pathway helped to design siRNA 
to target specific sequences that could be incorporated into the RNAi pathway 
(Fewell and Schmitt 2006). Tuschl and his collaborators (Tuschl, Zamore et al. 
1999) were able to transfect mammalian cells to further increase the scope of 
its applications; however, it was not until shRNAs could be cloned into vectors 
that mimicked the endogenous triggers of the RNAi pathway that this technique 
could be expanded to most kinds of cells and tissues present in an organism 
with more stable and longer expression (Hannon and Rossi 2004, Chang, 
Elledge et al. 2006). Following the evolution of such techniques, research 
groups such as the group lead by Hannon and Elledge (Paddison, Silva et al. 
2004) were able to create large libraries of putative shRNAmir sequences which 
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target most genes in the human, mouse and rat genomes, and which are 
capable of obtaining a more robust reduction of gene expression (Chang, 
Elledge et al. 2006). This effort has helped researchers to better understand the 
role of genes.  
 
It has been demonstrated that the knockdown efficiency of siRNA sequences in-
vitro and in-vivo is highly dependent on their design, which is based on 
algorithms developed from empirical testing to predict efficient sequences 
(Reynolds, Leake et al. 2004, Pei and Tuschl 2006, de Fougerolles, Vornlocher 
et al. 2007). However, it is worth noting that even if there are sophisticated 
software programmes engineered to reduce the expression of the target gene 
available, they do not always succeed in providing sequences with good 
knockdown efficiency and thus it is important to test more than one sequence 
in-vitro (Rozema and Lewis 2003, Tiscornia, Singer et al. 2006). Even the 
commercially available shRNAmir libraries lack in-vitro validation for most of the 
clones since that is out of the scope of those companies (Chang, Elledge et al. 
2006).   
 
Moreover, not only is the type and design of the silencing sequence important in 
achieving high knockdown efficiency, but also the backbone vector used for 
their cloning. Lentiviral vectors have been shown to be a suitable choice 
because of their ability to infect non-dividing and fully differentiated cells, as well 
as dividing cells like stem cells (Rubinson, Dillon et al. 2003, Weber, Bartsch et 
al. 2008). In addition, it has been reported that the shRNA or transgene they 
encode is expressed for long periods of time, making it useful for long-term 
Chapter 2 
64 
experiments or clinical studies (Blomer, Naldini et al. 1997, Kafri, Blomer et al. 
1997).  
 
The required in-vitro validation for these sequences relies on suitable cell 
models to test their efficiency. When searching for one, the intrinsic 
characteristics of the target gene should be considered. In the case of Myt1l, 
since it is a neuron-specific transcription factor, it was appropriate to validate 
the knockdown effect of the sequences on neuron-related cells such as PC-12 
and Neuro-2a (N2A), which have been widely used as neuronal models 




The development of this research project depended upon finding an 
oligonucleotide sequence whose expression resulted in efficient knockdown of 
Myt1l. This chapter had the purpose of testing the efficiency of three lentiviral 
vectors containing shRNAmir sequences designed to reduce the expression of 








The Myt1l expression in the cell lines PC-12 and N2A was assessed in a single 
biological replication consisting of triplicates. Upon confirmation, PC-12 and 
Human Embryonic Kidney 293 T cells (HEK293T) were transduced in 
duplicates with each one of the lentiviral vectors containing one of the three 
shRNAmir sequences or a non-silencing shRNAmir for a control. HEK 293T 
cells do not express Myt1l, but they were used as a positive control for infection 
because they are easily transduced (Torres, García et al. 2011). This 
experiment consisted of three biological replications and the data were 
analysed together. The shRNAmir that caused the most significant decrease of 
Myt1l expression was used to transduce N2A cells. This experiment followed 
the same design as described for PC-12 (three biological replications consisting 
of two technical replications).  
 
2.2.2 Mammalian cell culture  
 
All cell lines were maintained at 37o C in a humidified incubator at 5% CO2. The 
media for all flasks and plates was changed to fresh complete media every 
second day, unless stated otherwise. The Fetal Bovine Serum (FBS) and horse 
serum were heat inactivated by incubation in a water bath at 56o C for 30 
minutes. 
 
2.2.2.1 Culture N2A and HEK293T cells 
 
N2A is a mouse cell line derived from neuroblastoma cells capable of 
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differentiating into neurons within days (Augusti-Tocco and Sato 1969, 
Tremblay, Sikorska et al. 2010). This cell line was bought from American Type 
Cell Collection (ATCC; USA). 
 
HEK 293T cells, derived from human embryonic kidney cells, were modified to 
express the SV-40 large T antigen, which allows very high levels of plasmid 
replication (Wurm and Bernard 1999, Pham, Kamen et al. 2006). This cell line 
was purchased from ATCC (USA).  
 
1) Cell media: The complete media was composed of high glucose (4500 
mg/L) Dulbecco’s Modified Eagle Medium (DMEM; Sigma, UK) supplemented 
with 10% inactivated FBS (Sigma, non-USA origin) and 1% 
penicillin/streptomycin (P/S; Sigma, UK).  
 
2) Cell revival: The cells were revived from liquid nitrogen storage by 
immersing the cryogenic tube containing them in a water bath at 37o C for 2 
minutes. The cells were transferred into a tube containing 4 ml of complete 
media and centrifuged for 5 minutes at 1500 revolutions per minute (RMP). The 
supernatant was discarded and the cell pellets were resuspended in 10 ml of 
complete media before plating them all in a T75 flask.  
 
3) Passaging: N2A and HEK 293T were expanded in Falcon T75 culture flasks 
and were passaged when they reached 80-90% confluency. For this, the 
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complete media was removed from the flask; the cells were washed using 
sterile Phosphate Buffered Saline (PBS) and then trypsinized using Trypsin-
EDTA 0.05% solution (Gibco, UK) for 5 minutes at 37o C. This last reaction was 
inactivated by the addition of complete media before the cells were collected 
and centrifuged for 5 minutes at 1500 rpm. The supernatant was carefully 
discarded, the cell pellets resuspended in fresh complete media and the cells 
plated into a T75 flask at a 1:3 ratio for further cell expansion. For RNA 
extraction, cells were seeded at a density of 1x106 cells per well in 6-well plates 
and harvested two days later as detailed below (2.2.5). 
 
4) Cell freezing: N2A and HEK 293T were frozen at a density of 3x106 cells per 
vial in complete media supplemented with 10% Dimethyl Sulfoxide (DMSO; 
Sigma, UK). The vials were frozen at 1oC per minute using a Mr Frosty freezing 
container (Nalgene®) for 24 hours at -80oC and then transferred to liquid 
nitrogen storage. 
 
2.2.2.2 Culture PC-12 cells:  
 
PC-12 is a rat cell line derived from the rat adrenal phaeochromocytoma with 
the remarkable characteristic of responding to the nerve growth factors (NGF) 
and differentiating into neuron-like cells (Greene and Tischler 1976, Zhou, Xu et 





1) Cell media: PC-12 cells were expanded in complete media composed of 
high glucose (4500mg/L) DMEM without pyruvate (Gibco, UK) supplemented 
with 10% inactivated horse serum (Gibco, UK), 5% inactivated FBS and 1% 
P/S. 
 
2) Coating of flasks: T75 Falcon flasks were freshly coated with 2.5 ul/cm2 rat-
tail tendon collagen diluted in 0.2% acetic acid (2 mg/ml; Roche, USA) and left 
to air dry for two hours at room temperature before plating the cells. 
 
3) Cell revival: The cells were revived as described for N2A and HEK293T 
cells (above). 
 
4) Passaging and seeding: The cells were passaged when they reached 80-
90% confluency. First, the cells were mechanically detached using a sterile cell 
scrapper and then the media-containing cells centrifuged for 5 minutes at 1500 
RPM. The supernatant was discarded, the cells resuspended in complete media 
and plated at a 1:3 ratio into a T75 flask for further expansion. For RNA 
extraction, cells were seeded at a density of 1.5 x106 cells per well in 6-well 
plates and harvested two days later as detailed below (2.2.5). 
 
5) Cell freezing: PC-12 were frozen at a density of 4x106 cells per vial in 
complete media supplemented with 10% Dimethyl Sulfoxide (DMSO; Sigma, 
UK). The vials were frozen as described for N2A and HEK293T cells (above).  
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2.2.2.3 Cell counting and seeding 
 
Cells were counted and their viability was assessed before plating them for 
RNA extraction, transfection (non-viral introduction of nucleic acids into cells to 
produce virus) and transduction (viral introduction of nucleic acids into cells). 
Cell number and viability were analysed using NucleoCounter® NC-100 
(Chemometec, Denmark). This device is an integrated fluorescence microscope 
capable of detecting signals from the fluorescent dye propidium iodine (PI). This 
dye is present in the interior of the NucleoCassette™ (Chemometec, Denmark) 
and binds to the DNA of the lysated cells.  
 
For total cell number, a sample of at least 40 ul of resuspended cells was mixed 
with equal amounts of Reagent A (Chemometec, Denmark) and Reagent B 
(Chemometec, Denmark). The mixture was loaded into a NucleoCassette™ and 
placed into the NucleoCounter® to obtain the cell concentration. This value was 
multiplied by the dilution factor to obtain the total number of cells. The principle 
behind this device is that Reagent A disrupts the plasma membrane and 
Reagent B stabilizes the reaction. This allows the PI dye to interact with the 
DNA of all the cells. 
 
For cell viability, at least 40 ul of the resuspended cells was mixed with equal 
amounts of PBS and Reagent B. The mixture was then loaded into a 
NucleoCassette™ (Chemometec, Denmark) and placed into the 
NucleoCounter® to obtain the cell concentration. This value was multiplied by 
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the dilution factor to obtain the total number of cells that were non-viable after 
resuspension. Since no Reagent A was added to the mixture, this reaction only 




2.2.3 Lentiviral vectors  
 
Three different pGIPZ lentiviral vectors containing shRNAmir and which 
targeted Myt1l were selected and bought from the Open Biosystem shRNAmir 
library (Thermofisher Scientific Open Biosystems, UK). Additionally, a non-
silencing shRNAmir was bought as a negative control. These sequences were 
developed in collaboration with Hannon and Elledge (Paddison, Silva et al. 
2004) and cloned by them into a pGIPZ vector (a full description of the vector is 
provided in Chapter 1). The shRNAmir sequences were designed using a 
proprietary algorithm of Rosetta Inpharmatics (Chang, Elledge et al. 2006). The 
detailed sequences of each used for this chapter can be found in Table 2.1. 
 
In-silico analysis blasting of all the sequences was performed to confirm their 
selectivity for Myt1l and the species affected. All blasts were done using the 
information provided on the National Centre for Biotechnology Information 
(NCBI) website (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
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Table 2.1 shRNAmir sequences for the possible candidates to knockdown Myt1l and a non-
silencing negative control.  
 
2.2.3.1 Generation of plasmid vectors 
 
2.2.3.1.1 Transformation of bacteria  
 
The manufacturer provided the pGIPZ lentiviral vectors as bacteria in glycerol 
stocks. After thawing and mixing by gentle pipetting, these stocks were used to 
transform Escherichia coli MAX efficiency Stbl2 competent cells (Invitrogen, UK) 
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30 minutes on ice, then heat-shocked for 25 seconds at 42o C and incubated for 
an additional 2 minutes on ice. To maximize transformation efficiency, 0.9 ml of 
S.O.C. medium (Invitrogen, UK) was added to each transformation and the 
bacteria were incubated further at 30o C (the ideal temperature to prevent DNA 
recombination) for 1.5 hours, while being shaken at 350 RPM. After incubation 
was complete, the transformed bacteria was gently mixed and evenly spread on 
Luria-Bertani (LB) broth (Lennox; Invitrogen, UK) agar plates containing 
100 ug/ml Ampicillin (Sigma, UK). The plates were incubated overnight at 30o 
C.  
 
2.2.3.1.2 Preparation of DNA plasmids 
 
Single bacteria colonies that grew on the plate were chosen and allowed to 
proliferate in a pre-culture of 5 ml of LB Broth media (Invitrogen, UK) containing 
100 ug/ml Ampicillin at 30o C overnight and used for small- or large-scale 
plasmid production as follows: 
 
For small-scale plasmid production, the tubes containing the 5 ml of pre-culture 
bacteria were centrifuged at 1500 RPM for 5 minutes at room temperature. Only 
approximately 4 ml of the supernatant was carefully discarded, leaving 1 ml to  
resuspend the bacteria in before being transferred to a microcentrifuge tube for 
further centrifugation at 11,000 x g for 1 minute. The remaining supernatant was 
carefully removed and the bacterial pellet was used for DNA extraction using 
the NucleoSpin® Plasmid kit (Marcherey-Nagel, UK), as per the manufacturer’s 
instructions. Briefly, the bacterial pellet was resuspended in 250 ul of RNase A-
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containing buffer A1 (100 ug/ml). Following the addition of 250 ul of lysis buffer 
A2, the suspension was mixed by inversion (6 to 8 times), incubated at room 
temperature for 5 minutes and the lysis neutralized by the addition of 300 ul of 
buffer A3. Bacterial debris were pelleted by centrifugation at 11,000 x g for 5 
minutes and the plasmid-containing supernatant was carefully removed and 
transferred into a NucleoSpin® Plasmid column. Column-bound plasmids were 
washed twice with 80% ethanol (in buffer A4) by centrifugation for 1 minute at 
11,000 x g and plasmid DNAs eluted with 40 ul of buffer AE [5 mM TrisHCl (pH 
8.5)].  
 
For large-scale plasmid preparation, 1 ml of the pre-culture bacteria was added 
to 400 ml of LB Broth media (supplemented with 100 ug/ml Ampicillin) and 
incubated at 30o C overnight. The bacteria were then collected by centrifugation 
at room temperature for 20 minutes at 1500 RPM. Supernatants were discarded 
and the bacterial pellets used for plasmid maxi-prep using the Qiagen Plasmid 
Maxi Kit (Qiagen, UK), as per the manufacturer’s instructions. Briefly, bacteria 
were resuspended in 10 ml buffer P1 [50 mM TrisHCl (pH 8.0) and 10 mM 
EDTA] supplemented with RNase A (100 ug/ml) and lysed for 5 minutes at 
room-temperature by addition of 10 ml of buffer P2 (200 mM NaOH and 1% 
SDS). Lysates were neutralised by the addition of 5 ml of pre-chilled buffer P3 
[3.0 M potassium acetate (pH 5.5)]; the neutralised lysates were cleared by 
filtration into a QIAfilter cartridge and further incubated on ice for 30 minutes in 
the presence of 2.5 ml of buffer ER. The filtered lysates were then applied into 
an equilibrated QIAGEN-tip 500 column and allowed to go through by gravity 
flow and washed twice with 30 ml of buffer QC [1 M NaCl, 50 mM MOPS (pH 
7.0) and 15% isopropanol]. The plasmid DNAs were eluted in 15 ml of buffer 
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QN [1.6 M NaCl, 50 mM MOPS (pH 7.0) and 15% isopropanol], precipitated by 
the addition of 10.5 ml of isopropanol (Sigma, USA) followed by centrifugation 
at 30,000 x g for 30 minutes at 4o C. After washing with 5 ml endotoxin-free 
70% ethanol, the mixture underwent centrifugation for 10 minutes at 30,000 x g 
at 4o C; the plasmid DNA pellets were then air-dried for 5 minutes and 
resuspended in 150 ul of TE buffer [10 mM Tris-HCl (pH 8.0) and 1 mM EDTA].  
 
DNA plasmid concentration was measured by UV spectrophotometry using a 
nanospectrophotometer (NanoDrop 1000, Thermo Scientific) at a wavelength of 
230 nm. By measuring the ratio of absorbance at 260nm and 280 nm (260/280), 
the purity of the plasmid was assessed. A ratio above 1.8 was accepted as 
“pure” for DNA. If the ratio was lower, it could indicate contamination of protein, 
phenol or other contaminant. The DNA plasmids were stored at -20o C till 
required.  
 
2.2.3.1.3 DNA restriction digestion 
 
In order to verify the correct size of the vector, the plasmids were digested with 
EcoR1 (20,000 units/ml; New England Biolabs, UK). Each reaction included 1 
ug of plasmid, 1 ul of 10 X NEBuffer EcoRI (New England Biolabs, UK), 10 units 
of EcoRI enzyme, and dH2O up to a final volume of 10 ul. The reaction was 
incubated at 37o C for 1 hour.  
 
The DNA plasmid digestions were separated by electrophoresis on a 1.3% 
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agarose gel (Sigma, UK) made up with 1X TBE buffer (0.0089 M Tris, 0.089 M 
Borate, 0.002 M EDTA; Merck, Germany) and supplemented with 1% Ethidium 
Bromide (Electron, UK). The digestion samples were mixed with 2 ul of 6X gel-
loading buffer (Thermo Scientific, UK) and loaded into the wells of the gel. 
Additionally, one well was used for loading the 1 kilobases DNA ladder (250-
10,000 bp Sigma, UK). Electrophoresis was performed using 1X TBE buffer at 
120 V for 1 hour. The DNA bands obtained in the gel were visualized using 
ultraviolet light. 
 
In addition, the DNA plasmids were sent for DNA sequencing (Source 
Bioscience, UK) to check the correct shRNAmir sequence and verify no 
recombination of the sequence occurred while it was being amplified inside the 
bacteria.  
 
2.2.3.1.4 Virus production  
 
Replication incompetent lentiviruses containing Myt1l or non-silencing 
shRNAmir were created using the Trans-lentiviral GIPZ Packaging System 
(Thermofisher Scientific Open Biosystems, UK). To ensure high titre of 
lentiviruses, the HEK 293T cells were used for transfection till they reached a 
rapid replication state. This means that after the cells reached 70% confluency, 
they were passaged at a 1:2 ratio for at least two consecutive days, till the cells 




The day before transfection, HEK 293T cells were seeded at a density of 5.5 
x106 into 10 cm dishes in 14 ml of regular media. The next day, the following 
mixture was prepared in a 15 ml-sterile tube for each plate: 42 ul lentiviral 
vector plasmid (containing either Myt1l or non-silencing shRNAmir), 30 ul of 
Trans-Lentiviral Packaging Mix (Thermofisher Scientific Open Biosystems, UK) 
and sterile dH2O (Gibco, UK) up to a final volume of 945 ul. Then, 105 ul of 
calcium chloride (Thermofisher Scientific Open Biosystems, UK) was applied to 
each tube, followed by drop-wise addition of 1050 ul of 2X HBSS (Thermofisher 
Scientific Open Biosystems, UK) while the tube was being mixed by air bubbling 
using a serological pipette. The solution was left for incubation for 3 minutes at 
room temperature. The resulting 2.1 ml solution was then added drop-wise to 
each 10 cm plate and left in the incubator (37o C and 5% CO2) for the next 16 
hours. The plates were microscopically examined for the presence of GFP 
(fluorescent reporter), an indicator of transfection efficiency. The media was 
changed to 14 ml of reduced serum media composed of high glucose DMEM, 
5% inactivated FBS, 1% P/S and 2 mM L-glutamine (Sigma, UK). The plates 
were incubated for 48 hours (37o C and 5% CO2). Afterwards, the supernatant 
was collected and centrifuged at 1600 x g for 10 minutes at 4o C to pellet the 
cell debris. The lentiviral supernatant was filtered before being aliquoted and 
stored at -80o C till required.  
 
2.2.4 Cell transduction 
 
One day before transduction, 5 x 105 PC-12 cells were plated in each well of a 
6-well plate and incubated overnight. The following day, the media was 
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removed and changed to 1 ml of serum free and antibiotic free high glucose 
DMEM media and 2 ml of lentiviral supernatant. Each received an additional 3 
ul of 8 mg/ml polybrene (Sigma, USA) to increase transduction efficiency. The 
plates were centrifuged for 90 minutes at 2500 RPM and put at 37o C in 5% 
CO2 incubator for 2.5 hours. The media was then changed to 3 ml of complete 
media and incubation continued for a further 72 hours. After incubation, the 
media was removed and 3 ml of complete media supplemented with 5 ug/ml of 
puromycin (MP Biomedicals, France) was added to each well to selectively kill 
the non-transduced cells. After 48 hours, only transduced cells were observed 
and the media was changed to complete media. It has been reported that the 
peak in transgene expression for lentiviral vectors is around seven days 
(Doherty, Schaack et al. 2011), so the cells were left incubating for expansion 
for two more days.  
 
HEK 293T cells and N2A cells followed the same transduction protocol. 
However, the puromycin concentration (5 ug/ml) was used only for cell selection 
of N2A as HEK293T cells were only required as a control for infection and for 
that reason not selected. In addition, the N2A cells required a further step after 
the 72-hour incubation following transduction owing to their high division rate. 
The cells therefore were trypsinized and plated into 10 cm dishes. The following 
day, the N2A cells underwent puromycin selection for two days and the cells 
were left for expansion for only one additional day. Images of both transduced 





2.2.5 RNA extraction 
 
Before harvesting the cells for RNA extraction, all the equipment and surfaces 
were sprayed with RNAseZAPTM (Sigma, UK) to eliminate RNAse and avoid 
RNA degradation. The media was removed from the wells or dishes and the 
cells were washed twice with sterile PBS. 350 ul of RLT buffer (QIAGEN, UK) 
supplemented with 1% β-mercaptoethanol (Sigma, UK) was added to each well 
or 600 ul to each dish. The cells were mechanically removed using a sterile cell 
scrapper. The lysate was placed in 2 ml collection tubes (QIAGEN, UK) and 
stored at -80o C until RNA extraction took place. 
 
The lysate was homogenized using a QIAshredder spin column (QIAGEN, UK) 
placed over a 2 ml collection tube and centrifuged at full-speed for 2 minutes. 
The RNA extraction was performed using the RNeasy® mini kit (QIAGEN, UK). 
One volume of 70% nuclease-free ethanol was added to each homogenized 
lysate and mixed well by pipetting. The mixture was then transferred into an 
RNeasy spin column over a 2 ml collection tube and centrifuged for 15 seconds 
at 21.1 x g. The flow was discarded and 350 ul of RW1 buffer was applied to 
each column before centrifuging it for 15 seconds at 21.1 x g. The flow was 
discarded and 80 ul at 1:8 ratio of DNase treatment mixed (DNase I and Buffer 
RDD; QIAGEN, UK) was applied to each column. The reaction was left to 
incubate for 15 minutes at room temperature before 350 ul of RW1 buffer was 
added. The columns were centrifuged again for 15 seconds at 21.1 x g. The 
flow was discarded and the column washed with 500 ul of RPE buffer followed 
by centrifugation for 15 seconds at 21.1 x g, discarding the flow at the end. A 
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second wash with 500 ul of the same buffer was applied and the column was 
centrifuged for 2 minutes at 21.1 x g. After the second wash, the column was 
centrifuged for an additional minute. The column was transferred into a clean 
RNase-free collection tube. RNA was eluted by adding 40 ul of RNase-free 
water directly to the membrane of the column and centrifuging it for 1 minute at 
21.1 x g. RNA concentration was measured by UV spectrophotometry using a 
nanospectrophotometer (NanoDrop 1000; Thermo Scientific) at 230 nm 
wavelengths. By measuring the absorbance ratio (260/280) the purity of the 
plasmid was assessed. A ratio above 2 was accepted as “pure” for RNA. If the 
ratio was lower, it could indicate contamination of protein, phenol or other 
contaminant. The RNA was stored at -80oC till required.  
 
2.2.6 Reverse transcription 
 
Reverse transcription was performed using the SuperscriptTM III First-Strand 
Synthesis System for RT-PCR (Invitrogen, UK). Two micrograms of RNA were 
mixed with 1ul of 50 uM Oligo(dT)20, 1 ul of 10 mM dNTP mix and RNAse-free 
water in a final volume of 10 ul and denatured by incubation at 65o C for 5 
minutes followed by incubation on ice for at least 1 minute. 10 microliters of 
cDNA synthesis mix composed of 2 ul of 10X RT buffer, 4 ul of 25 mM MgCL2, 
2 ul of 0.1 DTT, 1 ul of RNase OUTTM (40 U/ul) and 1 ul of SuperscriptTM III RT 
(200 U/ul) was added to the previous solution and the resulting 20-ul solution 
incubated at 50o C for 50 minutes, followed by incubation at 85o C for 5 minutes 
to deactivate the enzymes. 1 ul of RNase H (2 U/ul) was added and the solution 
was further incubated at 37o C for 20 minutes to remove residual RNA. The 
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cDNA was then diluted with 179 ul of RNase free water to have an estimated 
final concentration of 10 ug/ul and stored at -20o C till required.  
 
2.2.7 Quantitative Polymerase Chain Reaction (qPCR) 
 
qPCR amplification was performed in a 20 ul solution containing 4 ul of cDNA 
(10ug/ul), 10 ul of 2X Power SYBR® Green PCR master mix (Applied 
Biosystems, UK), 0.14 uM forward primer (Table 2.2), 0.14 uM reverse primer 
(Table 2.2) and 5.72 ul of RNase free water. All the amplifications were carried 
out in triplicate using a ABI Prism® 7900 HT Sequence detection system 
(Applied Biosystems) under the following thermal cycle: 95o C for 15 minutes 
(initial denaturation); 40 cycles of 95oC for 30 seconds and 60oC for 30 seconds 
(amplification); finishing with 50o C for 10 seconds and 95o C for 10 seconds 
(dissociation stage). The ABI Prism® SDS 2.1 software (Applied Biosystems) 
was used to analyse the specificity and relative quantification of the amplicons. 
The dissociation curve generated by the software was used to determine the 
specificity of the PCR products. The relative quantification curve of the amplicon 
was calculated using the cycle threshold (Ct), which represents the number of 
cycles required by the sample to cross a fixed fluorescence threshold. The 
fewer cycles required to cross the threshold, the higher the expression of the 
gene in the sample. In the case of the first experiment quantifying the 
endogenous expression of Myt1l, this curve was used to assess the expression 
of this gene in both cell lines when compared to a positive control 
(housekeeping gene). An additional cell line was used as a negative control 
(cDNA from undifferentiated B35 cells, kindly provided by Dr Alinda Fernandes); 
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its amplification curve was also compared to the housekeeping gene.  
 
For the experiments where cells were transduced with lentiviral vectors, the 
mean of the triplicate Ct values were normalized against the mean of the 
triplicates of the housekeeping gene, β-Actin, to produce ΔCT (ΔCT=CtMyt1l-Ctβ-
Actin). The difference in expression of Myt1l mRNA was compared in the two 
conditions--infected with non-silencing shRNAmir and infected with Myt1l 
shRNAmir--to calculate ΔΔCt (ΔΔCt=ΔCtMyt1l shRNAmir-ΔCtnon-silencing shRNAmir).  
 
Table 2.2 Sequence of the qPCR primers for rodent Myt1l and β-Actin 
 
2.2.8 Statistics  
 
To assess the effect of the three different knockdown sequences in the 
expression of Myt1l in PC-12 cells, the ΔΔCt values were firstly tested for 
normality using the Shapiro-Wilk test. After corroborating that the data was 
normally distributed, the ΔΔCt values were analysed using one-way ANOVA 
with factor treatment followed by Turkey’s LSD post-hoc. An independent 
sample t-test was carried out to compare the ΔΔCt values of Myt1l in N2A cells 
infected with Myt1l shRNAmir against non-silencing shRNAmir. All statistical 
analyses were done using IBM SPSS Statistics 20 (IBM Corp., USA). A p-value 
 Forward Reverse 
Rodent Myt1l GAGCCAGTCCCTGATCCAC CCGTCAAAGTAGTCACGTAAGC 
β-Actin GCTCGTCGTCGACAACGGCTC CAAACATGATCTGGGTCATCTTCTC 
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<0.05 was considered statistically significant. The data was expressed as mean 
± Standard Error of the Mean (S.E.M.). The graphs were presented as the 
relative change in expression. This was obtained by elevating 2 to the negative 
power of ΔΔCt (relative fold expression=2-ΔΔCt) (Livak and Schmittgen 2001). The 
error bars were adjusted to reflect the logarithmic scale. They were calculated 
as follow, the upper and lower limits of the ΔΔCt (ΔΔCt minus or plus the 
standard error of Ct values) were converted to relative fold expression. Then, 
these limits were subtracted from the mean fold relative expression to get the 
size of the error bars. 
 
2.3 Results  
 
In order to accomplish this, two cell lines were tested to determine their 
endogenous expression of this gene. Once Myt1l expression was corroborated 
in those cell models, the silencing sequences were tested. The sequence with 
the highest efficacy as well as lowest toxicity would provide a useful tool to 
investigate the possible roles of Myt1l. 
 
2.3.1 In-silico confirmation of selectivity of shRNAmir sequences for Myt1l 
 
The shRNAmir sequences were blasted to confirm their specificity to recognize 
Myt1l. As expected, the sequences numbered 32678 [Figure 2.1 (a)] and 90785 
[Figure 2.1 (b)] aligned 100% to the Myt1l mRNA sequence in the rat, mouse 
and human. On the other hand, the sequence numbered 428227 only had 
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perfect alignment with the rat and mouse Myt1l sequences. The alignment of 
this sequence with the human MYT1L sequence presented three mismatches: 
the first and last nucleotides and one in the middle of the sequence [Figure 2.1 
(c)]. The correct design and specificity of the sequences are crucial to achieving 
gene silencing.  
 
Additionally, the non-silencing shRNAmir structure, which consists just as Myt1l 
shRNAmir of a mir-30, sense, loop and antisense sequences, was inspected to 
verify its lack of specificity for any known gene sequence. The results 
demonstrated that neither the sense nor the antisense sequences targeted any 




Figure 2.1 In-silico analysis of the antisense strands of the shRNAmir numbered 32678 
(a), 90785 (b) and 428227 (c).  




2.3.2 Corroboration of Myt1l expression in two rodent cells lines 
 
 Using qPCR, the cDNAs were isolated from two neural rodent cell lines (PC-12 
and N2A) and analysed in order to find whether they naturally expressed 
measurable quantities of Myt1l. Both PC-12 and N2A cells showed a good 
expression of Myt1l when their amplification curves (Figure 2.2) and Ct values 
(Table 2.3) were compared to that of β-Actin (positive control). β-Actin was 
selected as the housekeeping gene and positive control because of its good 
and invariant expression in the samples tested. High Ct values comparable to 
those observed for β-Actin indicated that the gene is well expressed in the cell 
line. The Myt1l amplification curve obtained from PC-12 and N2A was further 
compared to the curve obtain from undifferentiated B35 cells (negative control). 
The choice of this last cell line as a negative control was because of its 
undifferentiated state, hence its lack of Myt1l expression. The Myt1l 
amplification curve in PC-12 and N2A cells was closer to their housekeeping 
gene, indicating good expression [Figure 2.2 (a) and (b)]. As expected, the 
negative control had no Myt1l amplification curve [Figure 2.2 (c)].  
 
By examining the dissociation curve, the specificity of the PCR products could 
be assessed. Figure 2.3 illustrates the changes in fluorescence which were 
observed as the temperature was increased. When the melting point was 
reached due to the dissociation of the double-stranded DNA, SYBR® was 
released and the fluorescence decreased. The melting point is different for 
every amplified product: it depends on several factors such as length, GC 
concentration and the presence of base mismatches. If a single peak is yielded 
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after amplification, as it is for Myt1l and β-Actin in N2A [Figure 2.3 (c) and (d)] 
and PC-12 [Figure 2.3 (a) and (b)] in this experiment, it indicates that the 
primers only amplified the region for which they were designed. These results 
together with the high Ct values observed for Myt1l in the N2A and PC-12 cell 
lines provided good evidence of their utility to assess the effects of Myt1l 
shRNAmirs.  
 
Table 2.3 Ct values obtained from analysing Myt1l expression in three cell lines: PC-12, N2A and 
B35.  
The data are expressed as mean ± S.E.M. 
Cell Type Ct β-Actin Ct Myt1l 
PC-12 20.75±0.36 24.01±0.41 
N2A 19.42±0.39 23.39±0.28 





Figure 2.2 The expression of Myt1l in four different cells lines:  
PC-12 cells (a), N2A (b) and undifferentiated B35 (c). This chart plots the changes in the 
magnitude of the signal generated by the amplicon across cycles. Each graph shows the 
amplification of Myt1l and the housekeeping gene used for normalization. PC-12 (a) and N2A 
(b) possess a good expression of Myt1l as the amplification curves are not far from the 
housekeeping gene curve. The last figure is an example of a cell line that does not express 






Figure 2.3 Confirmation of β-actin (a and c) and Myt1l (b and d) qPCR primer specificity in 
the cell lines PC-12 (a and b) and N2A (c and d).  
The dissociation curves derived from the qPCR analysis of Actin and Myt1l, yielded only one 
peak (i.e., one PCR product) per primer pair in each cell line, indicating the specificity of these 
primers. The plot illustrates the derivative data (the rate of change in fluorescence as a function 
of temperature) versus the temperature interval at which fluorescence changes.  
 
2.3.3 Screening for anti-Myt1l shRNAmir in rodent cells lines 
 
Two cells lines commonly used as neuronal models were used to corroborate 
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the efficiency of Myt1l shRNAmir sequences: one derived from rat (PC-12) and 
the other one from mouse (N2A). For the first set of experiments, PC-12 cells 
were infected with each one of the three putative silencing sequences (Myt1l 
32678, Myt1l 428227, or Myt1l 90785 shRNAmir) and one negative control 
(non-silencing shRNAmir). PC-12 was first investigated because its 
fluorescence is easier to detect under the fluorescent microscope in comparison 
to N2A. Following transduction, pictures were taken after the cells were 
selected using Puromycin in order to obtain only cells that were actively 
expressing the shRNAmir of interest as well as GFP (seen in Figure 2.4). This is 
because GFP is expressed from the same CMV-EI promoter that regulates the 
shRNAmir expression. Most cells are expressing green fluorescent, 
demonstrating that the cells were infected and were expressed either Myt1l or 






Figure 2.4 The fluorescent microscope images on the right illustrate the GFP expression 
in PC-12 cells obtained with each of the three different Myt1l shRNAmirs and control 5 
days after transduction.  




The RNA extracted from those transduced cells was used to perform a qPCR 
analysis to determine the effect of Myt1l shRNAmir in-vitro. The plots were 
obtained by calculating the relative fold expression of each Myt1l shRNAmir 
infection in comparison to non-silencing. As seen in Figure 2.5, the expression 
of Myt1l was found to be decreased by 55% in shRNAmirs 32678 (2.23-fold 
change), 26% in 428227 (1.35-fold change) and 31% 90785 (1.45-fold change) 
when compared to the control. A one-way ANOVA test analysing the ΔΔCt 
values indicated significant group differences when comparing Myt1l expression 
in the control and Myt1l-shRNAs infected samples (F3,23=7.378, p=0.002). Post-
hoc analyses using the Tukey LSD test found a significant reduction between 
the control and Myt1l shRNAmir 32678 (p=0.012), while the control versus 
either Myt1l shRNAmir 428227 (p=0.331) or Myt1l shRNAmir 90785 (p=0.127) 






Figure 2.5 This graph illustrates the relative fold expression of Myt1l in PC-12 cells after 
being transduced with either one of the three different Myt1l shRNAmirs or non-silencing 
shRNAmir.  
The data are expressed as mean ± S.E.M. *p<0.05 Myt1l knockdown versus control pre-
planned pairwise comparison followed by Tukey LSD correction of ΔΔCt values (n=6 per group). 
 
After analysing the results obtained from the experiments performed on PC-12 
and corroborating the efficiency of at least one of the shRNAmir sequences, the 
transduction of the N2A cell was restricted to that shRNAmir construct. The 
reasons behind using N2A were to try to replicate the effect seen in PC-12 and 
to validate the shRNAmir construct in the mouse for the following in-vivo 
experiments.  
 
Even though it was hard to capture the fluorescence of this cell line in pictures, 
the microscopy inspection of GFP expression in the cells indicated high 
transfection efficiency after Puromycin selection (Figure 2.6). This was further 
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corroborated when the RNA extracted from those cells was analysed. The 
relative expression of Myt1l in 32678 shRNAmir-transduced cells compared to 
control cells had a 2.64-fold reduction, which represented a reduction of 65% 
An independent t-test analysing the ΔΔCt values revealed a significant 
difference between the control and the treated cells [T(10)=-7.036; p=0.000036; 
Figure 2.7], indicating that the Myt1l shRNAmir sequence was capable of 
downregulating Myt1l in the mouse cell line too. The results of these 
experiments corroborated the efficiency of shRNAmir 32678 to significantly 
knockdown Myt1l in the rat and the mouse. 
 
 
Figure 2.6 The figures on the right illustrate the GFP expression in N2A cells of Myt1l 
shRNAmir and the control after 5 days of being transduced.  





Figure 2.7 This graph illustrates the relative fold expression of Myt1l in N2A cells after 
being transduced with either Myt1l 32678 shRNAmir or non-silencing shRNAmir.  




This initial experimental chapter focused on identifying a silencing sequence 
capable of downregulating the expression of Myt1l. To address this aim, three 
sequences designed for such a purpose were acquired from the shRNAmir 
library of Hannon and Elledge (Paddison, Silva et al. 2004) as well as a non-
silencing shRNAmir as a negative control (Open Biosystems Thermo Scientific). 
The use of this last construct as a control was to make the experiment as 
similar as possible in terms of transgene incorporation into the host genome. 
The results yielded from this study have identified an shRNAmir sequence 
capable of significantly reducing the expression of Myt1l in-vitro in a rat and a 
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mouse cell line. This finding allowed us to address some of our current 
hypotheses about Myt1l involvement in cell development and the resultant adult 
mouse.  
 
2.4.1 Myt1l knockdown  
 
In order to validate their efficiency in-vitro, expression of Myt1l was assessed in 
two cell lines (one rat and one mouse) commonly used as neuronal models. 
Both of them showed a good expression of Myt1l when compared to the 
expression of a well-expressed gene. Following these results, the three Myt1l 
shRNAmirs were used to transduce the rat cell line PC-12 and Myt1l expression 
was compared between them and the control shRNAmir. Not surprisingly, only 
one of them (Myt1l 32678 shRNAmir) was capable of reducing the expression 
of Myt1l by 55.05 ± 9.13%. The other two failed to significantly decrease Myt1l 
expression when compared to the control. Although all the sequences were 
designed to decrease the expression of the gene of interest and their specificity 
was validated, it is common to find variability in the results when the sequences 
are tested in-vitro. One possible reason why the efficiency of shRNAs is 
variable could be due to the silencing sequence. It has been observed that the 
following factors are the most determinant on shRNA functionality: sequence 
specificity (Du, Thonberg et al. 2005); low guanine and cytosine content; 
internal stability of the 5’ antisense; thermodynamic properties; and absence of 
internal repeats of the nucleotides (Reynolds, Leake et al. 2004). Most of the 
current software integrates these factors when designing shRNA sequences; 
but silencing is still not always achieved in its totality or a significant percentage. 
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Another possible explanation is because the secondary and tertiary structures 
of the targeted mRNA have an important impact on the activation of the RNA-
induced silencing complex (RISC) (Brown, Chu et al. 2005, Overhoff, Alken et 
al. 2005). RNA is prone to forming this kind of structure and they can block the 
access to the target site sequence, which results in low cleavage of the 
endogenous mRNA (Brown, Chu et al. 2005).  
 
Furthermore, the efficiency to downregulate Myt1l in a mouse cell line was 
replicated. In this case, validation in-vitro in a mouse cell line was necessary to 
further pursue the aims intended for Chapter 4. For this experiment, only the 
Myt1l shRNAmir vector that significantly reduced the gene expression in PC-12 
cells was used to transduce N2A cells. The results further supported the finding 
in PC-12, that is, that the Myt1l shRNAmir was capable of reducing by 
64.50±4.40% of the Myt1l mRNA in those cells in comparison to the non-
silencing vector. Nevertheless, even though the expression of Myt1l recorded 
for Myt1l-shRNAmir infected PC-12 and N2A represented only a partial 
knockdown of the gene, this effect was not unforeseen as other studies have 
described similar knockdown effects (Moffat and Sabatini 2006, Singh, 
Spoelstra et al. 2008, Muruganandan, Dranse et al. 2013). 
 
2.4.2 Conclusion and limitations 
 
The results of these experiments were crucial to the future development of this 
project. A silencing sequence targeting Myt1l mRNA was necessary to address 
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the questions about the function of this gene in stem cell development and 
mouse behaviour. In the case of the animal model, the use of an shRNAmir 
cloned into a lentiviral vector was chosen over other techniques such as a 
conditional knockout the same construct can be used for in-vitro purposes as 
well (Davidson and Boudreau 2007). Moreover, the use of stereotaxic surgery 
and lentiviral vectors provided the opportunity to localize the manipulation of 
gene expression (Cetin, Komai et al. 2007). However, this could also be 
interpreted as a disadvantage depending on the size of the region where the 
gene would be downregulated. Another disadvantage of this approach is the 
subtle effects which may be created, possibly due to the decrease rather than 
elimination of the expression of the gene of interest (Gao and Zhang 2007). An 
additional shortcoming is the unknown temporal expression of the shRNAmir 
sequence, although this largely depends on the choice of vector, and lentiviral 
vectors are known to be expressed for long periods of time (Howarth, Lee et al. 
2010); however, the exact time is unknown and it should be checked for every 
vector+shRNAmir construct. Lastly, an additional inconvenience of this 
approach is the possibility of causing off-target effects on other genes. Such 
effects are considerable due to the RISC machinery loading the passenger 
strand instead of the guiding strand and can be minimized by ensuring the 
precise Dicer cleavage of the guiding strand out the microRNA (Gu, Jin et al. 
2012, Fellmann, Hoffmann et al. 2013). Although, the design of shRNAmirs 
used in this study tried to minimize such effects by mimicking the structure of 
the endogenous microRNAs, off-target effects cannot be dismissed. In the 
future, the results of these experiments could be replicated using an additional 
and capable shRNAmir sequence, in order to fully reject that the results 
obtained here were due to any off-target effect.  
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Chapter 3 : Effects of MYT1L knockdown on gene expression 




A complex organ like the brain develops through multiple stages that rely on 
cellular processes such as neural stem cell proliferation, differentiation, 
migration and synaptogenesis, among others. The process of differentiation of 
neural stem cells is largely dependent on genes and their transcriptional 
products, which ultimately determine the end fate of these stem cells 
(Paczkowski and Chun 2009). In light of technological advances devoted to 
measuring the expression of large quantities of genes in a single experiment, 
new genes are being associated to neuronal cell differentiation (Wen, Gu et al. 
2002). Among these, a wide repertoire of the genes coding for transcription 
factors seem to have an important input into deciding the cell-type specification 
(Bang and Goulding 1996). In the quest to investigate the impact of transcription 
factors such as MYT1L on the transcription of other genes, the use of stem cells 
as an in-vitro model of neuronal differentiation in parallel with gene knockdown 
appeared to be a suitable model. In this way, we sought out to unravel the 
importance of MYT1L in the genetic pathway of cell differentiation.  
 
3.1.1 Stem cells as an in-vitro model of neurodevelopment 
 
Tissue culture of neural stem cells is among the procedures commonly used to 
Chapter 3 
99 
understand the cellular processes taking place during the development of the 
central nervous system, in particular as a model of cell proliferation and 
differentiation (McKay 1997). The term ‘neural stem cells’ or ‘neural 
progenitors’, refers to cells that are able to differentiate into neural cells 
(neurons and glial cells) and which are capable of self-renewing as well as 
undergoing asymmetric cell division (Figure 3.1) (Gage 2000). The isolation and 
culture of neural stem cells is possible due to the protocols developed by 
Evans, Kaufman (Evans and Kaufman 1981) and Martin (Martin 1981) to obtain 
embryonic stem cells directly from a mouse embryo (Figure 3.1). The availability 
of these types of cell lines and their capacity to differentiate brought a new in-
vitro approach to studying mammalian development and it represented a 
watershed in the field of developmental biology (Keller 1995).  
 
New protocols have been developed to improve techniques to isolate stem cells 
from different regions of the brain at different stages of life (embryonic, foetal, 
adult) (Pollock, Stroemer et al. 2006). These cell lines can be expanded by the 
addition of growth factors such as fibroblast growth factor–2 (FGF-2) and 
epidermal growth factor (EGF). The removal of those factors consequently 
leads to the induction of differentiation (Reynolds and Weiss 1992, Rietze and 
Reynolds 2006). Moreover, depending on the cell line and the neuronal 
phenotypes pursued, other factors might be required for differentiation (Gage 
2000). Although these protocols have produced good neurodevelopmental in-
vitro models, these cells are prone to genetic instability as well as a tendency to 
create tumours. A protocol overcoming those difficulties was developed by 
Pollock and collaborators (Pollock, Stroemer et al. 2006) and it incorporated c-
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mycERTAM technology, which comprises a growth promoting gene (c-myc) and a 
hormone receptor that is activated by 4-hydroxy-tamoxifen (4-OHT). This 
selective growth regulator provides protection against uncontrolled division and 
tumour formation, in addition to the generation of genetically stable cell lines.  
 
 
Figure 3.1 This figure illustrates the different types of stem cells and their differentiation potential.  




3.1.2 The use of microarrays to identify the genes involved in proliferation 
and differentiation 
 
Even though the use of stem cells has facilitated the study of development, 
studying the genetic pathways that control it remains a long and extensive task. 
One manner of possibly solving this is by correlating the protein or mRNA 
expression patterns from the cell or tissue with the degree of development at 
which the sample was taken and comparing it to other earlier or later stage of 
development (Lillien 1998). Applying the same principles in a more ambitious 
approach, the use of large-scale gene profiling techniques such as microarrays 
has helped identify the genetic pathways leading to proliferation and 
differentiation of neural cells (Aiba, Sharov et al. 2006). This technology has 
evolved from the early work performed by Schena and collaborators (Schena, 
Shalon et al. 1995) and it has benefited from the advancements of technology 
such as an increase in the specificity and number of probes analysed per 
experiment (Peeters and Spek 2005). 
 
Relying on the information provided by microarray analysis, an initial pool of the 
putative genes involved during proliferation was established for neural stem 
cells (Ramalho-Santos, Yoon et al. 2002, D'Amour and Gage 2003) and 
embryonic stem cells (Ramalho-Santos, Yoon et al. 2002, Tanaka, Kunath et al. 
2002, D'Amour and Gage 2003). It was not surprising that both types of stem 
cells shared the expression of some common genes given the fact that 
embryonic stem cells and neural stem cells are still differentiating, although the 
latter had a more restricted phenotypic output in comparison to the former 
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(Figure 3.1). Among those genes, most of them belonged to transcription 
regulation, signalling and cell cycle regulation (Ramalho-Santos, Yoon et al. 
2002, D'Amour and Gage 2003).   
 
Further experiments using the same stem cell line tried to identify the genes 
whose expression differed significantly during differentiation in comparison to 
proliferation. It was found that a large number of genes coding for transcription 
factors and cell signalling were upregulated during differentiation (Karsten, 
Kudo et al. 2003, Ahn, Lee et al. 2004, Gurok, Steinhoff et al. 2004). 
Particularly, it was observed that the expression of transcription factors in a 
temporospatial manner had an important input into deciding the fate of 
progenitor cells (Levine and Davidson 2005). This is to regulate the expression 
of a large number of genes required to be expressed in order to switch the cell 
from an undifferentiated progenitor type to a highly specialized neural cell 
(Gurok, Steinhoff et al. 2004).  
 
3.1.3 Neural stem cells and gene knockdown  
 
The aforementioned studies have provided global gene expression profiles, 
which have laid down the roots for the discovery of the putative genes involved 
in cell proliferation and differentiation of stem cells. One way of investigating the 
role of those genes individually is by increasing or reducing their expression in-
vitro and in-vivo and observing the changes at both phenotype and genotype 
level. The use of lentiviruses has demonstrated that foreign genes can be 
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efficiently introduced into the genome of stem cells, and therefore lentiviruses 
are a valuable tool to analyse gene function during developmental processes 
(Zaehres, Lensch et al. 2005, Wang, Oron et al. 2012). In addition, this 
particular type of vectors also offers the advantage of infecting dividing and non-
dividing cells (Naldini, Blomer et al. 1996, Dissen, McBride et al. 2012). 
Moreover, transduction of embryonic stem cells has shown stable transgene 
expression, a long-lasting effect that continued throughout differentiation 
(Pfeifer, Ikawa et al. 2002). Furthermore, specifically referring to gene silencing, 
the use of lentiviral vectors containing shRNA sequences in these kinds of cells 
showed a stable expression of siRNAs capable of reducing gene expression 
(Rubinson, Dillon et al. 2003, Zaehres, Lensch et al. 2005, Wang, Oron et al. 
2012).  
 
One example of the use of lentiviral vectors to transduce human dividing cells 
was performed by Zaehres and collaborators (Zaehres, Lensch et al. 2005). 
They used lentiviral vectors to silence the expression of two transcription 
factors: octamer-binding transcription factor 4 (OCT-4) and Nanog homeobox 
(NANOG) in human embryonic stem cells. The phenotypic changes indicated 
that the cells were leaving the proliferation stage and were beginning cell 
differentiation. In terms of gene expression, they found that the expression of 
OCT-4 had an impact on the expression of NANOG and vice versa when tested 
separately. In addition, the expression of markers associated with the 
undifferentiated stage indicated that these transcription factors might be 
involved in maintaining the pluripotency of these cells. These results were 
further confirmed by Wang and colleagues (Wang, Oron et al. 2012), who used 
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microarrays and siRNAs to demonstrate the coregulation of OCT-4 and NANOG 
in cell self-renewal mechanisms. Moreover, the same study showed that over 
100 genes expressed during human embryonic stem cell development required 
OCT-4, NANOG and SRY (sex determining region Y)-box 2 (SOX2) to maintain 
proper expression.  
 
In a similar type of experiment which used non-dividing cells, Lin and 
collaborators (Lin, Bloodgood et al. 2008) tested the impact of removing 
transcription factor Neuronal PAS Domain Protein 4 (Npas4) through the use of 
lentiviral vectors in mouse neuronal cultures. The results indicated that the 
expression of this gene was involved in the development of inhibitory synapses 
and its absence disturbed the naturally occurring homeostatic balance between 
excitatory and inhibitory synapses. One of the putative downstream targets that 
stood out in this experiment was brain-derived neuro-trophic factor (BDNF), 
which is known to associate to inhibitory synapse maturation and function.  
 
3.1.4 MYT1L and neuron development 
 
The previous studies exemplified how the use of lentiviral vectors incorporating 
siRNA and shRNAs has been useful in understanding the pathways lead by 
transcription factors. Applying such technologies to other transcription factors 
such as MYT1L, whose downstream targets have not yet been discovered, 
could be helpful in better understanding the transcriptional pathway initiated by 
this gene. So far, it is known that this transcription factor is actively expressed in 
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the central nervous system, in particular in the neurons (Berkovits-Cymet, 
Amann et al. 2004). More precisely, its expression begins around embryonic 
day 13 in the rat and peaks right before birth, but continues to have a detectable 
expression during adulthood (Chapter 1, Figure 1.7) (Kim, Armstrong et al. 
1997).  
 
In-vitro studies have provided further evidence of the importance of MYT1L in 
neuron development. Since Vierbuchen and collaborators (Vierbuchen, 
Ostermeier et al. 2010) demonstrated that Myt1l in combination with 
transcription factors Ascl1 and Brn2 was sufficient to revert mouse fibroblast 
into functional neurons, other protocols with similar purposes have been 
developed. In addition to mouse fibroblasts, these new protocols adjusted the 
genes required to convert human pluripotent stem cells (Pang, Yang et al. 
2011) and human fibroblasts (Ambasudhan, Talantova et al. 2011, Pfisterer, 
Kirkeby et al. 2011, Son, Ichida et al. 2011, Yoo, Sun et al. 2011) into functional 
neurons. All of the aforementioned protocols require the expression of MYT1L 
in order to obtain mature neurons capable of action potentials and synapse 
formation.  
 
Additional information about the role of MYT1L has been provided by clinical 
studies. These studies which use genome maps or expression profiles of 
patients have found a disruption in MYT1L in major depression disorder (Wang, 
Zeng et al. 2010), schizophrenia (Vrijenhoek, Buizer-Voskamp et al. 2008, 
Addington and Rapoport 2009, Lee, Mattai et al. 2012), autism (Meyer, Axelsen 
et al. 2012, Rio, Royer et al. 2012) and mental retardation (Gruchy, Jacquemont 
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et al. 2007, Zou, Van Dyke et al. 2007, Bonaglia, Giorda et al. 2008, Stevens, 
van Ravenswaaij-Arts et al. 2011). These four complex disorders have been 
thought to be, to some extent, the result of disrupted genes and environmental 




The role that MYT1L plays in the transcription of other genes during 
development has not yet been fully understood. The fact that it is highly 
expressed during development and that it is necessary to convert other cellular 
types into functional neurons provides evidence of its importance for neuronal 
development. Further support of this comes from associations some studies 
have made between MYT1L and psychiatric diseases developed during 
neurodevelopment. Taking into account all the information available about this 
gene, it is not surprising that its reduced expression during differentiation would 
have an impact on the expression of other genes and ultimately on the proper 
differentiation of the brain. The aims of this chapter are to examine the role of 
MYT1L in the differentiation of human neural stem/progenitor cell line SPC04 by 
selectively knocking it down using a lentiviral shRNAmir vector and analysing 
the consequences on gene expression profile through qPCR and microarray at 
two different time points: pre-differentiation and day 7 of differentiation. Due to 
limitations in the quantity of RNA, only the expression of nine genes was 
assessed. Those genes were chosen on the basis of being highly co-expressed 
with MYT1L in a previous experiment attempting to investigate the expression 
profile of SPC04 cells during differentiation (data not shown). The differences 
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found in gene expression due to MYT1L knockdown could help determine the 
genes that might require this transcription factor to initiate transcription. The 
results of this study would help unravel the putative downstream targets of 
MYT1L during differentiation.  
 
3.2 Materials and Methods 
 
3.2.1 Experimental setup  
 
The human neural stem/progenitor cell line SPC04 cells were seeded into 6-
well plates. The wells were infected with lentiviral vectors containing either 
MYT1L shRNAmir or non-silencing shRNAmir. RNA was extracted from those 
cells at two time points: pre-differentiation and day 7 of differentiation. The 
choice of those time points was decided after analysing data of a pilot study 
demonstrating a knockdown effect of MYT1L after 7 days of differentiation. The 
experiment consisted of 2 biological replications with 3 technical replications for 
each condition and time point.  
 
The RNA was used to analyse gene expression through microarray analysis. 
Further validation was performed by qPCR but only on a handful of genes due 
to the limitation in the quantity of RNA. Unfortunately the results of the 
microarray were inconclusive and therefore this chapter is only based on the 
findings of the qPCR analyses. The genes that had a significant reduction in 
expression when treated with MYT1L knockdown in comparison to the control 
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underwent in-silico analysis of the transcription binding sites present in their 
promoter region. This last step was important in assessing the possibility of 
them being direct downstream targets.  
 
3.2.2 Concentrated lentiviral production 
 
The lentiviral supernatant containing shRNAmirs against MYT1L and the control 
was produced exactly as described in Chapter 2 (2.2.3). After the supernatant 
was filtered, it was loaded into ultracentrifugation tubes (Beckman Coulter) and 
spun down at 25,000 revolutions per minute (RPM) for 1.5 hours at 4o C. The 
supernatant was carefully removed from the tubes without disturbing the 
lentiviral pellet. 30 ul of PBS was added to each tube and left overnight at 4o C. 
The next day, the pellet was resuspended, aliquoted and stored at -80o C.  
 
3.2.3 Lentiviral titration 
 
In order to determine the viral titre, 1x105 HEK293T cells were seeded into each 
well in a 24-well plate using complete media (details about cell culture are found 
in 2.2.2). The next day, HEK293 cells were transduced with serial dilutions of 
the concentrated virus. The concentrated virus was diluted as follows: 10-2, 10-3, 
10-4, 10-5, 10-6, 10-7 and 10-8 in serum and antibiotic free high glucose DMEM 
media supplemented with polybrene (8 ug/ml). The plates were centrifuged at 
2500 RMP for 1.5 hours, followed by 2.5 hours in the incubator (37o C and 5% 
CO2). The media was replaced with 1 ml of complete media and the cells were 
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incubated for 72 hours without disruption. Following this step, the cells were 
carefully washed twice with sterile PBS and trypsinised using Trypsin-EDTA 
0.05% solution for 5 minutes at 37o C. Once the cells were detached, 500 ml of 
sterile PBS was added to each well and centrifuged for 5 minutes at 1000 RPM. 
The supernatant was carefully discarded and each sample was resuspended in 
500 ul of 4% paraformaldehyde (PFA). The samples were analysed by flow 
cytometry using a fluorescence-activated cell sorting (FACS) analysis to count 
the transduced cells, which were recognized by their GFP expression 
(fluorescent reporter). Only dilutions resulting in about 10 to 15% GFP positive 
cells were used for titre calculation. This percentage represents a single viral 
integration per cell.  
 
The viral titre was calculated using the following formula: 
Transducing units (TU/ml)= (%GFP positive cells/100%) x nb x dilution factor  
nb= number of cells plated x 2 number of days after plating  
 
3.2.4 Human neural stem/progenitor cell line SPC04  
 
The human neural stem/progenitor cell line, SPC04, used for this study is a 
conditionally immortalized cmyc-ERTAM human spinal cord cell line (kindly 
provided by the Jack Price Lab), which was generated from 10-week old foetal 
cervical spinal cord tissue (Kubinová, Horák et al. 2010, Jeffries, Perfect et al. 
2012, Růžička, Nataliya Romanyuk et al. 2013). In brief, the foetal cervical 
region of the spinal cord was finely cut into pieces to generate primary cells. 
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Those cells were gently dissociated using 0.25% trypsin in Dulbecco’s modified 
Eagle’s medium/Ham’s F12 (DMEM:F12) at 37o C. The reaction was inactivated 
using 0.25 mg/ml of soybean trypsin inhibitor (Cocks, Romanyuk et al. 2013). 
The cells were conditionally immortalized following the protocol described by 
Pollock et al. (Pollock, Stroemer et al. 2006). The cells were plated into laminin-
coated plates. When 60% confluency was reached, they were transduced with 
the retroviral vector pLMCX-2 encoding the transgene cmyc-ERTAM for 12 hours. 
This gene combines the cmyc transcription factor with a mutant of oestrogen 
receptor regulated by 4-OHT. The transfected cell colonies were selected using 
neomycin before being expanded as a clonal cell line. In the presence of 4-
OHT, the conditional cell line continues to proliferate remaining phenotypically 
and karyotypically stable.  
 
3.2.4.1 Cell growth  
 
1) Cell media: Reduced modified media plus (RMM+) was composed of 
DMEM:F12 (Gibco, UK) supplemented with 4-OHT (100nM; Sigma, UK) and all 
the components written in Table 3.1 (preparation of stock solution is described 
in Table 3.2). The media was filtered through a 0.2 uM Stericup filter (Millipore, 
UK) and stored at 4o C for a maximum of 4 weeks. Differentiation media RMM- 
was prepared in the same manner but this media was depleted from the growth 
factors and 4-OHT.  
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Components Concentration Company 
Human Albumin Solution 0.03% Baxter 
Human Transferrin  100 µg/ml Sigma-Aldrich 
Putrescine DiHCL 16.2 µg/ml Sigma-Aldrich 
Human recombinant Insulin 5 µg/ml Sigma-Aldrich 
Progesterone 60 ng/ml Sigma-Aldrich 
L-glutamine 2 mM Sigma-Aldrich 
Sodium Selenite 40 ng/ml Sigma-Aldrich 
bFGF (basic Fibroblast Growth 
Factor) 
10 ng/ml PeproTEc 
EGF (Epidermal Growth Factor) 20 ng/ml PeproTEc 
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Table 3.2 Preparation of stock solutions for RMM and differentiation factors  






No preparation was required 4o C  
Human 
Transferrin  
50mg/ml Dissolved in DMEM:F12 containing 1mM of HEPES 
(pH 7.4; Sigma, UK) 
-20 o C 
Putrescine 
DiHCL 




10 mg/ml No preparation was required 4o C 
Progesterone 20 ul/ml Dissolved in molecular biology grade ethanol (Sigma, 
UK) 
-20o C 
L-glutamine 200mM No preparation was required -20o C 
Sodium 
Selenite 
20 ug/ml Dissolved in DMEM:F12 -20o C 
bFGF  10 ug/ml Dissolved in DMEM:F12 containing 1mM HEPES and 
0.03% human albumin solution 
-20o C 
EGF 10 ug/ml Dissolved in DMEM:F12 containing 1mM HEPES and 
0.03% human albumin solution 
-20o C 
4-OHT 1mM Dissolved in molecular biology grade ethanol -20o C 
ATRA 10mM Dissolved in DMSO (Sigma, UK) -20o C 
DAPT 10mM Dissolved in DMSO -20o C 
 
2) Coating of flasks: cell expansion was carried out in Nunc Delta surface 
treated (Thermo Scientific, UK) T75 and T175 culture flasks freshly coated with 
mouse laminin and DMEM:F12 at a ratio of 1:50 (20ug/ml; Sigma, UK) for at 
least three hours at 37o C in a humidified incubator at 5% CO2. Prior to cell 
seeding, the excess laminin was aspirated and the flask was washed with 
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DMEM:F12 to remove any extra laminin present in the flask. This media was 
aspirated and replaced by RMM+ before returning it to the incubator.  
 
3) Cell revival: In order to revive the cells from liquid nitrogen storage, they 
were thawed and centrifuged with RMM+ at 900 revolutions per minute (RPM) 
for 5 minutes. The supernatant was carefully removed and the cell pellet was 
resuspended in RMM+. Before plating, the cells were counted and their viability 
was analysed using NucleoCassettes™ and the NucleoCounter® 
(Chemometec, Denmark) as indicated in Chapter 2. The SPC04 cells were 
seeded at a density of 20,000 per cm2 in freshly coated flasks and they were 
proliferated in RMM+. The media was changed for fresh RMM+ every two days.  
 
4) Cell passaging: The cells were passaged when they reached 80% 
confluency. For passaging, the flask was washed with Hank’s Balanced Salt 
Solution (HBSS) without calcium and magnesium (Gibco, UK) before 
trypsinising using TrypZean EDTA (Lonza, UK) for 3 to 5 minutes at 37o C. 
Deattachment of the cells was verified using an inverted microscope. This was 
followed by the addition of trypsin inhibitor solution [DMEM:F12, 0.023 U/ml of 
Benzonase (Merck, UK), 0.5 mg/ml of Trypsin inhibitor (Sigma, UK) and 0.91% 
human albumin (Baxter, UK)] and centrifuged for 5 minutes at 900 RPM. The 
cell pellet was resuspended and they were either seeded in a freshly coated 
flask (20,000 per cm2) or frozen.  
 
5) Cell freezing: The SPC04 cells were frozen at a density of 2x106 cells per 
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vial in RMM+ supplemented with 10% DMSO. The vials were frozen at 1oC per 
minute using a Mr Frosty freezing container (Nalgene®) for 24 hours at -80oC 
and then transferred to liquid nitrogen storage. The isopropanol in the Mr Frosty 
container was changed after 4 freezes.  
 
3.2.4.2 Cell differentiation  
 
For differentiation and transduction, the cells were plated at a rate of 15,000 per 
cm2 in freshly laminin-coated 6-well plates (Nunc Delta surface treated; Thermo 
Scientific, UK). After the cells reached around 80% confluency, the cells were 
washed twice with RMM- to remove any traces of growth factors. Subsequently, 
differentiation was triggered by the addition of RMM- supplemented with 10 uM 
of the γ-secretase inhibitor DAPT (Sigma, UK) and 100 nM all-trans-retinoic 
acid (ATRA; Sigma, UK). Additionally, for transduction, a 3.50x105 TU/ml 
concentrated stock of lentiviruses containing MYT1L or non-silencing shRNAmir 
was added to the media. Cells were transduced at this stage because 
preliminary observations showed that there was a higher cell survival rate in 
comparison to infection during undifferentiation. The SPC04 cells were 
incubated in this media for 48 hours prior to replacing it with RMM-. The stage 
at the end of the 48-hour incubation was known as “pre-differentiation”. 
Differentiation day 1 was counted as the day after pre-differentiation had 
finished. The plates were microscopically examined for phenotypic differences 
and the presence of GFP, an indicator of transfection efficiency. The media was 
changed every 2 days till the end of the experiment. Images of transduced cells 
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were taken using Leica DMIL supplied with a Leica camera DFC420C (x10 
objective). 
 
3.2.5 Cell harvesting and RNA extraction 
 
Before harvesting the cells, all the equipment and surfaces were sprayed with 
RNAseZAPTM (Sigma, UK) to eliminate RNAse and avoid RNA degradation. 
The media was carefully removed from the wells and 350 ul of RLT buffer 
(Qiagen, UK) supplemented with 1% β-mercaptoethanol was added to each one 
(Sigma, UK). The cells were mechanically disturbed using a sterile cell scraper. 
The lysate was placed in 2 ml collection tubes (Qiagen, UK) and stored at -80o 
C until RNA extraction took place. 
 
The lysate was homogenized using a QIAshredder spin column (Qiagen, UK) 
placed over a 2 ml collection tube and centrifuged at full-speed for 2 minutes. 
The RNA extraction was performed using the RNeasy® mini kit (Qiagen, UK) 
and followed the same protocol as in Chapter two (2.2.5), including the optional 
on-column DNAse digestion using the RNase-Free DNase Set (Qiagen, UK). 
RNA was eluted in 30 ul of RNase-free water added directly to the membrane of 
the column and centrifuged for 1 minute at 21.1 x g. RNA concentration was 
measured using UV spectrophotometry using the nanospectrophotometer 
NanoDrop 1000 (Thermo Scientific) at 230 nm wavelength. Measuring the ratio 
sample absorbance at 260 nm and 280 nm (260/280) assessed plasmid purity. 
A ratio above 2 was accepted as “pure” for RNA. If the ratio was lower, it could 
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indicate contamination of protein, phenol or other contaminant. The RNA was 
stored at -80oC till required.  
 
3.2.6 Reverse transcription 
 
Reverse transcription was performed in 1 ug of RNA using SuperscriptTM III 
First-Strand Synthesis System for RT-PCR (Invitrogen, UK). The same protocol 
described in Chapter 2 was followed here (2.2.6). The cDNA was then diluted in 
79 ul of RNase free water to have a final concentration of 10 ug/ul. The cDNA 
was stored at -20o C till required.  
 
3.2.7 Quantitative Polymerase Chain Reaction (qPCR) 
 
qPCR was used to validate the microarray data. Unfortunately due to limitations 
in the quantity of RNA, only the expression of nine genes was assessed. These 
analysed genes were selected because of their co-expressed with MYT1L in a 
previous experiment performed by Dr Desrivières (data not shown) that 
intended to show the gene expression profile of SPC04 during differentiation [B-
cell lymphoma/leukemia 11B (BCL11B), Cyclin-dependent kinase 5 activator 1 
(CDK5R1), Junctophilin 3 (JPH3), Myelin transcription factor 1 (MYT1), Neural 
cell adhesion molecule 2 (NCAM2), seizure related 6 homolog (mouse)-like 2 
(SEZ6L2), Synaptosomal-associated protein 25kDa (SNAP25), Synaptosomal-
associated protein 91kDa (SNAP91) and Synapsin 1 (SYN1)]. qPCR 
amplification was performed in a 20 ul volume containing 4 ul of cDNA 
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(10ug/ul), 10 ul of 2X Power SYBR® Green PCR master mix (Applied 
Biosystems, UK), 0.14 uM forward primer (Table 3.3), 0.14 uM primer reverse 
(Table 3.3) and 5.72 ul of RNase free water. All the amplifications were carried 
out in triplicate using the ABI Prism® 7900 HT Sequence detection system 
(Applied Biosystems) under the following thermal cycle: 95oC for 15 minutes 
(initial denaturation); 40 cycles of 95oC for 30 seconds and 59oC for 30 seconds 
(amplification); finishing with 50oC for 10 seconds and 95oC for 15 seconds 
(dissociation stage). The ABI Prism® SDS 2.1 software (Applied Biosystems) 
was used to analyse the specificity and relative quantification of the amplicons. 
The dissociation curve generated by the software was used to determine the 
specificity of the PCR products. The relative quantification curve of the amplicon 
was calculated using the cycle threshold (Ct). The mean Ct values of the 
triplicates were normalized against the mean of the triplicates of the 
housekeeping gene Ribosomal Protein L18 (RLP18) to produce ΔCT 
(ΔCT=CtGene-Ctβ-RPL18). To calculate ΔΔCt, the difference in expression of each 
gene mRNA was compared against undifferentiated and non-infected SPC04 




Table 3.3 qPCR primers  
 
3.2.7.1 In-vitro validation of MYT1L primer specificity  
 
The approximately 20ul of MYT1L products obtained after qPCR amplification 
were separated by electrophoresis on a 1.2% agarose gel made up with 1X 
TBE buffer and supplemented with 1% Ethidium Bromide. The samples were 
mixed with 4 ul of 6X gel loading buffer (Thermo Scientific, UK) and loaded into 
the wells of the gel. Additionally, two wells were used for loading the 1 kilobase 
DNA ladder (250-10,000 bp Sigma, UK). Electrophoresis was performed using 
1X TBE buffer at 120 V for 1.5 hours. The DNA bands obtained in the gel were 
visualized using ultraviolet light. 
 
 
Gene Forward Reverse 
Human RPL18 GAGAGGTGTACCGGCATTTC CTCTGGCACGCTCGAACT 
Human MYT1L TGGAGAGCAACCTGAAGACC ATTCCTCTCACAGCCTGCTT 
Human BCL11B CGAAGATGACCACCTGCTCT GCAAATGTAGCTGGAAGGCT 
Human CDK5R1 CAGTGTGAAGCCTGTCGTGT CTTCATAGCAGCATGGCAAA 
Human JPH3 AATCCTTGCCTGTCGCTCTA GAGCAAGATCACCATGACCA 
Human MYT1 TTCATGATTGCTTTCCGTGA CCGTGTGTCCACCTCTGATT 
Human NCAM2 CAAGACTGACTGGCACCAAC CATACACATGCAGGGCCTTC 
Human SEZ6L2 CACTCCTACAGCCCCATCAC GTCTTGGGGTTCAGATGGAA 
Human SNAP25 CTGTCTTTCCTTCCCTCCCT AGTGACGGGTTTGGCTCTG 
Human SNAP91 AGCGTTACAGGCTCTGCTGT CATTGGTCTCGTTGGTAGCC 
Human SYN1 TCAGACCTTCTACCCCAATCA GTCCTGGAAGTCATGCTGGT 
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3.2.8 Bioinformatic analysis of the putative downstream targets of MYT1L 
 
Additional in-silico analyses were performed on the genes investigated in this 
chapter through qPCR assays. Special attention was given to the genes that 
appeared to be affected when MYT1L was knocked down. This additional 
investigation had the purpose of identifying whether the genes could be direct or 
indirect downstream targets of MYT1L. Firstly, the MYT1L binding site was 
obtained from Matrix Library 9.0 (www.genomatix.de). This sophisticated 
software creates nucleotides or position weight matrices, which are selective 
descriptions of DNA patterns. They are based on nucleotide distributions 
detected after aligning DNA sites where a particular transcription factor is 
known to have a binding site. Then, the programme records each one of the 
nucleotides and their position to determine their frequency there. In this way, 
the binding site for that transcription factor is obtained (Stormo 2000).  
 
In order to determine whether the putative genes analysed by qPCR had a 
MYT1L binding site, ElDorado software in conjunction with MatInspector V 8.06 
software (www.genomatix.de) were used. ElDorado extracted the proximal 
promoter regions following the patterns established by the “Genomatix 
optimized length”. This region was normally defined as 500 bp upstream of the 
first transcription start site (TSS) and 100 bp downstream of the last TSS. In 
case no MYT1L binding sites were found in that region, the parameters were 
increased to cover up to 3000 bp upstream and 300 bp downstream. This 
modification caused an increase in the length of the DNA sequence inspected 
for transcription factor binding sites. ElDorado automatically provided the TSS 
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to all possible transcripts of each gene on the basis of the 5’ cap site. Then, 
MatInspector used the large library of transcription factor binding sites obtained 
through weight matrices to locate which ones could be a match for the DNA 
sequence of the gene of interest (Cartharius, Frech et al. 2005).  
 
3.2.9 RNA labelling and microarray analysis 
 
All the necessary processing of RNA samples for microarray analysis was 
performed by Eric Nasser at the NIHR comprehensive BRC, King’s College 
London. A representative number of samples were re-quantified using Qubit® 
RNA assay kit (Life Technologies, UK) on a Qubit® 2.0 fluorometer following 
the manufacturer’s protocol. Since the sample concentrations matched the ones 
obtained with the nanospectrophotometer, the concentrations obtained with the 
nanospectrophotometer were used for the following step. Additionally, the RNA 
integrity was analysed using Agilent RNA 6000 Nano Kit© (Agilent 
Technologies, Inc; Germany) on an Agilent 2100 Bioanalyzer© (Agilent 
Technologies, Inc). 
 
500 ng of mRNA taken from each of the samples were labelled (biotinylation) 
using TargetAmp™ Nano Labeling Kit (Cambio Ltd.) and the procedure was 
followed according to the manufacturer’s instructions. The biotinylated samples 
were then hybridised into Illumina HumanHT-12 v4 Expression BeadChips 
(Illumina Inc., USA) following the recommendation of the manufacture. The 
BeadChips were scanned using an Illumina Bead array confocal scanner 
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(Illumina Inc.). All samples were done in triplicate using a loading pattern 
determined by the BRC team.  
 
3.2.10 Statistical analysis  
 
3.2.10.1 qPCR quantification  
 
To assess the effect of the MYT1L shRNAmir on the expression of the selected 
genes in the SPC04 cell line, the ΔΔCt values obtained for each gene were 
analysed using a 2-way ANOVA with the factors ‘differentiation stage’ and 
‘treatment’; additionally ‘biological replication’ was used as a covariance. 
Unfortunately, one of the biological replications was composed of only two 
technical replications due to a small quantity of RNA in the third replication (n=5 
samples per treatment and differentiation stage). All results were presented as 
mean± standard error of the mean (S.E.M.). The graphs plotted the relative 
change in expression. This was obtained by elevating 2 to the negative power 
of ΔΔCt (relative fold expression=2-ΔΔCt) (Livak and Schmittgen 2001). 
Additionally, the error bars of the graphs were adjusted to reflect the logarithmic 
scale as described in Chapter 2 (2.2.8). Also, the variance due to the biological 






3.2.10.2 Microarray quantification  
 
The data were analysed by Dr Venu Pullabhatla (NIHR comprehensive BRC, 
King’s College London) using GenomeStudio Data Analysis Software (Illumina). 
The data were processed as follows:  
 
1) Background subtraction  
2) Quantile normalisation 
3) Within a group independent t-test model for identifying differentially 
expressed probes and genes between pre-differentiation and day 7 of 
differentiation. The reference group here was pre-differentiation.  
4) Within treatment independent t-test model for identifying differentially 
expressed probes and genes between treatments on day 7 of differentiation. 
The reference group was non-silencing shRNAmir samples.  
5) Benjamini and Hochberg error correction for multiple testing (FDR). 
 
The differences in gene expression were assessed using the Differential Score, 
which is a transformation of the p-value that provides the directionality (i.e. 
upregulated or downregulated) of the difference between the average signal in 
the tested group in comparison to the reference group. A Differential Score of ± 
13 was considered significant and equivalent to a p-value of 0.05, while a 





3.3.1 SPC04 viral infection and differentiation 
 
The human neural stem/progenitor cell line SPC04 was used as neural 
development model in-vitro. The cells were transduced with either MYT1L or 
non-silencing shRNAmir at the same time as differentiation was being induced. 
This model brought the possibility to test the effects of MYT1L knockdown in the 
transcription of other genes throughout differentiation. The pictures in Figure 3.2 
showed SPC04 cells without infection (a and d) or after infection with either 
non-silencing shRNAmir (b, and e) or MYT1L shRNAmir (c, and f) at two 
different time points of differentiation. The morphology of the cells in all 
conditions changed noticeably within differentiation, specifically in regards to 
neurite elongation. No apparent differences were found between cells treated 






Figure 3.2 This figure illustrates the human neural stem/progenitor cell line SPC04 differentiation 
and transduction with MYT1L shRNA and non-silencing shRNA.  
Each row shows a differentiation stage and each column represents one condition obtained for this 
experiment. The first column contains phase-contrast pictures of normal differentiation occurring without 
transduction. The second and third rows have fluorescent microscope images indicating the GFP 
expression of transduced cells. All photographs were taken using objective x10.  
 
3.3.2 qPCR analysis 
 
The RNA harvested from the transduced SPC04 cells (n=5 per treatment and 
differentiation stage) was firstly used to test the knockdown efficiency of MYT1L 
shRNAmir, which was about a 59% reduction [Figure 3.5 (a)]. Secondly, it was 
used to analyse the differences in the expression of a handful of genes that 
could be possible downstream targets of MYT1L: BCL11B, CDK5R1, JPH3, 
MYT1, NCAM2, SEZ6L2, SNAP25, SNAP91 and SYN. These genes were 
chosen because they were co-expressed with MYT1L when SPC04 cells were 
differentiating in a previous experiment performed by our group (data not 
shown). Figure 3.3 illustrates the dissociation curves of the PCR products 
obtained for abovementioned genes. The single peak yielded during 
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amplification ensured that the PCR product was specific for each gene. Further 
corroboration of the specificity of MYT1L required the amplified PCR product to 
be separated by electrophoresis. The single band observed in this test agreed 
with the size determined by the primer design (Figure 3.4). In addition, the 
samples corresponding to MYT1L knockdown during day 7 of differentiation 
were fainter in comparison to the control, indicating the lower expression of 




 Figure 3.3 
Confirmation of RLP18 (a), MYT1L (b), BCL11B (c), CDK5R1 (d), JPH3 (e), MYT1 (f), 
NCAM2 (g), SEZ6L2 (h), SNAP25 (i), SNAP91 (j), SYN (k) qPCR primer specificity.  
The dissociation curves derived from the qPCR analysis yielded only one peak (i.e., one PCR 
product) per primer pair in each cell line, indicating the specificity of these primers. The plot 
illustrates the derivative data (the rate of change in fluorescence as a function of temperature) 
versus the temperature interval at which fluorescence changes.  
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 Figure 3.4 Agarose electrophoresis patterns of qPCR MYT1L amplification product.  
The pre-differentiation and 7 day differentiation samples for MYT1L knockdown (n=3) and 
control (n=3) were used for electrophoresis. They corresponded to the second technical 
replication. The last and first columns belong to the 1kb DNA ladder used as a marker (1.2% 
agarose in 1xTE buffer, 120 V for 1.5 h).  
 
3.3.3 Validation of MYT1L knockdown in SPC04 cells 
 
The efficiency of MYT1L knockdown in differentiating SPC04 cells was 
assessed through a two-way ANOVA. Although there were no significant 
differences due MYT1L shRNAmir alone (F1,15=0.486, p=0.496), the results 
found a significant interaction between the treatment and differentiation day 
(F1,15=11.322, p=0.004). Specifically, pre-planned pairwise comparisons 
followed by Bonferroni correction demonstrated a significant reduction in the 
expression of MYT1L when the cells were treated with MYT1L shRNAmir 
(p=0.012) in comparison to the cells treated with the control vector at 
differentiation day 7. In terms of relative fold expression, this reduction of 
expression was about 2.42-fold and represented 59% less MYT1L mRNA 
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[Figure 3.5 (a)]. The results also indicated that the expression of MYT1L 
increased as differentiation progressed to day 7 (F1,15=12.209, p=0.003). 
Particularly, control cells had a 3.99-fold increase in MYT1L expression at day 7 
of differentiation in comparison to the pre-differentiation stage, while MYT1L 
mRNA levels remained unchanged during this period in MYT1L shRNAmir-
containing cells [Figure 3.5 (a)].  
 
3.3.4 Possible downstream targets of MYT1L  
 
In brief, after verifying the efficiency of MYT1L shRNAmir to decrease MYT1L 
expression in SPC04 cells after 7 days of differentiation, the expression of a 
small number of genes was assessed to determine whether they were affected 
by this downregulation. Statistical analysis of the data produced through qPCR 
assays showed that the expression of all tested genes (MYT1L, BCL11B, 
CDK5R1, JPH3, MYT1, NCAM2, SEZ6L2, SNAP25, SNAP91 and SYN) 
increased, as expected, throughout differentiation. After 7 days of 
differentiation, the expression of BCL11B, MYT1, JPH3, SYN1 and SNAP25 
was significantly decreased due to the knockdown effect of MYT1L shRNAmir in 
comparison to the control. The remaining tested genes (SNAP91, CDK5R1, 
NCAM2 AND SEZ6L2) were unaffected by the aforementioned construct.  
 
Analysing genes individually, a 2-way ANOVA found a significant effect of 
treatment (F1,14= 14.565, p= 0.002) on the expression of BCL11B. Pairwise 
comparison with Bonferroni correction showed a significant effect of MYT1L 
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shRNAmir in comparison to the control at day 7 of differentiation (p=0.004). In 
terms of relative fold expression, a 3.35-fold decrease was observed during this 
differentiation stage [Figure 3.5 (b)]. No interaction between treatment and 
differentiation was observed (F1,14= 0.922, p= 0.353). Moreover, the results 
demonstrated that the expression of this gene was significantly induced during 
differentiation (F1,14= 52.547, p= 0.000004). Comparisons within groups showed 
that non-silencing treated cells had a 7.72-fold increase, while cells treated with 
MYT1L knockdown only had a 4.17-fold change [Figure 3.5 (b)].  
 
The decreased expression of MYT1L seemed to also have an effect on the 
expression of JPH3. A 2-way ANOVA revealed that there was an interaction 
between treatment and differentiation (F1,15= 5.157, p=0.038). This test was 
followed by pairwise comparison with Bonferroni correction that showed a 
significant decrease in the expression of JPH3 when cells were transduced with 
MYT1L shRNAmir in comparison to the control (p=0.006). Figure 3.5 (c) 
illustrates this decrease, which was about 1.85-fold. The test also revealed a 
significant treatment effect (F1,15= 5.119, p=0.039). Moreover, the expression of 
this gene had a statistically significant increase due to differentiation (F1,15= 
194.006, p=5.50x10-10). When comparing pre-differentiation to 7 days 
differentiation, the cells infected with non-silencing shRNAmir had a 6.81-fold 
increase. On the other hand, cells transduced with MYT1L shRNAmir 




 Figure 3.5 This graph illustrates the relative fold expression of MYT1L (a), BCL11B (b), 
MYT1 (c), JPH3 (d), SYN1 (e) and SNAP25 (f) in SPC04 cells transduced with MYT1L and 
non-silencing shRNAmir at two different points of differentiation.  
The relative expression was obtained by elevating 2 to the negative power of ΔΔCt. The data 
are expressed as mean±adjusted S.E.M. (n=5 per group). *p<0.05 MYT1L knockdown versus 
control pre-planned pairwise comparison followed by Bonferroni correction of ΔΔCt values. 
 
Another gene that was disrupted when MYT1L was knocked down is a family 
member of MTY1L called MYT1. The expression of this gene due to treatment 
showed to be statistically different when analysed using a 2-way ANOVA (F1,15= 
8.187, p= 0.012). During day 7 of differentiation, pre-planned pairwise 
comparison followed by Bonferroni correction showed a significant reduction in 
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the expression of MYT1 in cells transduced with MYT1L shRNAmir when 
compared to the control (p=0.047). This was a 2.74-fold reduction in MYT1L 
shRNAmir treated cells in comparison to the non-silencing construct [Figure 3.5 
(d)]. The test also indicated no interaction between factors (F1,15= 0.041, 
p=0.842). However, similar to the other genes, the expression of MYT1 
changed significantly from pre-differentiation to 7 days differentiation (F1,15= 
118.619, p=1.607x10-8). In terms of relative fold expression, the control cells 
underwent an increase of 31.05 times, while cells with reduced MYT1L 
expression had a 19.30 fold change [Figure 3.5 (d)]. 
 
The expression of SYN1 was also compromised when MYT1L was knocked 
down, as indicated by a 2-way ANOVA (F1,15= 8.112, p=0.012). A significant 
decrease in SYN1 expression was observed during day 7 of differentiation in 
comparison to non-silencing construct when pre-planned pairwise comparison 
with Bonferroni correction was employed (p=0.026). The difference was a 1.60-
fold reduction in SPC04 treated with MYT1L shRNAmir in comparison to the 
control [Figure 3.5 (e)]. Although there was no significant interaction between 
treatment and differentiation (F1,15= 0.426, p=0.524), a significant change in 
expression was observed along differentiation (F1,15= 100.130, p=4.954x10-8). 
Figure 3.5 (e) illustrates this change, which accounted for a 4.29-fold increase 
in cells infected with the non-silencing vector and a 3.55-fold increase for cells 
infected with MYT1L shRNAmir.  
 
In case of the expression of SNAP25, a 2-way ANOVA showed that the MYT1L 
shRNAmir had a knockdown effect on the expression of this gene (F1,15= 4.668, 
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p=0.047). A pairwise comparison followed by Bonferroni correction 
demonstrated a significant decrease of SNAP25 mRNA when MYT1L was 
decreased (p=0.03). This reduction was equivalent to a 1.61-fold change, as 
seen in Figure 3.5 (f). No interaction between factors was found (F1,15= 2.028, 
p=0.175). However, similar to the expression of the aforementioned genes, the 
expression of SNAP25 did significantly increase during differentiation (F1,15= 
85.006, p=1.439x10-7). This change within treatment was about 3.73-fold in 
control cells and 2.55-fold in cells with reduced MYT1L expression [Figure 3.5 
(f)].  
 
Analysing the expression of SNAP91 with a 2-way ANOVA also indicated it had 
been affected during differentiation (F1,15= 9.785, p=0.007). A 5.92-fold increase 
was observed when SPC04 cells were treated with non-silencing shRNAmir, 
while a more modest 1.80-fold change was seen when they were treated with 
MYT1L shRNAmir. Although a decrease of 2.85 fold in SNAP91 expression 
between treatments was observed on day 7 of differentiation [Figure 3.6 (a)], 
the result failed to be significant due to treatment (F1,15= 1.649, p=0.219) or 
interaction (F1,15= 3.656, p=0.075). 
 
Similar results were seen when the expression of CDK5R1 was analysed with a 
2-way ANOVA. Both treatments increased the expression of this gene during 
differentiation (F1,15= 23.479, p=0.0002) without a significant effect of treatment  
(F1,15= 0.202, p=0.659) or an interaction between factors (F1,15= 0.003, 
p=0.960). In terms of fold expression, there was a 1.44-fold change for cells 
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treated with the control vector and a 1.40-fold change for cells that underwent 
MYT1L knockdown [Figure 3.6 (b)].  
 
Figure 3.6 This graph illustrates the relative fold expression of SNAP91 (a) and CDK5R1 
(b) in SPC04 cells transduced with MYT1L and non-silencing shRNAmir at two different 
points of differentiation.  
The relative expression was obtained by elevating 2 to the negative power of ΔΔCt. The data 
are expressed as mean±S.E.M. (n=5 per group). 
 
NCAM2 expression also had a significant increase during differentiation, as 
reported by a 2-way ANOVA (F1,15= 141.400, p=4.890x10-9). This increase due 
to treatment was not significant (F1,15= 2.552, p=0.131) nor was the interaction 
between this and differentiation (F1,15= 0.16, p=0.906). Both groups had a 
similar within-group increase in fold expression when comparing pre-
differentiation to 7 days differentiation [Figure 3.6 (c)]. The expression of 
NCAM2 increased 10.72 times in cells transduced with non-silencing shRNAmir 
and an 11.90-fold change for cells which were infected with MYT1L shRNAmir.  
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When analysing the expression of SEZ6L2, a significant effect attributed to 
differentiation was observed in a 2-way ANOVA (F1,15= 194.006, p=4.837x10-
14), both without a treatment effect (F1,15= 2.038, p=0.174) and interaction 
between factors (F1,15= 0.171, p=0.685). The SEZ6L2 expression in both, the 
control and the MYT1L knockdown samples, had an increase in fold expression 
of 5.65 and 5.23 respectively [Figure 3.6 (d)].  
 
3.3.5 Bioinformatic analysis of putative MYT1L target genes 
 
3.3.5.1 Identification of MYT1L binding site 
 
In order to determine whether the genes that were affected by the MYT1L 
shRNAmir could be direct targets of this transcription factor, in-silico analyses 
were performed. The first one, Matrix Library 9.0, was used to determine the 
binding site for MYT1L. Figure 3.7 shows the graphical representations of the 
results obtained from aligning the MYT1L binding site weight matrices. Figure 
3.7 (a) shows the degree of conservation of the nucleotides at each position 
through varying stack height. The red letters indicate that those nucleotides 
were highly conserved at each position across the matrices; the capital red 
letters denote the core sequence of the binding site and were used by 
MatInspector to predict binding sites. Figure 3.7 (b) provided a more precise 
description of the frequency of the nucleotides yielded by the matrix alignment 




Additional information provided by the MYT1L weight matrices indicated that it 
matched approximately 36.7% of the promoters present in vertebrates (human, 
rat and mouse). It has 0.82 random matches for every 1000 bp in the human 
genome and only 0.66 for every 1000 bp in the promoter sequences.  
 
 
Figure 3.7 Graphical representation of MYT1L binding site.  
Figure (a) illustrates the results of the MYT1L binding site weight matrix. The single nucleotides 
(A, C, G, T) are written when its frequency is above 50% and at least twice as high as the 
second most frequent nucleotide. Letter “Y” represents when 2 nucleotides occur in more than 
75% of the underlying sequences but none of them is present in less than 50%. The letter “n” 
represents all other distributions. Figure (b) is a graphical illustration of the weight matrix, 
illustrating the nucleotides observed at each position. The height of each stack of nucleotides 
represents its conservation at that position. The height of the letter is a reflection of its 





3.3.5.2 Identification of MYT1L putative downstream targets  
 
Having found a MYT1L-specific binding matrix in the Matrix Library 9.0, we 
matched it against the promoter regions of the genes tested using qPCR, giving 
special attention to the genes selected above whose expression depended on 
MYT1L. The results yielded by the MatInspector software indicated putative 
MYT1L binding sites in BCL11B, CDK5R1, JPH3, MYT1, NCAM2, SEZ6L2 
SNAP25, SNAP91 and SYN1 (Figure 3.8) within 3000 bp upstream and 1000 
bp downstream of the first TSS. The indicated core similarity is based on how 
similar the core sequence of the transcription factor binding site and its potential 
binding site located in the promoter region of the analysed gene are; however, 
the matrix similarity is more important since it takes into account all the bases 
over the whole matrix length. A perfect match for any of the previous similarity 
scores is 1. The core and matrix similarity values for each one of the potential 
MYT1L binding sites in the analysed genes was higher than 0.8, indicating a 










Table 3.4 Location of MYT1L binding sites within the promoter region of putative target genes 
using MatInspector.  
Accession no. indicates the particular transcript where a binding site was found. The start and end 
positions are relative to upstream and downstream nucleotides from the TSS used to localize MYT1L 













BCL11B GXP_121128 340 352 0.818 0.927 tgaaAGATcaact 
CDK5R1 GXP_122933 54 66 0.909 0.95 ggaaAGCTgtccc 
JPH3 GXP_107484 418 430 1 0.986 ggaaAGTTgcctg 
MYT1 GXP_3671835 456 468 0.909 0.95 ggaaAGCTtggtg 
MYT1 GXP_3671836 1419 1431 0.818 0.927 tgaaAGATcacat 
NCAM2 GXP_196197 717 729 1 0.931 ggacAGTTtcaaa 
NCAM2 GXP_1819684 6 18 1 0.967 agaaAGTTaagtg 
NCAM2 GXP_1819684 393 405 1 1 tgaaAGTTttgta 
NCAM2 GXP_2055710 191 203 1 0.958 tgatAGTTcatgt 
NCAM2 GXP_3185310 291 303 0.909 0.964 tgaaAGCTggcca 
SEZ6L2 GXP_91352 328 340 1 0.945 agagAGTTtcctt 
SEZ6L2 GXP_3662955 334 346 1 0.945 ggagAGTTgtcgc 
SNAP25 GXP_153694 217 229 1 0.945 ggatAGTTtaaac 
SNAP25 GXP_153695 1019 1031 1 0.945 ggatAGTTtaaac 
SNAP25 GXP_3183905 466 478 0.909 0.922 tgagAGCTtatat 
SNAP91 GXP_1502044 416 428 1 0.925 agagAGTTaaaaa 
SNAP91 GXP_1826254 50 62 0.818 0.927 tgaaAGGTgctag 
SNAP91 GXP_3206048 97 109 1 0.967 agaaAGTTactct 
SNAP91 GXP_3206048 332 344 1 0.945 agagAGTTttact 
SNAP91 GXP_3206050 1 13 0.818 0.927 tgaaAGGTttact 
SNAP91 GXP_3206050 183 195 1 1 tgaaAGTTtaatg 
SNAP91 GXP_3206051 401 413 1 0.931 ggacAGTTgttac 
SNAP91 GXP_3678501 121 133 0.909 0.95 ggaaAGCTcacaa 
SYN1 GXP_261907 440 452 1 0.931 agacAGTTtgggg 




The parameters to locate a MYT1L binding site in BCL11B and SYN1 were 
adjusted since they were outside the “Genomatix optimized length”. Both genes 
had only one possible promoter region. While the gene BCL11B had only one 
MYT1L binding site [antisense strand over 2500 bp upstream from the TSS; 
Figure 3.8 (a) and Table 3.4]; SYN1 had two [both on the sense strand, one 
within 1200 bp and the other one less than 2500 bp upstream from the TSS; 
Figure 3.8 (d) and Table 3.4]. As for MYT1, there was a MYT1L binding site 
present in two out of the five possible promoter regions for this gene. The first 
one was located less than 50 bp upstream on the antisense strand, while the 
second was over 800 bp downstream from the TSS [Figure 3.8 (b) and Table 
3.4]. In the case of JPH3, it had a MYT1L binding site in only one of the five 
possible promoter regions identified for this gene [less than 100 bp upstream of 
the TSS; Figure 3.8 (c) and Table 3.4]. Lastly, there were seven possible 
promoter sites for SNAP25 and there was a MYT1L binding site in three of 
them. For two of them, the binding sites were in the upstream region, one on 
the sense strand (within 300 bp from the TSS) and one on the antisense strand 
(less than 150 bp from the TSS). The third one was around 1550 bp 
downstream of the TSS on the sense strand [Figure 3.8 (e) and Table 3.4].  
 
The results for the remaining genes (CDK5R1, NCAM2, SEZ6L2 and SNAP91), 
which were not affected by fluctuations in MYT1L expression, were not reported 
in detail, but the main features of their MYT1L binding sites were written in 




Figure 3.8 Graphical representation of the location of MYT1L binding site in BCL11B (a), 
MYT1 (b), JPH3·(c), SYN1 (d) and SNAP25 (e).  
The pink semi-ovals represent the binding sites for the MYT1 family; the MYT1L binding sites 




In the quest to expand the analyses described above and identify a more 
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comprehensive list of possible downstream targets of MYT1L, microarray 
analyses were performed to compare the gene expression profiles of SPC04 
cells infected with MYT1L or non-silencing shRNAmir harvested at the pre-
differentiation (n=3 per treatment) and day 7 differentiation (n=3 per treatment) 
stages. Unfortunately, when the expression was compared within groups 
between pre-differentiation and 7 days differentiation, no statistically significant 
differences were found (data not shown). Moreover, the statistical analysis of 
the microarray data did not show any differences when comparing the gene 
profile expression of SPC04 infected with either MYT1L or non-silencing 
shRNAmir during day 7 of differentiation. The expression of any of the genes in 
the aforementioned comparisons led to a Differential Score ≥ 13. The entire 
dataset is not shown in this thesis, only the results obtained when comparing 
gene expression of the neurodevelopmental genes previously tested with qPCR 
at day 7 of differentiation (non-silencing versus MYT1l shRNAmir) (Table 3.5). It 
is worth mentioning that the directionality of the effect seen across technical 
replicates (n=3 for each condition and time point) is inconsistent, which is 
reflected in the large standard deviations calculated for the expression of each 
gene. This could be a reason for the lack of significant differences in gene 








Table 3.5 Differences in gene expression between SPC04 cells treated with non-silencing 
shRNAmir and MYT1L shRNAmir harvested at day 7 of differentiation (n=3 per treatment).  
The Differential Score is a transformation of the p-value providing the directionality of the p-
value. It is based on the difference between the average signal of MYT1L shRNAmir versus 
non-silencing shRNAmir. A value of ± 13 (equivalent to p-value 0.05)  
 Non Silencing shRNAmir 
 














MYT1L	   8.3	   12.912	   5.1	   17.437	   0	  
BCL11B	   -­‐1.2	   6.551	   -­‐2.4	   5.987	   0	  
CDK5R1	   1164.2	   381.941	   958.2	   64.412	   -­‐0.001	  
JPH3	   0.7	   3.365	   -­‐17	   4.296	   -­‐0.001	  
MYT1	   199.8	   327.315	   42.7	   28.328	   -­‐0.001	  
NCAM2	   -­‐2.2	   10.264	   -­‐0.7	   7.445	   0.001	  
SEZ6L2	   44.5	   42.884	   31.7	   18.181	   0	  
SNAP25	   775.8	   637.544	   409.4	   159.661	   -­‐0.001	  
SNAP91	   39	   26.075	   5.7	   4.055	   -­‐0.001	  




The information acquired in this chapter by knocking down MYT1L in the stem 
cell line SPC04 and the bioinformatic data retrieved from MatInspetor 
(Genomatix) have provided valuable evidence about the downstream targets of 
this transcription factor. Even though the analysis of the microarrays was 
inconclusive, the qPCR assays found that BCL11B, JPH3, MYT1, SNAP25 and 
SYN1 had decreased expression due to MYT1L shRNAmir after 7 days of 
differentiation. Further in-silico analyses of the promoter regions of these genes 
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revealed they all have a binding site for MYT1L, suggesting that they could all 
be direct targets of this transcription factor.   
 
3.4.1 Possible MYT1L downstream targets according to qPCR 
 
Due to the unfortunate results obtained through microarrays, this chapter had to 
rely only on the results obtained by qPCR. Firstly, these results validated the 
knockdown efficiency of the MYT1L shRNAmir in the human neural 
stem/progenitor cell line SPC04 at day 7 of differentiation. MYT1L expression 
observed in these experiments was very low during the undifferentiated and 
pre-differentiated stages, gradually increasing as differentiation progressed. At 
day 7 of differentiation, there was around 59% less MYT1L mRNA present in 
the SPC04 cells transduced with MYT1L shRNAmir in comparison to cells 
infected with the control vector. As a consequence, this reduction in MYT1L 
expression was significantly associated with decreased expression of five out of 
the nine genes tested in this experiment during day 7 of differentiation: BCL11B, 
MYT1, JPH3, SYN1 and SNAP25. The nine genes had been selected on the 
basis of being co-expressed along with MYT1L during the differentiation of the 
SPC04 cell line in a previous experiment (data not shown).  
 
In order to determine whether these genes could be directly affected by the 
expression of MYT1L, their promoter regions were matched against the MYT1L 
binding site. Interestingly, seven of them (CDK5R1, JPH3, MYT1, NCAM2, 
SEZ6L2, SNAP25 and SNAP91) had a MYT1L binding site within 1000 bp 
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upstream of a TSS, while BCL11B and SYN1 that had one within 2500 bp 
upstream. Still, it has been reported that both distal and proximal transcription 
factor-binding sites can promote transcription (Koudritsky and Domany 2008).  
 
It is worth mentioning that the MatInspector software, which provided the 
previous in-silico results, has been optimized to reduce the number of false 
positives. Additionally, the MYT1L binding site obtained by the programme was 
quite specific. Randomly, it only matched 0.66 for every 1000 bp of the 
promoter region. Nevertheless, this software only infers the binding potential of 
a transcription factor, but not the functionality of such site. The functionality can 
only be assessed through an in-vitro experiment (Cartharius, Frech et al. 2005). 
The results yielded by the qPCR assay performed in this chapter only supported 
a co-expression between MYT1L and BCL11B, MYT1, JPH3, SYN1 and 
SNAP25. This outcome possibly suggests that the MYT1L binding site located 
on the aforementioned genes is functional, making those genes downstream 
targets of MYT1L.  
 
Among the genes disrupted by MYT1L expression, MYT1 and BCL11B are also 
transcription factors. The former belongs to the same CCHHC zinc finger family 
as MYT1L (Jiang, Yu et al. 1996, Kim, Armstrong et al. 1997). It is highly 
expressed during brain development in neural progenitor cells (Kim, Armstrong 
et al. 1997). It has potentially been involved in oligodendrocytes differentiation 
by regulating the expression of myelin specific genes (Nielsen, Berndt et al. 
2004). Similarly, BCL11B is increasingly expressed in the brain during 
development (Leid, Ishmael et al. 2004). It has been linked to the Brain-derived 
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neurotrophic factor (BDNF) signalling pathway (Tang, Di Lena et al. 2011), 
critical for neuronal differentiation and survival (Bekinschtein, Cammarota et al. 
2008). Specifically, Arlotta and collaborators (Arlotta, Molyneaux et al. 2008) 
confirmed that BCL11B is an important factor in the differentiation of striatal 
medium spiny neurons and the development of axonal projections of the 
corticospinal motor neurons.  
 
The expression of MYT1L seemed to have an effect on two genes related to 
synaptic vesicles and the release of neurotransmitters: SNAP25 and SYN1. The 
former codes for presynaptic plasma membrane protein which regulates vesicle 
trafficking (Bark, Hahn et al. 1995); at synaptic level, SNAP25 is important for 
neurotransmitter release evoked by action potentials (Washbourne, Thompson 
et al. 2002) and during development, it helps the growth cone to extend by 
modulating vesicle fusion, which promotes axonal growth (Osen-Sand, Staple et 
al. 1996). On the other hand, SYN1 codes for a neuron-specific phosphoprotein 
present at nerve terminals (De Camilli, Harris et al. 1983, Huttner, Schiebler et 
al. 1983), which also regulates neurotransmitter release by controlling the 
anchoring of synaptic vesicles to the cytoskeleton (Moretto, de Mattos-Dutra et 
al. 1999) and clustering them in a pool near the synaptic terminal (Greengard, 
Valtorta et al. 1993). One study showed that during neuron development in a 
Syn1 knockout mouse, the formation of synapses occurred at a slower rate and 
the neuron elongation was shorter and less branched (Ferreira, Chin et al. 
1998). 
 
Lastly, MYT1L expression also modified JPH3 expression. This gene belongs to 
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a family of junctional membrane complexes between the plasma membrane and 
the endoplasmic reticulum. This family is present in excitable cells and is 
believed to participate in the foundation of crosstalk between ion channels in 
order to regulate calcium influx (Nishi, Mizushima et al. 2000, Takeshima, 
Komazaki et al. 2000), a process which is important for synaptic plasticity in the 
neurons (Bardo, Cavazzini et al. 2006, Garbino, van Oort et al. 2009). 
 
3.4.2 Microarray results  
 
Microarrays represent a good approaches to acquiring gene expression profiles 
(Hoheisel 2006). Unfortunately, in this study there were discrepancies in the 
results obtained through the microarray and qPCR analyses. According to the 
microarray data, there were no significant differences between the genes 
expressed by SCP04 cells transduced with non-silencing or MYT1L shRNAmirs 
on either pre-differentiation or 7 days differentiation. Additionally, no differences 
were found within group when the expression was compared between the two 
time points of differentiation. The lack of differences between the genes 
expressed during pre-differentiation and 7 days differentiation is incongruent 
with the phenotypic changes observed during differentiation (Gurok, Steinhoff et 
al. 2004).  
 
The results obtained through qPCR assay and the incongruence observed in 
directionality among technical replications during the analysis of microarray data 
suggested possible technical problems (e.g. with the processing of the RNAs for 
Chapter 3 
146 
the hybridisations, the chip itself or its loading). Irizarry and collaborators 
(Irizarry, Warren et al. 2005) noted in a multiple laboratory comparison of 
microarray platforms that the variability observed between microarray results 
among different laboratories was likely due to the laboratory techniques. RNA 
samples require the synthesis of double stranded cDNA and biotin labelling 
before being hybridized into the microarray chips. This process can be a tedious 
and time-consuming protocol making it prone to human error. Any error in the 
protocol or mislabelling can lead to inconclusive results (Knight 2001). Since 
this part of the experiment was not directly performed in our laboratory, it is only 
possible to speculate on this being the possible cause for the failure of the 
experiment.  
 
Another possible reason why the microarray analysis did not perform as 
excepted is the RNA quality. Although RNA was carefully extracted, underwent 
quality control and all possible measures were taken to avoid its degradation 
throughout the process performed by us, it is known to be less stable than DNA 
(Kim, Zakharkin et al. 2010). One of the problems encountered when dealing 
with low quality RNA is the degree of degradation of the samples between 
different time points, which could lead to differences in expression (Gingrich, 
Rubio et al. 2006). In this experiment, all samples were always kept in optimal 
storage condition and samples belonging to each time point were extracted and 
stored simultaneously. If degradation occurred within storage, then the variance 
should be similar between all the samples belonging to a specific time point of 
differentiation. Gingrich and collaborators (Gingrich, Rubio et al. 2006) have 
noted that using degraded RNA in microarrays can compromise the detection of 
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genes, especially those whose expression is low. By contrast, qPCR has been 
reported of being capable of amplifying degraded RNA such as the RNA coming 
from formalin fixed and paraffin-embedded tissue (Specht, Richter et al. 2001).  
 
Even though microarray technology has matured in the past decades and 
standardized protocols have been implemented, it still has its limitations. Among 
these limitations is its lack of consistency in data extracted from different 
platforms or different laboratories, especially with low expressed genes, as 
confirmed by qPCR validation (Irizarry, Warren et al. 2005, Liu, Kuo et al. 2012). 
Moreover, the data acquired through microarrays are still subject to qPCR 
validation (Larkin, Frank et al. 2005). Whilst qPCR has shown to produce more 
reliable, powerful and replicable data (Bustin and Nolan 2004, Bahat, Kedmi et 
al. 2013), there is still variability which could cause issues and it has been 
determined that it largely depends on technical replications (Taylor, Wakem et 
al. 2010). Optimizing the reaction has been useful in homogenising the results 
and reducing variability. The two most important measures which should be 
taken are avoiding the amplification of genomic DNA by removing it when RNA 
is extracted and using optimal primer design (Sinicropi, Cronin et al. 2007). In 
this study, both were followed. One extra step was undetaken while extracting 
the RNA to remove genomic DNA. In addition, the optimal primer design was 
corroborated by the analysis of the dissociation curves, which provided 





3.4.3 Conclusions and limitations of this study  
 
Dysregulations in the sequence and expression of MYT1L have been linked to 
some neurodevelopmental disorders such as major depression disorder (Wang, 
Zeng et al. 2010), schizophrenia (Vrijenhoek, Buizer-Voskamp et al. 2008, 
Addington and Rapoport 2009, Lee, Mattai et al. 2012), autism (Meyer, Axelsen 
et al. 2012, Rio, Royer et al. 2012) and mental retardation (Gruchy, Jacquemont 
et al. 2007, Zou, Van Dyke et al. 2007, Bonaglia, Giorda et al. 2008, Stevens, 
van Ravenswaaij-Arts et al. 2011). The pathology of these disorders appears to 
be caused by impairments, which arise during the course of brain development 
(Van Loo and Martens 2007). Additionally, information obtained from in-vitro 
trials has demonstrated the importance of MYT1L expression for the 
development of functional neurons. Although, it can be inferred that the 
appropriate expression of MYT1L is important for neurogenesis, the precise 
genetic pathway in which this transcription factor is active during brain 
development remains largely unknown. The use of human/progenitor stem cells 
to model neural differentiation along with gene silencing techniques has brought 
about the possibility of studying at least one important part of development: cell 
differentiation. The results from this study have enriched the knowledge of the 
possible downstream targets of MYT1L during brain development. According to 
the results of Kim and collaborators (Kim, Armstrong et al. 1997), the 
expression of Myt1l in the rat started around embryonic day 13-15. 
Coincidentally in the rat, neurogenesis in some brain structures such as the 
cranial sensory and vestibular nuclei begin around the same day and there is no 
record of neurogenesis starting earlier than embryonic day 12 (Finlay and 
Darlington 1995, Workman, Charvet et al. 2013). The fact that it continues to 
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express and reaches its maximum expression right before birth coincides with 
the formation of synaptic connections and the peak in neurogenesis for most 
areas of brain (Workman, Charvet et al. 2013). This overlap, coupled with 
evidence indicating the importance of Myt1l for neuronal maturation, could 
possibly indicate that this transcription factor is responsible, to some degree, for 
the induction of neurogenesis and synaptogenesis in the rat and possibly in the 
human. The fact that all the genes that appeared to be targets of MYT1L in this 
study, apart from JPH3, are known to be involved in brain development further 
supports this hypothesis. In the particular case of JPH3, it might not be involved 
directly in the development of the neuron but, it is believed to play a role in the 
formation of the junctional membrane complex (Holmes, O'Hearn et al. 2001). 
This complex is thought to anchor the plasma membrane and the endoplasmic 
reticulum to connect intracellular and extracellular channels to allow the release 
of intracellular calcium required for cell signalling (Nishi, Sakagami et al. 2003, 
Garbino, van Oort et al. 2009). This mechanism is likely to be present in some 
forms of synaptic plasticity (Rose and Konnerth 2001, Kakizawa, Kishimoto et 
al. 2007), which may contribute to the reorganization of neuronal networks 
(Johnston 2009).  
 
The results obtained in this chapter should be taken with caution. First, SPC04 
is an immortalized cell line derived from week 12 of foetal development and it is 
possible that the genes expressed by this line differ from the mature in-vivo 
spinal cord cells. Another important limitation was the sample size. Taylor and 
collaborators (Taylor, Wakem et al. 2010) have suggested that having three 
biological replications consisting of two technical reapplications each is enough 
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to mitigate the variability. In order for this study to fulfil these criteria, an 
additional biological replication would be required to decrease the variance and 
possibly increase the significance of the results.  
 
A further limitation of this study was the lack of results obtained through 
microarray. The genes that were analysed through qPCR were very limited and 
a global expression profile could have broadened the MYT1L downstream 
targets. The study of MYT1L downstream targets could be further expanded 
and enriched by repeating the microarray experiment and the production of a 
MYT1L antibody. The former could provide evidence of other possible MYT1L 
downstream targets, while the latter would allow for additional tests such as 
chromatin immunoprecipitation and DNA sequencing (ChIP-sequencing). ChIP-
sequencing has the goal of identifying functional elements in the DNA such as 
transcription factors (Yip, Cheng et al. 2012). In this type of experiment, the 
proteins that bind the DNA are cross-linked to their binding site and an antibody 
against the protein of interest recognizes the site of interaction. This site is 
isolated by immunoprecipitation and a readout of the binding site can be 
produced to identify the gene it belonged to (Valouev, Johnson et al. 2008). 
Finally, the study also has limitations due to the specificity of the antibody and 
might have been unable to detect transient binding of transcription factors 
(Tang, Di Lena et al. 2011). If the study presented in this chapter could be 
complemented with consistent data from microarray experiments and ChIP-
sequencing, more robust results could be achieved to unravel the transcriptional 




Chapter 4 : Behavioural characterization of Myt1l knockdown in 




As previously mentioned in Chapter 1, the discovery of the endogenous RNAi 
pathway was followed by the development of new experimental techniques to 
modulate the activity of a gene (Hommel, Sears et al. 2003, Zamore and Haley 
2005). This alteration of gene expression has opened new possibilities not only 
for the study of gene function but also for the therapeutic applications it offers 
(Blomer, Naldini et al. 1997). An indispensable element to modify genetic 
material in-vitro and in-vivo is a reliable vector capable of efficiently integrating 
into the genome of the host cell (Amado and Chen 1999). Lentiviral vectors 
have been proven to achieve this task in cell culture, as shown in Chapter 2 and 
3, but they also may be used for in-vivo experiments (Baekelandt, Claeys et al. 
2002). Neuroscience research has benefited from these approaches to widen 
our understanding of the role of genes in neurobiological processes (Genc, 
Koroglu et al. 2004). 
 
4.1.1 Lentivirus mediated gene delivery in the mouse brain by stereotactic 
surgery  
 
Producing animal models is essential to studying the function of a gene. These 
models provide an insight into the physical and behavioural consequences of 
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modifying gene expression (Heldt and Ressler 2009). The production of 
transgenic animals using conventional approaches such as gene knockout 
remains expensive and time consuming (Jaenisch 1988). In the particular case 
of reducing the expression of a gene, an alternative method uses viral vectors 
containing small interfering RNAs capable of integrating into the RNAi pathway 
of the host cells as described in Chapter 1 (Hommel, Sears et al. 2003). One 
type of vector commonly employed in animal work because of their long-term 
gene expression is the lentiviral vector (Baekelandt, Claeys et al. 2002). These 
vectors offer great advantages over other types of vectors due to their ability to 
infect proliferating and non-proliferating cells; they are replication defective to 
avoid spread of infection, do not trigger a humoral response from the host 
animal (Naldini, Blömer et al. 1996); and they integrate complex expression 
cassettes like the shRNA into the host genome (Jakobsson and Lundberg 
2006). The delivery of these vectors into the brain is through stereotactic 
surgery. In the past, this technique has been a valuable tool to create lesions to 
mimic diseases, insert probes for microdialysis or implant electrodes to 
stimulate or record brain activity (Messier, Émond et al. 1999). In recent years, 
this surgery has been helpful for virus mediated gene delivery, allowing the 
manipulation of gene expression within a particular region of the brain (Cetin, 
Komai et al. 2007). Additionally, the surgery can be performed at any stage of 
the life of an organism, giving the opportunity to study the impact of gene 
expression at particular time points (Kuroda, Kutner et al. 2008).  
 
Rodents have been extensively used as models for gene modification because 
of the number of pure genetic lines commercially available (Messier, Émond et 
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al. 1999). In particularly the mouse has been employed because 99% of the 
human genes have a mouse homolog gene (Ahmad-Annuar, Tabrizi et al. 2003, 
Austin, Battey et al. 2004). Furthermore, when the gene expression of the brain 
was compared between those two species, it was found that there is a high 
correlation between gene expression profiles in human and mouse (Strand, 
Aragaki et al. 2007). Moreover, humans and mouse have similar physiology and 
mice are prone to some of the human pathologies (Rosenthal and Brown 2007). 
Although these are good arguments in favour of the mouse as a model, it is 
important to consider that the complexity and size of the brain in humans and 
mice is quite different and mice do not have the same higher cerebral functions 
as humans (Seong, Seasholtz et al. 2002).  
 
4.1.2 Using a mouse model to study Myt1l function 
 
Taking advantage of the techniques described above, it is possible to 
investigate the function of Myt1l in the mouse brain. As previously mentioned in 
Chapter 1, the expression of Myt1l remains at detectable levels in the adult 
brain of both human and mouse. Interestingly, as observed in Figure 4.1, there 
is an increased expression of Myt1l in the dorsal hippocampus in comparison to 
other regions, especially in the pyramidal and oriens cell layers of the dorsal 
hippocampus. It is well-known that the hippocampus plays a crucial role in 
memory and learning (Gilbert and Kesner 2003), in particular the dorsal 
hippocampus is involved in spatial learning (Moser, Moser et al. 1993). 
However, the hippocampus also has been associated with emotional 
behaviours like anxiety (Gray and McNaughton 2000, Rezayat, Roohbakhsh et 
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al. 2005). The observation of increased Myt1l expression in the dorsal 
hippocampus during adulthood might indicate that this gene is required in this 
area for learning and memory, and emotional behaviour. Additionally, genome 
studies have associated the following mental disorders with Myt1l: 
schizophrenia (Vrijenhoek, Buizer-Voskamp et al. 2008, Addington and 
Rapoport 2009, Lee, Mattai et al. 2012, Li, Wang et al. 2012), major depression 
disorder (Wang, Zeng et al. 2010), autism (Garbett, Ebert et al. 2008, Meyer, 
Axelsen et al. 2012) and mental retardation (Gruchy, Jacquemont et al. 2007, 
Bonaglia, Giorda et al. 2008, Stevens, van Ravenswaaij-Arts et al. 2011); and 
these disorders all have been related, at least in part, to neuropathological 
changes in the hippocampus (Huttenlocher 1991, Raymond, Bauman et al. 
1995, Lodge and Grace 2007, Belmaker and Agam 2008). Owing to these 
reasons,  it is reasonable to assess the behavioural outputs resulting from 
decreasing Myt1l expression in this region.  
 
The aforementioned diseases are very different from one another and they are 
thought to be caused by a diverse set of genes (Chelly, Khelfaoui et al. 2006, 
van Os, Rutten et al. 2008, Wall, Esteban et al. 2009, Bosker, Hartman et al. 
2011). Since the function of Myt1l in the adult brain remains largely unknown, 
this chapter focused on the effects Myt1l has on certain behavioural patterns 
instead of trying to model the psychiatric disorders linked to Myt1l. The 
behaviours of interest for this chapter were learning and memory, anxiety, and 
social interaction. These behaviours were selected based on a careful review of 





Figure 4.1 Expression of Myt1l in the mouse inbred strain C57BL/6J (Postnatal day 56).  
All images were obtained from the Allen Mouse Brain Atlas. (a) In situ hybridization (ISH) for Myt1l mRNA 
in a sagittal brain section. (b) This image is another form of representing the gene expression obtained by 
ISH. Each ISH image undergoes a detection algorithm to create a high-resolution greyscale image to 
identify pixels that correspond to gene expression. The intensity of the signal is colour-coded, with blue 
representing the lowest gene expression and red the highest (Lein, Hawrylycz et al. 2007). 
 
4.1.3 Aims of the study 
 
Recent evidence has named Myt1l as a putative candidate gene for a wide 
range of psychiatric disorders (schizophrenia, autism, major depressive disorder 
and mental retardation) that might suggest its importance during adulthood. The 
aim of this chapter was to investigate the role Myt1l plays in the dorsal 
hippocampus of the adult mouse by selectively knocking it down using 
shRNAmir lentiviral vectors. The dorsal hippocampus was selected because of 
its high Myt1l expression, possibly suggesting a role of this gene in memory and 
learning, or emotional behaviours that have been associated with this brain 
region. Moreover, it was observed that the psychiatric diseases linked to MYT1L 
presented some neuropathological changes in the hippocampus, probably 
indicating the relevance of this structure to each one of those pathologies. 
Although, those diseases appeared to be neurodevelopmental, it is unclear 
whether the reduced expression of MYT1L in the adult could induce some of the 
symptoms presented in the disorders. Therefore, it was decided to use adult 
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mice in this project, since creating an adult model represented a more cost-
efficient approach.  After surgery and in order to elucidate the possible effect of 
knocking down this gene on behaviour, the animals underwent a battery of tests 
that included locomotor activity, anxiety, memory and learning, and social 
interactions. These tests were selected based on some of the dorsal 
hippocampus-associated behaviours and symptoms shown by the patients 
affected with mutations in MYT1L. It is hoped the results of this study will give 




4.2.1 Lentiviral vectors 
 
pGIPZ lentiviral vectors containing shRNAmir targeting Myt1l and non-silencing 
shRNAmir (negative control) were produced as described in Chapter 2. The 
viral particles were further concentrated and the titre was measured as 
described in Chapter 3. The lentiviral stock titre used for subsequent 





Upon arrival, male C57BL/6J mice (7 to 8 weeks old; Charles River Ltd., UK) 
were housed in Tecniplast cages (32cm x 16 cm x 14 cm) containing sawdust  
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(Litaspen premium), a cardboard house and bedding material (Sizzlenest, 
Datasand Ltd., UK) in groups of 4 or 5 mice per cage. After surgery, animals 
were single housed and allowed to recover for 4 weeks and then remained 
singly housed for the duration of the behavioural test battery. The mice were 
housed in a room of their own in order to minimize any behavioural disruption 
caused by other mice or people. The sawdust and bedding material were 
changed every two weeks and cages were changed once a month, on days 
when the mice were not being tested or after the daily experiment was over to 
minimize disruption to the mice.  
 
The conditions of the housing room were kept constant with a temperature of 
21o C, humidity of 45% and under a 12-hour light/dark cycle, lights were on at 
8:00 am (270 lux). They had ad libitum access to food (Rat and Mouse No.3 
Diet, Special Diet Services, UK) and water. The weight of the mouse was 
recorded before surgery, one week after surgery, two months after surgery and 
on the day of perfusion. 
 
Mice were left for 2 to 3 weeks to adapt before surgery. All procedures and tests 
were scheduled at least 1 hour after the lights were on and ended 1 hour before 
the lights went off. All housing and experimental procedures were performed 
according to the Animals (Scientific Procedures) Act 1986 and they were carried 
out at the Biological Services Unit located in the Institute of Psychiatry, King’s 




4.2.3 Experimental setup 
 
Mice were divided into two experimental groups (n=19/group). One group 
received lentiviral vectors containing non-silencing shRNAmir and the other 
group received Myt1l shRNAmir. Three mice in each group were used for 
validation of the in-vivo knockdown effect and did not undergo behavioural 
testing. The remaining 16 mice in each group were separated into two batches 
for testing: testing of batch 1 and 2 was separated by 7 days. Each animal 
received two viral vector injections, one in each hemisphere targeting the dorsal 
hippocampus. Before the start of behavioural tests, the identity of each mouse 
was blinded by a separate experimenter. The initial test battery included: open 
field, novel object recognition and Morris water maze. Based on preliminary 
findings, the mice then were tested on the elevated plus maze, light/dark box, 
three-chamber social approach, food burying task and social investigation 
(Figure 4.2). The last three tasks were performed on a smaller cohort of animals 
(shRNAmir non-silencing n=11 and shRNAmir Myt1l n=11) because eight mice 
were required for immunohistochemical verification of the injection site. 
Reducing the number of animals was taken into account when designing the 
experiment.   
 
 




4.2.4 Stereotaxic surgery and validation of site of injection 
 
The mouse was deeply anaesthetised by an intraperitoneal injection (IP) of 0.2 
ml per 100 g of a mixture composed by Ketamine (37.5 mg/ml; Pfizer, UK), 
Medetomidine (0.38 mg/ml; Janssen, Finland) and sterile water (Hameln, UK). 
To deepen analgesia, the mouse received a subcutaneous (SC) injection of 
Rimadyl (5 mg/Kg; Pfizer, UK) immediately before surgery. The animal was 
then mounted onto a Kopf stereotactic frame, followed by a midline incision in 
the skull and skin retraction to localize Bregma. Coordinates were adjusted to 
this anatomical point to bilaterally drill burr holes above the dorsal hippocampus 
(AP -2 mm, ML ± 1.5 mm) (Paxinos and Franklin 2003). A cannula, connected 
through polyethylene tubing to a 10ul-Hamilton syringe mounted into syringe 
pump (CMA 400) was lowered (DV -1.8 mm from the top of the brain) to inject 1 
ul of lentiviral viral stock of pGIPZ shRNAmir non-silencing (n=19) or pGIPZ 
shRNAmir Myt1l (n=19). The delivery rate of the virus was 0.1 ul per minute. 
Following injection, the cannula was left for 2 minutes to allow diffusion of the 
virus and then removed in steps of 0.5 mm every 2 minutes till the cannula was 
out of the brain. The holes in the skull were covered with dental cement and the 
incision was sutured using silk braided non-absorbable suture (Ethicon, UK). 
After surgery, the mouse received a SC injection of 0.1 ml/100 g Antisedan 
(1mg/ml; Janssen, Finland) to revert the sedative effect; and was put in heated 
cage until it awakened. Mice were checked daily and allowed to recover for four 
weeks before starting behavioural testing.  
 
After behavioural testing was completed, the tested mice (n=16 mice each 
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group) received a lethal dose of the anaesthetic pentobarbital sodium (200 
mg/ml IP; Merial, UK) before being transcardially perfused. Once the animal 
was fully anaesthetized, an incision below the rib cage and another one along 
the diaphragm helped to expose the heart. A single injection of 0.1 ml of heparin 
(5000 U/ml; Leo, UK) was administered into the bottom of the left ventricle to 
prevent clotting and allow better flushing of the blood. Subsequently, a cannula 
connected through polyethylene tubing to a pump (Watson-Marlow, UK) was 
inserted into the location of the injection. The pump was adjusted to deliver 40 
to 50 ml of 0.1 M filtered PBS (pH adjusted to 7.4) at a rate of 3 ml per minutes. 
The right atrium was cut to allow the incoming flow of blood and PBS out of the 
system. After the volume of PBS had been exhausted and the emerging fluid 
from the atrium was clear, the pump was switched to administer 40 to 50 ml of 
4% of filtered PFA (pH adjusted to 7.4). Early signs of perfusion such as body 
tremors were observed. Once the tissue fixative had finished passing through 
the mouse, it was decapitated and the extracted brain was postfixed in 4% PFA 
for 24 hours at 4o C. The brains were washed with 0.1M PBS and transferred 
into a cryoprotective solution composed of 30% sucrose, 0.5 M Tris-buffered 
saline (TBS, pH 7.6) and 0.05% sodium azide (NaN3; Sigma, UK) and left at 4o 
C until the brains sunk before proceeding to sectioning.  
 
Brain sectioning was performed in order to corroborate the site of injection. The 
brain was removed from the solution and placed over embedding matrix 
(Thermofisher scientific, UK) on the already frozen specimen clamp of the 
sliding microtome (Microm). Additional embedding matrix was applied over the 
brain before freezing it with crushed dry ice. Once the brain was fully frozen, 50 
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um-coronal sections were cut and stored in anti-freezing cryoprotective solution 
[30% ethylene glycol (Sigma, UK), 15% sucrose (Sigma, UK) and 0.05% NaN3 
in 0.5 M TBS] at -20o C. Unfortunately, one mouse was found dead (cause 
unknown) and its brain could not be collected. 
 
4.2.5 In-vivo Myt1l knockdown validation  
 
4.2.5.1 RNA extraction 
 
Mice designated for RNA extraction to validate the in-vivo knockdown of Myt1l 
were killed by cervical dislocation. The brains were quickly extracted and frozen 
on crushed dry ice. Brains were kept at -800 C until dissection. Before starting 
the RNA extraction, all the equipment and surfaces were sprayed with 
RNAseZAPTM (Sigma, UK) to eliminate RNAse and minimise RNA degradation. 
The frozen brain was placed in a brain matrix (Stoelting, USA) and the area 
targeted by the central injection was cut using a razor blade (Stoelting, USA). 
The resulting 1 mm-coronal slice was dissected using a scalpel to isolate the 
dorsal hippocampus of both sides. The tissue was put in microcentrifuge tubes 
containing 600 ul of RLT buffer (Qiagen, UK) supplemented with 1% β-
mercaptoethanol (Sigma, UK). The brain tissue was first disrupted using a 
plastic pestle. Then, the tissue lysate was homogenized by passing it through a 
20-gauge needle eight times using an RNAse-free syringe. Additional 
homogenization was carried out using the QIAshredder kit (Qiagen, UK). The 
lysate was transferred into a spin column placed in a 2 ml collection tube and 
centrifuged at full-speed for two minutes. Once finished, the spin column was 
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removed and the collection tube was capped for an additional three minutes of 
centrifugation at full-speed. The supernatant was carefully transferred to a new 
microcentrifugation tube for further processing using RNeasy® mini kit (Qiagen, 
UK). The following steps for RNA extraction were performed as described in 
Chapter 2 (2.2.5), including the optional on-column DNAse digestion (Qiagen, 
UK). The resulting RNA was eluted in 30 ul of RNAse-free water (Qiagen, UK) 
and the RNA concentration was quantified by UV spectrophotometry using a 
nanospectrophotometer (NanoDrop 1000; Thermo) at 230 nm wavelengths. A 
absorbance ratio (260/280) above 2 was accepted as “pure” for RNA. If the ratio 
was lower, it could indicate contamination of protein, phenol or other 
contaminant. The RNA was stored at -80o C till required for reverse 
transcription. The correct placement of the viral injection was confirmed by 
visual inspection using the Paxinos and Franklin brain atlas (Paxinos and 
Franklin 2003).  
 
4.2.5.2 Reverse transcription 
 
Reverse transcription was performed in 1 ug of RNA using SuperscriptTM III 
First-Strand Synthesis System for RT-PCR (Invitrogen, UK). The same protocol 
described in Chapter 2 was followed here (2.2.6). The cDNA was then diluted in 
79 ul of RNase free water to have a final concentration of 10 ug/ul. cDNA was 





4.2.5.3 Quantitative Polymerase Chain Reaction (qPCR)  
 
qPCR amplification was performed in a 20 ul volume containing 4 ul of cDNA 
(10ug/ul), 10 ul of 2X Power SYBR® Green PCR master mix (Applied 
Biosystems, UK), 0.14 uM forward primer (Table 4.1), 0.14 uM primer reverse 
(Table 4.1) and 5.72 ul of RNase free water. All the amplifications were carried 
out in triplicate using the ABI Prism® 7900 HT Sequence detection system 
(Applied Biosystems) under the following thermal cycle: 95o C for 15 minutes 
(initial denaturation); 40 cycles of 95oC for 30seconds and 59oC for 30 seconds 
(amplification); finishing with 50o C for 10 seconds and 95o C for 15 seconds 
(dissociation stage). The ABI Prism® SDS 2.1 software (Applied Biosystems) 
was used to analyse the specificity and relative quantification of the amplicons. 
The dissociation curve generated by the software was used to determine the 
specificity of the PCR products. The relative quantification of the amplicon was 
calculated using the cycle threshold (Ct), which represents the number of cycles 
required by the sample to cross a fixed threshold. The mean Ct values of the 
triplicates were normalized against the mean triplicates of the housekeeping 
gene β-Actin to produce ΔCT (ΔCT=CtMyt1l-Ctβ-Actin). The difference in expression 
of Myt1l mRNA was compared in two conditions: infected with non-silencing 
shRNAmir and infected with Myt1l shRNAmir, to calculate ΔΔCt (ΔΔCt=ΔCtMyt1l 




Table 4.1 Sequence of the qPCR primers for rodent Myt1l and β-Actin 
 
4.2.6 Behavioural testing 
 
4.2.6.1 Open Field 
 
The open field is a widely used test to measure locomotor activity as well as a 
validated test for anxiety-like behaviours (Prut and Belzung 2003, Crawley 
2007). When mice are exposed to the open field arena, they will explore it in 
order to collect information about the environment. Following repeated exposure 
to the open field, their behaviour will change and this process is normally 
referred to as habituation (Crusio and Schwegler 1987, Thiel, Müller et al. 
1999). Mice placed in a new environment will tend to explore the periphery of 
the arena and avoid the inner area, which is seen as a threatening and 
potentially dangerous zone. The time spent in, and latency to enter, the inner 
zone are indicators of reduced anxiety (Prut and Belzung 2003).  
 
The open field arena used in this experiment was a TruScan arena (26 cm wide 
x 26 cm long x 38.5 cm height; Coulbourn Instruments, USA) placed in a sound-
isolated room evenly lit (20 lux) by a white light lamp on the floor below the 
arena. Before and in-between trials, the apparatus was wiped clean with a 1% 
 Forward Reverse 
Rodent Myt1l GAGCCAGTCCCTGATCCAC CCGTCAAAGTAGTCACGTAAGC 
β-Actin GCTCGTCGTCGACAACGGCTC CAAACATGATCTGGGTCATCTTCTC 
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Trigene® solution to avoid build-up of olfactory cues that could affect behaviour. 
At the start of each trial, a mouse was taken out of its home cage and placed in 
the peripheral zone of the arena facing an outer wall. The trial was recorded 
using an overhead camera for 20 minutes. At the end of the experiment, the 
mouse was returned to its home cage. Each animal was tested the next day 
following the same protocol. The recordings were analysed using the automated 
tracking EthoVision software (Noldus, Spink et al. 2001, Spink, Tegelenbosch et 
al. 2001). A squared area (13 cm x 13 cm) equidistant from the periphery was 
defined as the inner zone. The locomotor activity, in both the outer and the inner 
zone of the arena (distance moved and velocity), time spent in each zone and 
the number of entries to the inner zone were measured. Two types of 
habituation were calculated: the first was within the same trial by comparing the 
performance of the animal across four 5 minute time bins; the second was 
calculated by comparing the activity observed on day one with day two. The 
locomotion in the outer arena was used to calculate habituation instead of the 
total arena since these measurements are confounded by anxiety as it included 
the activity in the inner zone (anxiogenic).  
 
4.2.6.2 Novel Object discrimination (NOD) 
 
The NOD task relies on the natural tendency of mice and rats to be attracted to 
novel objects. It has been shown that after a single explorative session with an 
object, the rodents can differentiate between a familiar object and a novel one 
(Dere, Huston et al. 2007, Antunes and Biala 2012). The amount of time that 
the mouse spends interacting with the new object indicates the capacity of the 
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animal to discriminate between the familiar and novel (Bevins and Besheer 
2006). Depending on the delay between the first contact with the objects and 
the presentation of the new one, both short-term memory (after one hour) and 
long-term memory (after 24 hours) could be assessed (Stefanko, Barrett et al. 
2009).  
 
An empty home cage (i.e. without sawdust and bedding material) was used as 
the arena for the NOD task along with 4 different objects (white cubes, black 
cubes, white pyramids, black pyramids). Preliminary observations using these 
objects suggested the preference of the mouse for a specific type. In order to 
avoid this preference, only cubes were used for short-term memory and only 
pyramids for long-term memory (Figure 4.3). Before and in-between trials, the 
test cage and the objects were washed with commercially available washing up 
liquid (Fairy Original, UK) and wiped with 1% Trigene® solution to avoid any 
olfactory cues that could lead to a side preference. The cages were placed in a 
sound-isolated room and a lamp located on and facing the floor provided low 
white light (20 lux) to the test room. For trial one, either two white or black cubes 
were attached to the cage through hook-and-loop fasteners to prevent the 
objects from being displaced by the mouse. The mouse was removed from its 
home cage and placed in the centre of test cage facing an outer wall. The trial 
lasted for 10 minutes and was recorded with an overhead camera. At the end of 
each trial, the mouse was returned to its home cage. One hour later, the same 
mouse was tested again following the same protocol, but this time one of the 
cubes had a different colour from the one seen before. Long-term memory was 
assessed using the same procedure except white or black pyramids were used 
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and the inter-trial interval was 24 hours (Figure 4.3). The order and location of 
the new cube/pyramid (i.e. top or bottom) was counterbalanced within groups to 
avoid laterality bias. The exploration of the objects was hand coded using 
EthoVision software to calculate frequency and duration for each object. 
Exploration was defined as: a) direct look at the object (within 1 cm), b) direct 
sniff of the object, c) direct contact of the nose with the object. Discrimination 
ratios were calculated to establish whether or not the mouse was exploring the 
objects above the 0.5 chance ratio, which indicated a preference for that object 
(Bevins and Besheer 2006), where the preference for the novel object was 
calculated as follows: time spent exploring the novel object divided by the total 
exploration time (time spent exploring the familiar object + time spent exploring 
the novel object). A discrimination ratio assuming no preference for the novel 
object was calculated by dividing the time spent exploring the familiar object 








Figure 4.3 Graphical representation of the object presented during the NOD task.  
Figure (a) shows the setup used to assess short-term memory. Cubes could be either all black or all white 
for the first contact test, counterbalanced across groups. Figure (b) presents a similar setup, using white or 
black pyramids (counterbalanced across group) and a 24-hour delay between trials. 
 
4.2.6.3 Morris Water Maze (MWM) 
 
The water maze developed by Morris is a validated test to examine spatial 
learning in rodents (Morris 1984). The spatial learning ability is tested through 
the acquisition phase consisting of repetitive trials in which a mouse is forced to 
swim and locate a submerged platform inside a circular pool by relying on distal 
cues (D’Hooge and De Deyn 2001, Vorhees and Williams 2006). Additionally, 
retention of spatial memory is assessed when the platform is removed and the 
time spent swimming where the platform was located is measured (Rodgers 




For this experiment, a large pool, 1.3 m in diameter and 60 cm of height was 
used. Even though there is no standard size of pool, previous experiments have 
shown that 1.3 m in diameter is sufficient to have reliable estimates of learning 
without being overly stressful to the mouse (van der Staay 2000). The pool was 
filled with tap water (room temperature around 21o C) up to 30 cm of depth. To 
prevent the mouse from seeing the platform and to enhance video tracking 
using EthoVision software, 2 cups of white non-toxic aqueous emulsion (Acusol 
OP301 Opacifier, Tohm & Haas, Sweeden) were added to the water. Faecal 
boli were removed from the pool between trials and the water was changed 
weekly. The pool was lit from below using 4 lamps of white light (100 lux). To 
isolate the pool and prevent extra cues from affecting the behaviour, the 
periphery of the pool was delimitated using cream-coloured curtains. Big and 
bright extra-maze visual cues were hanging from this curtain to help navigation. 
The pool was virtually divided into 4 equally–sized quadrants in the EthoVision 
software: target (platform location; T), opposite to target (O), right of the target 
(R) and left of the target (L) (Figure 4.4). These quadrants were 
pseudorandomly assigned as the different starting points for the mouse in the 
successive daily trials and they were alternated between the testing days. The 
platform had a circular shape (10 cm in diameter) and was always positioned in 
the target quadrant.  
 
Each experimental batch was run in squads of 5 and 6 mice and each mouse 
underwent 4 trials (starting from either T, O, R and L) per day for 7 days. The 
starting points were alternated between daily trails. For each session, the mice 
were taken into the testing room in squads and left there till all of them 
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completed their trials. Afterwards, they were taken back to the housing room 
and the next squad would come into the testing room. Batch 2 was tested after 









Figure 4.4 Graphical representation of the Morris Water Maze pool division by quadrants: target (T), 
right (R), opposite (O) and left (L).  
The four figures drawn outside the pool represents the different cues attached to the curtain surrounding 
the pool. 
 
On day one (visible trial), the platform was positioned about 1 cm above the 
water level and the mouse was trained to identify and locate the platform. The 
trial started when the mouse was placed by the tail inside the pool close to and 
facing the wall in one of the four starting points. The mouse was allowed to 
swim and find the platform for 60 seconds. Finding the platform was defined as 
having the four paws on the platform. If the mouse could not locate it in the 
established time, it was guided towards it. Once on the platform, the mouse was 
permitted to remain there for 15 seconds before removing it. The mouse was 
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returned to its home cage and the rest of the squad tested before starting the 
2nd trial for each mouse, with an inter-trial interval of approximately 10 min. The 
mice groomed themselves dry in between trials. The subsequent three trials 
started in a different quadrant and the order was pseudorandomly assigned. 
From day two to day seven (hidden trial 1 to hidden trial 6), the same protocol 
was applied except that the pool was filled with more water to hide the platform 
1 cm below the water level. The latency was measured with a stopwatch from 
the moment the mouse was left inside the pool till it found the platform. On day 
seven, after completing the four trials, a fifth trial was added to the test (probe 
trial). In the probe trial, the platform was removed from the pool and the mouse 
was allowed to swim for 60 seconds. Retention was measured in this trial by 
comparing the time spent in the target quadrant to the time spent in the other 
quadrants. Times significantly above 25 seconds chance level were taken as an 
indication of retained memory of the platform location. 
 
The trials were recorded using an overhead camera for tracking locomotor 
activity (distance swum and swim speed) analysis using the EthoVision 
software. For the probe trial, the swimming activity was nested according to the 
quadrant location.  
 
4.2.6.4 Elevated plus maze (EPM) 
 
The elevated plus maze (EPM) has been described as a reliable model to 
measure anxiety-like behaviours in the mouse (Lister 1987). It relies on the 
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conflict between exploring a new environment and avoiding the aversive 
features of openness and height (Treit, Menard et al. 1993, Fernandes and File 
1996, File, Lippa et al. 2001). Hence, the avoidance of the open arms is 
measured as indicative of an anxiety response (Rodgers and Johnson 1995, 
Fernandes and File 1996). The floor of the EMP runway was 0.5 cm thick black 
Perspex and it consisted of four arms measuring 30 cm x 5 cm, having a centre 
in between them of 5 cm x 5 cm. Two arms opposite to each other were 
enclosed using two 15 cm high grey Perspex walls on each side and one at the 
end. The other 2 arms were open. It was supported in the centre by a Perspex 
stand that positioned the apparatus 40 cm over the floor. The apparatus was 
placed in a sound-isolated room and a lamp of white light facing the floor was 
used to light the testing room. The light intensity in the closed arms was (10 lux) 
and in the open arms (30 lux). Before testing and in between trials, the 
apparatus was wiped cleaned using 1% Trigene® solution to minimise olfactory 
cues that might interfere with behaviour. The trial started when the mouse was 
taken out of its home cage by the tail and placed in the centre of the EPM facing 
a closed arm. Each trial lasted for five minutes and then the mouse was 
returned to its home cage. An overhead camera recorded the session for further 
hand scoring using the EthoVision software. The exact number of entries and 
time spent in each arm were hand scored as well as the latency to enter into an 
open arm. An arm entry was considered only when the four paws were inside, 
while an exit was counted when at least two paws were out, in which case, the 
mouse was located in the central square. The additional behaviours scored 
were head-dipping (when the mouse lowered its head over the sides of an open 
arm while being located in the open arms or central square, (Rodgers and 
Johnson 1995) and scanning of the environment (when the mouse was on an 
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open arm and its head was moving from one side to the other, (Silva and 
Brandão 2000). The EthoVision software was used to track the distance moved 
and velocity in each arm and the central square. Unfortunately, due to a 
defective batch of recordable DVDs only 16 out 32 trials were available for hand 
scoring (n=7 from the shRNAmir group and n=9 from the shRNAmir Myt1l 
group). 
 
4.2.6.5 Light/Dark Box  
 
The light/dark test takes advantage of the innate conflict of mice to explore new 
environments and avoid open, brightly-lit areas (Crawley and Goodwin 1980). 
The apparatus consists of a larger, brightly-lit compartment and a smaller, dark 
compartment. Mice tend to stay in the dark compartment and increased time 
spent in the brightly-lit compartment is taken as a measure of anxiety (Crawley 
and Goodwin 1980, File, Lippa et al. 2001, Bourin and Hascoët 2003). The 
apparatus used for this experiment was a white acrylic box measuring 44 cm x 
21 cm x 21 cm divided by a tall, white acrylic separator into two chambers. It 
was located in a sound-isolated testing room and a white light lamp behind the 
separator faced only the larger chamber to provide bright illumination. This 
setup consisted of a larger compartment (two thirds of the box) which was 
brightly lighted (120 lux) and a small chamber with low lighting (<20 lux). Free 
transition of the mouse from one chamber to the other was possible through a 
small opening (5 cm x 7 cm) in the separator. Before testing and between trials, 
the box and the separator were wiped clean using 1% Trigene® solution to 
minimise olfactory cues. The mouse was removed from its home cage and 
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transferred into the dark compartment of the box facing the wall. The trial lasted 
for five minutes and it was recorded using an overhead camera. Once finished, 
the mouse was returned to its home cage. The recordings were later hand 
scored using a manual behaviour module in the EthoVision system. The 
behavioural patterns measured were the number of entries and time spent in 
the light compartment, as well as the number of rearings against the wall. Entry 
to either the light or dark compartment was counted only when all four paws 
were inside. Rearing against the wall was defined as a mouse standing upright 
on its hind legs with the two front paws on the wall. In addition, locomotor 
activity was automatically tracked by the EthoVision software and the data 
nested according to the two different compartments. 
 
4.2.6.6 Three-chamber social approach task  
 
Based on the natural tendency of a mouse to approach and investigate 
unknown conspecifics, the three-chamber social task was developed by 
Crawley and co-workers (Nadler, Moy et al. 2004). The mouse is known to be a 
social species and a low social approach could be analogous to the social 
deficit observed in patients suffering from autism. This behavioural test provides 
a relatively quick screen for impairments in sociability in mouse models of 
autism. It monitors social approach behaviours by letting the subject mouse 
choose between spending time with another mouse or a novel object. 
Sociability is defined in terms of the time spent in the chamber containing the 
mouse instead of the object. A subsequent test can be performed to investigate 
social novelty; it is important to note that this is not as relevant to autism-like 
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symptoms of sociability. In this case, the subject mouse is presented with the 
choice to interact with either the familiar mouse (presented in the previous trial) 
or a novel one. The experiment was performed as described by Yang et al., 
differing only by the fact that the conspecific mice were habituated in wire cups 
for 15 minutes before undergoing a trial (Yang, Silverman et al. 2001). The 
three-chambered social test apparatus was a rectangular acrylic box consisting 
of three equally sized chambers (20 cm x 40.5 cm x 22 cm). The dividing walls 
were made of clear Plexiglas with openings (10 cm x 5 cm) to allow the mouse 
access to the chambers (Figure 4.5). The apparatus was placed in a sound-
isolated room with a lamp placed and facing the floor to provide dim white light 
to the testing room (10 lux). All three compartments were filled with equally 
distributed clean sawdust and the sawdust was changed every time a new 
subject mouse was tested. Before testing and between subject mice, the box, 
the wire cups and the glass cups used to weigh down the wire cups were 
cleaned using 1% Trigene® solution to avoid olfactory cues which might 
interfere with behaviour. Additionally, between subject mice, both the wire and 
glass cups were washed using commercially available washing up liquid (Fairy 
Original, UK). The box was only washed with washing up liquid between test 
batches. The experiment was composed of three 10-minute trials. Trial one was 
used for habituation to the apparatus and it did not contain any objects. The trial 
started when the subject mouse was removed from its home cage and put into 
the central chamber facing the wall opposite to the experimenter. In trial two, an 
empty wire cup was placed upside down on either side of the chamber (novel 
object stimulus) and a novel juvenile same-sex conspecific mouse (novel 
mouse stimulus) was placed on another upside down wire cup on the other side 
chamber, leaving the central chamber empty. For trial three, a novel juvenile 
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same-sex conspecific mouse was placed inside the empty wire cup and the now 
familiar conspecific remained in the other wire cup. All trials were recorded 
using an overhead camera and were tracked using EthoVision. The location of 
the novel mouse across trials was counterbalanced within each group to avoid 
any bias related to a chamber preference. The tracked data obtained from 
EthoVision included the number of entries, time spent in, and latency to enter, 
each chamber, as well as locomotor activity (distance moved and velocity) 
nested by chamber. The data obtained from trial two (novel object vs. novel 
mouse) and three (familiar mouse vs. new mouse) were used to assess social 




Figure 4.5 This image illustrates the three-chamber social approach task.  
The image also represents the content of each chamber depending on the trial. During 
habituation (trial 1), the subject mouse is alone. To test sociability (trial 2), one chamber 
contains a novel mouse inside a wire glass and the other chamber just contained the wire cup. 
For the third trial (social novelty), a new mouse was place in the empty wire glass. A glass cup 
and a lead weight were placed above the wire glass to avoid the mouse from moving or 
climbing on top of the wire cups.  
 
4.2.6.7 Social investigation task  
 
The social investigation task provides a general assessment of the capacity of a 
mouse to respond to other conspecifics. Considering that the mouse possesses 
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a repertoire of well-characterized behavioural patterns, establishing an 
inventory (sometimes referred as an ethogram) of its behaviour while 
encountering a new mouse is relatively easy (Winslow 2001). In this 
experiment, clean home cages with only sawdust were used for the test arena. 
The cages were located in a sound-isolated room. A white light lamp located 
and facing the floor provided the lighting for the test room (10 lux). One hour 
before the experiment, the subject mouse was transferred from its home cage 
to the clean, test cage and it was left in the housing room. The trial began when 
the mouse in its test cage was transferred to the testing room and one juvenile 
same-sex conspecific was put inside the subject’s test cage. They were allowed 
to interact for five minutes after which the subject mouse was returned to its 
home cage. The trial was recorded using an overhead camera for further 
analysis using the EthoVision software. Social behaviours initiated by the 
subject mouse included anogenital sniffing, social sniffing (any sniffing from the 
trunk upwards), aggression and allogrooming (defined as the grooming 
performed by the test mouse on the conspecific mouse) were hand scored.  
 
4.2.6.8 Buried food task 
 
Odours provide critical information to mice that can influence behaviours such 
as navigation, foraging, mouse recognition, bond formation, mate selection, 
sexual behaviour, and parental behaviour (Keverne and Brennan 1996, 
Brennan and Keverne 2004, Restrepo, Arellano et al. 2004). A wide range of 
behavioural tests measuring social abilities and certain cognitive tasks rely on 
olfactory cues and therefore deficits in olfaction can confound the results from 
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these tests. The buried food task is a simple way to assess olfaction in mouse. 
This test was essentially performed using a well-established protocol by Yang 
and Crawley (Yang and Crawley 2001). Cleaned home cages evenly filled with 
5 cm of sawdust were used as test cages. The test room was sound-isolated 
and it was lit using a white light lamp placed on and facing the floor (lux 10). A 
small chocolate cookie (Nestle Cookie Crisp®, UK) was given to the mice in 
their home cages for three consecutive days. Every morning, the experimenter 
searched the home cage to check whether the cookie had been eaten. The 
mice then were food deprived for 24 hours before testing. On the day of the 
test, the mouse was transferred from its home cage to the test cage and was 
left to habituate for five minutes. Then, it was removed from the test cage and a 
cookie was hidden in the bottom of the test cage (right, left, centre). The 
location of the cookie was counterbalanced within groups across the trials. The 
mouse was returned to the test cage and allowed 60 seconds to find the cookie. 




50 um-coronal brain sections were washed three times in 0.1 M PBS (pH 7.4) 
for 10 minutes to remove the cryoprotective solution in which they had been 
immersed, followed by one hour incubation at room temperature in blocking 
solution [0.2 M PBS containing 1% bovine serum albumina fraction V (Roche; 
USA), 0.3% Triton X-100 (Sigma, UK) and 1% of normal goad serum 
(Invitrogen, USA); pH adjusted to 7.4]. The slices were further washed as 
described before and incubated overnight at 4o C in blocking buffer containing 
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rabbit polyclonal anti-GFP (1:1000; Abcam, UK). The next day, the brain slices 
were again washed in the same manner and incubated for one hour at room 
temperature in blocking buffer with fluorescently conjugated secondary antibody 
Alexa Fluor 488 antirabbit (1:1000; Invitrogen, UK). The slices were washed 
one last time before being mounted on microscopes slices using Vecta MountTM 
(Vector, USA) under a cover slip. Images were taken using Leica DMIL 




All statistical analyses were done using IBM SPSS Statistics 20 (IBM Corp., 
USA). A p-value <0.05 was considered statistically significant. 
 
 
4.2.8.1 In-vivo validation 
 
In order to validate the efficiency of shRNAmir targeting Myt1l mRNA in-vivo, an 
independent sample t-test was carried out comparing the ΔΔCt obtained from 
brains infected with shRNAmir Myt1l against non-silencing shRNAmir. The 
graph plotted the relative fold expression, which was obtained by elevating 2 to 
the negative power of ΔΔCt (relative fold expression=2-ΔΔCt) (Livak and 
Schmittgen 2001). The error bars were adjusted to reflect the logarithmic scale 
as described in Chapter 2 (2.2.8). 
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4.2.8.2 Behavioural testing 
 
The sites of injection for all mice that underwent behavioural testing were 
confirmed using immunohistochemistry. The animals that had misplacement of 
the injection were not included in the statistical analysis. In addition, the brain 
from the mouse found dead was too degraded to corroborate injection site, 
hence it also was excluded from the analysis. The data for all behavioural tests 
were expressed as mean± standard error of the mean (S.E.M.). Before 
analysing the data, the differences between batches were analysed and since 
there were no significant differences between them, batch effect was not used 
as a cofactor for statistical analysis. Different analyses were performed 
according to the behaviour studied in order to assess the differences in 
behaviour between the mice having Myt1l knocked down in the dorsal 
hippocampus in comparison to the control mice. For open field, a two-way 
ANOVA with the factors ‘treatment’ and ‘time interval’ was performed to assess 
within trial habituation. Between days habituation employed a two-way repeated 
measure ANOVA to compare day one against day two. Mauchly's sphericity test 
was used to validate the results of the two-way repeated measure ANOVA. If 
this test was significant, a Greenhouse-Geisser correction was applied to adjust 
the value of F and the degrees of freedom. To test for specific group differences 
within a test day, a paired t-test was used. A two-way ANOVA with the factors 
‘treatment’ and ‘time interval’ was employed to analyse the anxiety-like 
behaviours in the open field. In the particular case of NOD, a paired t-test was 
used to compare the time spent exploring the novel object in comparison to the 
familiar one. Additionally, one sample t-test was employed to compare the 
discrimination ratios against 50% chance ratio. An independent sample t-test 
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was used to analyse the differences between Myt1l knockdown mice and the 
control in the EPM, light/dark box, social investigation task and buried food task. 
For MWM and the three-chamber social approach task, a two-way repeated 
measures ANOVA was used with between-factor of Mtyl1 treatment and within-
factor of chamber (three-chamber social approach task) or session (Morris 
water maze). The results from the ANOVA were adjusted with a Greenhouse-
Geisser correction if the Mauchly's sphericity test was significant.  
 
4.3 Results  
 
4.3.1 Myt1l knockdown in the dorsal hippocampus using pGIPZ lentiviral 
vector microinjection 
 
pGIPZ lentiviral vector containing Myt1l shRNAmir (n=3) and non-silencing 
shRNAmir (n=3) were bilaterally injected in the dorsal hippocampus of the 
mouse to verify the knockdown efficiency of this construct. A 1-mm coronal 
brain slice for each mouse was obtained by isolating the injection site and 
extracting the dorsal hippocampus from both hemispheres. The RNA obtained 
from this tissue was used to carry out a qPCR analysis to determine the effect 
of Myt1l shRNAmir in-vivo. The specificity of the PCR products was assessed 
by examining the dissociation curve; in both cases, only one peak was 





Figure 4.6 Confirmation of β-actin (a) and Myt1l (b) qPCR primer specificity.  
The dissociation curves obtained from the qPCT analysis of β-actin and Myt1l indicate its 
specificity by yielding only one peak per gene.   
 
The ΔΔCt values of mice infected in the dorsal hippocampus with Myt1l 
shRNAmir and non-silencing shRNAmir were analysed using independent 
samples t-test. The results (Figure 4.7) confirmed a significant decrease of 
about 49% in the expression of Myt1l compared to the non-silencing control 
[T(4)=-3.207; p=0.033)]. This result proves the efficiency of Myt1l shRNAmir in 





Figure 4.7 This graph illustrates the relative fold expression of Myt1l in mice 
microinjected with Myt1l shRNAmir and non-silencing shRNAmir.  
The data are expressed as mean ± 1 S.E.M. (n=3 per group). * p<0.01  
 
4.3.2 Stereotactic lentiviriral injections and immunohistochemical analysis  
 
In order to investigate the effects of knocking down Myt1l in-vivo, lentiviruses 
containing Myt1l and non-silencing shRNAmir (n=16/group) were bilaterally 
injected in the dorsal hippocampus of the mouse. Given the presence of the 
marker GFP in the lentiviral vector, the infected cells could be tracked and the 
injection site detected. The sites of injection in the 31 mice (one mouse died 
during behavioural testing) that underwent behavioural testing were located by 
immunohistochemical analysis (Figure 4.8). Only three animals had 
misplacement of the injection. The viral spreading observed was very limited, 
around 300 um. This was likely due to the size of the lentiviral vectors (over 100 






Figure 4.8 These figures show a graphical representation of the injection site for mice 
injected with Myt1l and non-silencing shRNAmir.  
The grey dots represent each injection site in the mouse (n=14 per group). The pictures in the 
upper centre were taken after anti-GFP staining and the fluorescence indicates where the 
lentiviruses were expressed for both control and Myt1l; while the lower centre pictures are the 
corresponding phase-contrast images.  
 
An additional variable that was measured across the study was body weight. It 
was recorded at four time points (before surgery, one week after surgery, two 
months after surgery and at cull). Repeated measures ANOVA with 
Greenhouse-Geisser correction demonstrated a significant time effect (F1.674, 
53.571=75.127, p=4.82x10-15; Figure 4.9) but no treatment effect (F1.686, 





Figure 4.9 This graph illustrates the differences found in body weight at 4 different time 
points.  
The weight of both Myt1l knockdown and control mice increased significantly 2 months after 
surgery and at cull. There were no differences according to the treatment. The data are 
expressed as mean ± 1 S.E.M. (n = 17 per group).  
 
4.3.3 Open field 
 
The open field test was used to measure both the locomotor activity and 
anxiety-like behaviours of the modified mice. In order to analyse the within-trial 
habituation, the distance moved across the outer arena was divided in time 
intervals of four x 5 minutes. During day one, the two-way repeated ANOVA 
results indicated that Myt1l knockdown mice overall moved a significantly 
greater distance in trial one in comparison to the control (F1, 103= 4.542, 
p=0.035). However, there was no significant effect of treatment at any of the 
specific time bins. The same analysis applied to the data obtained on day two 
did not find any significant differences between treatment (F1, 100= 0.307, 
p=0.581) or time intervals (F3, 100= 2.137, p=0.100), indicating no within-trial 
habituation in either day [Figure 4.10 (a)]. Habituation between trials was 
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analyzed by an repeated measures ANOVA between trials and followed by 
Greenhouse-Geisser correction. The test showed no significant changes in the 
distance moved on day one in comparison to day two due to treatment (F1, 
99=1.202; p=0.276) or time point (F3, 99=1.013; p=0.391), possibly indicating no 
habituation between days [Figure 4.10 (a)]. 
 
The velocity at which mice moved around the outer zone in the overall 20-
minute trial was also measured. An independent t-test indicated no significant 
differences between the Myt1l knockdown and control on day one [T(25)=-
0.761, p=0.454] or day two [T(25)=1.280, p=0.212;  Figure 4.10 (b)]. A repeated 
measures ANOVA with a Greenhouse-Geisser correction revealed a significant 
decrease in velocity on day two in comparison to day one due to treatment [F1, 





Figure 4.10 These graphs illustrate the distance moved (a) and velocity (b) recorded in the 
outer zone of the open field over the 20-minute trial on day 1 and day 2.  
The data are expressed as mean ± 1 S.E.M. (n = 14 per group).  
 
As mentioned previously, the open field can be used to study anxiety-like 
behaviours by measuring certain behavioural patterns. The first of those is the 
latency to enter the inner zone of the arena. An independent t-test indicated no 
differences in this latency between Myt1l knockdown and control mice either on 
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day one [T(26)=0.144; p=0.886] or day two [T(25)=0.324; p=0.749; Figure 4.11 
(a)]. However, a repeated measures ANOVA with a Greenhouse-Geisser 
correction showed significant differences between the trial performed on day 
one and two (F1, 25 =27.068; p=0.000022), without interacting with treatment (F1, 
25 =0.121; p=0.731). A paired t-test applied to both the Myt1l knockdown 
(p=0.002) and the control (p=0.008) found a significant increase in the latency 
to enter the inner zone of the arena.  
 
A second possible indicator of anxiety-like behaviours is the number of entries 
to the inner zone [Figure 4.11 (b)]. In this experiment, a two-way ANOVA did not 
show any significant differences between groups (F1, 103=0.967; p=0.328) or 
time intervals on day one (F3, 103=0.721; p=0.542). During day two, both groups 
showed a significant increase in the number of entries into the inner zone 
across the time intervals (F3, 100=15.288; p=2.9x10-8) without any treatment 
effect (F1, 100=2.307; p=0.459). A repeated measures ANOVA with a 
Greenhouse-Geisser correction demonstrated a significant decrease in the 
number of entries to the inner zone along the time intervals when comparing 
day one versus day two (F3, 99=39.021, p=1.1x10-8), without a significant 
treatment effect (F1, 100=2.307; p=0.459). A further paired t-test comparing time 
bins from day 1 against day 2 found a significant decrease for Myt1l knockdown 
mice in the number of entries over the first three time intervals of open field 
testing (p=0.002; p=0.007; p=0.001). Similarly, control mice had a significant 
decrease in the frequency to enter the inner zone but only for the first and third 




Another measure of anxiety is the time spent in the inner arena. The results 
showed that there was a significant difference in treatment [F1,103=6.212, 
p=0.014; Figure 4.11 (c)]. Specifically, a pairwise comparison followed by 
Bonferroni correction indicated that Myt1l knockdown mice spent less time in 
the inner zone in the first five minutes in comparison to the control (p=0.009). 
The data recorded during day two indicated an overall treatment effect without 
interaction across time (F1,100=5.397; p=0.022). Moreover, changes between 
time intervals were also statistically significant (F3, 100=17.506; p=3.27x10-9), 
probably indicating within-trial habituation. Between day differences were 
calculated using repeated measures ANOVA with a Greenhouse-Geisser 
correction; this test demonstrated an interaction between treatment, time 
interval and trial day (F3,99=2.776, p=0.045). Paired t-tests showed that Myt1l 
knockdown mice spent less time in the inner zone on day two across the first 
and second time intervals when comparing it to day one (p=0.001; p=0.005); 
while during interval four, knockdown mice spent more time in the inner area in 
comparison to day one  (p=0.037). On the contrary, control mice only spent 
significantly less time on the first time interval when comparing between day 
trials (p=0.004). It is important to mention that the baseline for the time spent in 
this area was less than 20% of the duration in either the first five minutes or the 







Table 4.2 Summary of the percentage of the total time spent in the inner zone for both 
Myt1l shRNAmir and non-silencing shRNAmir recorded in the open field during the first 
five minutes and the 20-minute trial.  
The data are expressed as the mean ± S.E.M. (n = 14 per group). The percent duration for time 
intervals was calculated as follows: time spent in time interval/300, multiplied by 100. The 
percent duration for the total time spent was calculated as follows: total time spent inner 
zone/1200, multiplied by 100. * p<0.05 two-way ANOVA Myt1l knockdown versus control pre-
planned pairwise comparison followed by Bonferroni correction 




















Day 1      
Myt1l 
shRNAmir 
11.78±2.18 * 15.29±2.03 14.72±1.35 14.23±1.42 14.04±1.22 
Non-silencing 
shRNAmir 
21.12±4.31 15.31±2.17 16.08±1.70 20.27±3.22 18.22±1.99 
Day 2      
Myt1l 
shRNAmir 
3.36±0.85 11.64±1.49 14.34±1.79* 20.47±2.05 12.49±1.09 
Non-silencing 
shRNAmir 





Figure 4.11 These graphs illustrate the latency to enter (a), the number of entries into (b) 
and time spent in (c) the inner zone of the open field arena over the 20-minute trial on day 
1 and day 2.  
The data are expressed as mean ± 1 S.E.M. (n = 14 per group). * p <0.05 Myt1l knockdown 
versus control pre-planned pairwise comparison followed by Bonferroni correction. 
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The overall 20-minute locomotion recorded in the inner zone was analysed 
using an independent t-test. The results showed that the distance moved by 
Myt1l knockdown mice was not significantly different from the control on day 
one [T(25)=1.337, p=0.193; Figure 4.12 (a)]. However, during day two, there 
was a statistically significant difference between these groups [T(25)=2.613, 
p=0.015; Figure 4.12 (a)]. Habituation was analyzed by a repeated measures 
ANOVA between trials followed by a Greenhouse-Geisser correction. The test 
showed a statistically significant difference between the distance moved in the 
inner zone between trials (F1,24=25.752, p=3.45x10-5), without a treatment effect 
(F1,24=0.013, p=0.910). 
 
The overall velocity at which mice moved around the inner zone was also 
measured. The results of an independent t-test did not show any significant 
differences regarding the velocity either on day one [T(25)=-1.202, p=0.241] or 
day two [T(25)=0.389, p=0.700). The velocity was compared between day one 
and day two using repeated measures ANOVA with a Greenhouse-Geisser 
correction. The test indicated a significant decrease in the velocity on day two in 
comparison to day one (F1,24=67.283; p= 2.02x10-8) without an effect of 





Figure 4.12 These graphs illustrate the locomotion (a) and velocity (b) recorded in the 
inner zone of the open field arena over the 20-minute trial on day 1 and day 2.  
The data are expressed as mean ± S.E.M. (n = 14 per group). * p<0.05 
 
4.3.4 Novel object recognition 
 
During the training phase of the NOD test for short-term memory, mice were 
presented with two identical objects to explore for 10 minutes. Both groups 
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spent similar amounts of time exploring each object. Neither the mice with 
reduced expression of Myt1l [T(13)=0.166; p=0.870] nor the control mice 
[T(13)=1.386; p=0.189] showed any significant difference in time spent 
exploring the novel object [Figure 4.13 (a)]. The discrimination ratio was not 
significantly above 0.5 for the Myt1l knockdown [T(13)= ±0.239; p=0.815] or 
control [T(13)= ±1.228; p=0.241] suggesting this task was not sensitive enough 
to detect NOD above chance level in any of the groups [Figure 4.14 (a)]. There 
was not an effect of treatment on the overall exploration time [T(26)=0.553; 
p=0.585; Table 4.3].  
 
Table 4.3 Summary of the mean exploration time during training and testing phase for 
both a 1 hr delay and 24 hr delay.  
The exploration is presented as total exploration time and then divided into exploration of novel 
or familiar objects. Novel and familiar measures do not apply to the training test since identical 
objects were presented for the first time during training. The data are expressed as mean ± 
S.E.M. (n = 14 per group). The percent duration was calculated as follows: total time spent 
exploring/300, multiplied by 100. 
 Mean exploration time (s) ± S.E.M. 
Training Treatment %Total 
time spent 
exploring 
Total  Novel Familiar 
Myt1l 
shRNAmir 




14.77±1.42 88.64±8.53 46.31±6.55 42.33±3.46 
Myt1l 
shRNAmir 





15.54±1.29 93.25±7.72 50.93±5.73 42.32±4.03 
Myt1l 
shRNAmir 




16.95±1.29 101.70±7.71 51.06±4.51 50.64±4.83 
Myt1l 
shRNAmir 










Figure 4.13 These graphs illustrate the time spent exploring the novel object while testing 
for short-term (a) and long-term memory (b).  
Data are expresses as the mean ± S.E.M. (n=14 per group). 
 
When testing long-term memory, both groups of mice spent equal amounts of 
time exploring the objects in the training phase. After the 24-hour delay, the 
Myt1l knockdown [T(13)=0.890, p=0.389] and the control [T(13)=1.056, 
Chapter 4 
197 
p=0.310] spent similar time exploring the novel and familiar object [Figure 4.13 
(b)]. Moreover, neither Myt1l knockdown [T(13)= ±0.770; p=0.455] nor non-
silencing [T(13)= ±1.350; p=0.200] mice showed a significant NOD above 
chance level [Figure 4.14 (b)]. There was no effect of treatment on the total 
exploration time [T(26)=-0.982; p=0.335; Table 4.5].  
 
Figure 4.14 These figures illustrate the discrimination ratio calculated for short-term and 
long-term memory.  
Data are expressed as the mean ± S.E.M. (n=14 per group). The exploration time was used to 
calculate the discrimination ratio for assumed preference for novel (novel object exploration 
time/total exploration time) and assumed no preference (familiar exploration time/total 
exploration time). The dashed line represents the 50% chance. 
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4.3.5 Morris water maze 
 
Mice microinjected with Myt1l shRNAmir and the control non-silencing 
shRNAmir exhibited similar performance in the visible session of the Morris 
water maze (MWM). There was no significant change in MWM performance 
across the hidden sessions and therefore, no treatment effects could be 
assessed as this task did not work in either the control or Myt1l treated mice 
[F5,130=1.309;p=0.268; Figure 4.15 (a)]. There was no effect of treatment on the 
distance [F5,130=1.245; p=0.294; Figure 4.15 (b) or swim speed across the 
hidden sessions [F5,130=0.324;p=0.857; and Figure 4.15 (c)]. 
 
During the probe trial, repeated measure ANOVA with a Greenhouse-Geisser 
correction indicated a significant difference in the distance moved across the 
quadrants of the pool [Figure 4.16 (a); F2.322,60.370=10.278, p=6.6x10-5] and the 
time spent in each quadrant [Figure 4.16 (b); F2.440,63.443=10.135, p=5.3x10-5]. 
However, the difference was not significant between Myt1l knockdown mice and 
control mice. Bonferroni post hoc tests revealed a preference for both groups to 
swim longer and further in the target quadrant in comparison to the left 
(distance moved p<0.0003; time spent p<0.0004) and opposite to target 
(distance moved p<0.004; time p<0.002) quadrants [Table 4.4; Figure 4.16 (a) 
and (b)]. There was no statistically significant difference in the distance moved 
or time spent between the right and target quadrants. It is important to mention 
that all mice started the probe trial from the right quadrant and this could have 
led the mice to swim more than a 25% chance rate in this quadrant. However, 
given the lack of significant learning in the previous hidden sessions, it is more 
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likely that the mice had not fully learned the target location in the MWM.  
 
Figure 4.15 These graphs illustrate the latency to locate the platform (a), distance swum 
to the platform (b) and swim speed (c) of mice in the Morris water maze during the visible 
and hidden trials.  




Figure 4.16 These graphs illustrate the distance swum (a) and time spent (b) in each of 
the quadrants during the probe trial.  
Both the Myt1l shRNAmir and non-silencing shRNAmir mice, swam longer distances and spent 
more time in the right and target quadrant. Data are expressed as the mean ± S.E.M. (n = 14 
per group). 
 
Table 4.4 Summary of the percentages of time spent in each quadrant during the probe 
trial.  
The data are expressed as mean ± S.E.M. (n = 14 per group). The percent duration was 
calculated as follows: time spent in quadrant/300, multiplied by 100. 
 Quadrant 
 Left Opposite Right Target 
Myt1l shRNAmir 21.17±1.83 18.77±1.48 28.95±2.21 30.43±1.60 
Non-silencing 
shRNAmir 
20.75±2.09 21.36±2.18 26.07±1.91 31.08±2.41 
 
4.3.6 Elevated plus maze 
 
The results obtained from the EPM did not show any differences in the number 
of entries into [open arm T(14)=0.517, p=0.613; closed arm T(14)=0.725, 
p=0.480], or time spent in [open arm T(14)=0.561, p=0.584; closed arm T(14)=-
0.667, p=0.516], each arm between treatment groups (Figure 4.17). Similarly, 
there was no significant difference in the latency to enter an open arm [T(14)=-
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0.623, p=0.543; Figure 4.17 (a)]. Both groups of mice preferred to enter the 
closed arm [Figure 4.17 (b)] and spent most of the trial time in the closed arms 
[Figure 4.17 (c)]. Regarding the ethological measures, neither the frequency nor 
duration of head dipping [T(14)=0.454, p=0.657; T(14)=0.327, p=0.748; Figure 
4.17 (d) and (e)] or scanning showed a significant difference between groups 
[T(14)=0.888, p=0.390, T(14)=0.708, p=491; Figure 4.17 (f) and (g)]. The 
analysis of the distance moved and velocity further corroborated no locomotion 





Figure 4.17 These graphs illustrate the main findings of the EPM test.  
Data are expressed as the mean ± S.E.M. (Myt1l shRNAmir n = 9 per group and non-silencing 
shRNAmir n=7). 
 
4.3.7 Light/dark box 
 
As can be inferred by observing the graphs from Figure 4.18, the light/dark box 
test results did not show a significant difference in the latency to enter the light 
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compartment [(a); T(26)=-0.845, p=0.406], the number of entries to each 
compartment [(b); light T(26)=0.390, p=0.699; dark T(26)=0.272, p=0.787] or 
the time spent in each compartment [(c); light T(26)=1,219, p=0.234; dark 
T(26)=-1,219, p=0.234] between the mice injected with Myt1l or non-silencing 
shRNAmir. Both groups of animals made a similar number of entries to, and 
spent a similar time in, the light compartment. Additionally, no locomotion 
differences were observed in the velocity [Figure 4.18 (d); light T(26)=0.711, 
p=0.483; dark T(26)=0.344, p=0.733] or distance travelled [Figure 4.18 (e); light 





Figure 4.18 These graphs illustrate the main findings regarding the light/dark box.  
Data are expressed as the mean ± S.E.M. (n = 14 per group). 
 
4.3.8 Three-chamber social approach task 
 
During the habituation phase, mice that underwent Myt1l knockdown in the 
dorsal hippocampus and the control mice explored the three chambers of the 
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apparatus in a similar manner. There was no effect of treatment on the number 
of entries into (F1,20=2.899, p=0.104), or time spent in (F1,20=0.973, p=0.336), 
either the left or right chamber [Figure 4.19 (a) & (b)], showing no preference for 
either side in the habituation test (Trial 1). The analyses of the locomotor activity 
data showed no difference between groups in the velocity (F1,20=0.051, 
p=0.823) or distance travelled (F1,20=0.823, p=0.375) by the mice (Table 4.5). 
 
Figure 4.19 These graphs illustrate the results obtained in the habituation phase of the 
three-chamber social approach task.  




During the sociability test (Trial 2), both groups made a significantly greater 
number of entries into the chamber containing the mouse [F1,20=5.932, p=0.024; 
Figure 4.20 (a)] compared to the chamber with the novel object; but there was 
no significant difference between Myt1l knockdown and control groups 
(F1,20=0.274, p=0.606). The same effect was seen in the time spent in each 
chamber, with an overall increase in the time spent in the chamber with the 
novel mouse [F1,20=34.750, p=9.0x10-6; Figure 4.20 (b)], but there was no effect 
of treatment (F1,20=0.027, p=0.872). There were no differences in the velocity 
(F1,20=4.597, p=0.055) or the distance (F1,20=0.645, p=0.431) moved by the 





Figure 4.20 These graphs illustrate the results obtained during the sociability phase of 
the three-chamber social approach task.  
Data are expressed as the mean ± S.E.M. (n = 11 per group). 
 
During the last trial, preference for social novelty was assessed but neither 
group showed a significant difference in the number of entries to the chambers 
containing the new mouse compared to the chamber containing the previously 
explored mouse [F1,20=1.525, p=0.231; Figure 4.21 (a)]. However, both groups 
spent more time in the cage containing the new mouse [F1,20=5.277, p=0.033; 
Figure 4.21 (b)]. There was no effect of treatment on the preference for social 
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novelty (F1,20=0.035, p=0.854). The analyses of the locomotor activity data 
showed no difference between groups in the velocity (F1,20=0.116, p=0.737) or 
distance travelled (F1,20=0.002, p=0.964) by the mice in any of the three trials 
(Table 4.5).  
 
Figure 4.21 These graphs illustrate the results obtained in the social novelty phase of the 
three-chamber social approach task.  





Table 4.5 Summary of the distance travelled and the velocity for Myt1l knockdown and 
non-silencing groups of mice.  
The data are presented as mean ± S.E.M. 
 Myt1l shRNAmir Non-silencing shRNAmir 
 Distance  Velocity Distance  Velocity 
Habituation      
Left  1669.11±99.92 8.63±0.27 1620.73±11.04 8.54±0.45 
Right  1504.59±79.95 8.00±0.33 1292.19±100.54 8.00±0.33 
Central  1791.79±69.39 9.13±0.47 1844.26±74.61 9.13±0.47 
Sociability      
Novel mouse 1994.88±278.41 8.26±0.54 1757.52±110.75 7.64±0.35 
Novel object 1028.73±96.93 8.51±0.49 1096.34±96.93 8.87±0.41 
Central 1205.69±67.27 11.19±0.40 1298.17±96.72 12.14±0.63 
Social novelty     
Mouse 1154.41±128.08 7.82±0.58 1286.52±134.98 8.80±0.44 
Novel mouse 1521.78±235.74 7.84±0.44 1638.28±198.82 8.67±0.47 
Central 1225.50±72.79 10.94±0.57 1507.97±140.64 12.49±0.83 
 
4.3.9 Social investigation task 
 
The results of the behavioural patterns observed during the social investigation 
task are shown in Figure 4.22. There was no significant effect of treatment on 
any of the measures taken in the social interaction task [social sniffing 
T(20)=0.506, p=0.618; anogenital sniffing T(20)=-0.203, p=0.841; following 





Figure 4.22 This graph illustrates the results for the social investigation task.  
The data are expressed as the mean ± S.E.M. (n = 11 per group). 
 
Both Myt1l knockdown and control mice displayed minimal aggressive 
behaviours towards the conspecific and the duration of this aggression did not 
differ between groups according to independent-samples Mann-Whitney U test 
(U(20)=70.0, p=0.562; Table 4.6). This test was performed on these data 
because it was not normally distributed. Allogrooming was rarely observed and 
it was not analysed.   
 
Table 4.6 Summary of the aggression observed during the social investigation task. 
 Aggression 
 Mean± S.E.M. Median 
Myt1l shRNAmir 5.94±3.03 0.00 






4.3.10 Food burying task  
 
Olfaction appeared to be normal for both groups as all mice found the cookie 
within the allotted time and there were no significant differences between 
groups [T(20)=-0.772, p=0.449; Figure 4.23).  
 
 
Figure 4.23 This graph illustrates the latency (s) of the mice to find the hidden cookie in 
the home cage.  




Although Myt1l has been recently linked to psychiatric disorders along with 
other genes, the precise function of this individual gene remains unknown. The 
application of the methodological manipulation of gene expression discussed 
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here has made it possible to widen our understanding of gene function in-vivo 
(Blomer, Naldini et al. 1997). Combining it with stereotactic surgery brings the 
opportunity to modify the function in particular brain regions and at specific time 
points in the life of the organism. Mouse models produced in this manner have 
given a powerful insight into the impact of genes on the complex biological 
processes like development and behaviour (Gossen and Bujard 2002). In this 
chapter, the function of Myt1l in the dorsal hippocampus was investigated using 
lentiviral vectors containing Myt1l shRNAmir and non-silencing shRNAmir 
(control) microinjected in this area of the brain. The behavioural results 
suggested that a decrease in Myt1l expression in the dorsal hippocampus of the 
brain resulted in a very subtle, transient increase in anxiety-like behaviour, in 
the open field only, that normalized within time. This inference was reached 
after assessing Myt1l knockdown animals in the open field. Unfortunately, these 
results were not replicated in the EPM or the light/dark box tests. No other 
effects were seen across the other tasks aiming to determine the impact of this 
gene on memory and learning and social approaches in comparison to control 
mice.  
 
4.4.1 Anxiety-like behaviours  
 
The mice were first tested in the open field arena for two reasons: to analyze 
anxiety-like behaviours and to verify any locomotion effects due to the injection 
that could contribute to the changes observed in behaviour. This test relies on 
the conflict between the desire to explore the novel arena and to avoid the 
openness of the arena. A measure of anxiety is provided by the time the mice 
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spent in the inner area of the apparatus (Prut and Belzung 2003). According to 
the data obtained for this particular test, a subtle anxiogenic effect was 
observed on the Myt1l knockdown mice. This modified group of mice started the 
test on day one with differences in the time spent in the centre of the arena, 
without showing any within-trial habituation. This lack of habituation was also 
observed in the control mice and given the low baseline of time spent in the 
inner zone, it could be hypothesised that both groups of mice found the test too 
anxiogenic. The baseline exploration of this zone in the first five minutes of the 
first trial was around 12% for the knockdown and 21% for control, showing not 
only a clear difference but it was barely above one fifth of the test. During day 
two, initially both groups of mice showed longer latencies to enter the inner 
zone and spent significantly less time in this zone during the first five minutes of 
the task in comparison to the day before, giving further evidence for an effect of 
treatment on anxiety. As for the rest of the trial, Myt1l knockdown had an overall 
significant decrease in the time spent, and distance moved, in the centre in 
comparison to control, but by the end of the 20-minute trial they normalized and 
they reached the same level as the control. This indicates that the anxiogenic 
effect of treatment is not permanent in these mice but requires time to be 
overcome. Within-trial habituation was observed on day two for both groups, 
which could be an additional indicator of how anxiogenic this test was for these 
modified mice, considering that habituation to anxiety in this strain had not 
occurred on the first day (Bolivar, Caldarone et al. 2000). Also, it can be 
hypothesised from this within-trial habituation that the hippocampus was not 
fully disturbed as a consequence of the microtrauma caused by the injection, 
given that mice with considerable hippocampal damage do not habituate 
(Crusio and Schwegler 1987). Contradictory evidence to the previous 
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hypothesis was found in the distance travelled in the outer arena by these mice, 
as neither the Myt1l knockdown or control showed any differences in their 
locomotor activity within-trial or between-trials, with the exception of velocity, 
which did show habituation by exhibiting a decrease on day two. A possible 
explanation could be that behavioural habituation is dependent on cognitive and 
emotional components (Cerbone and Sadile 1994). The injection might have 
caused damage to the dorsal hippocampus that prevented the mice from 
creating a cognitive map of the arena. O’Keefe and Nadel (O'Keefe and Nadel 
1978) have suggested that this map is built within time and trials and that the 
mouse tends to reduce its exploration in the process. In this particular case, it 
could be possible that neither the knockdown mice nor control were able to fully 
create this map explaining why the overall arena exploration was not reduced. 
But the emotional component, that is the anxiety, might have encouraged these 
mice to explore the inner zone more and increase their cognitive map of the 
arena during trial two after realising no real danger occurred during trial one, 
hence the habituation observed for the anxiety measure.  
 
This anxiogenic effect of Myt1l in the dorsal hippocampus could not be 
replicated in the EPM or the light/dark box tasks. It is important to note that both 
of these tests were performed after the open field, NOD and MWM. Therefore, 
the mice were used to being handled on a daily basis. It is possible that the 
subtle anxiety effect found for Myt1l knockdown could have been overcome by 
handling habituation. Supporting information of this statement comes from some 
studies that have found handling rodents before EPM testing can significantly 
decrease the anxiety shown in these test (Andrews and File 1993, Lapin 1995, 
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Hogg 1996, Schmitt and Hiemke 1998). In the particular case of the light/dark 
box, it is also possible that the size of the arena could have been less 
threatening for the mice than the open field, failing to uncover the weak anxiety 
phenotype shown by the knockdown mice. Moreover, this test has shown high 
variability of results within and between the different laboratories, making it 
difficult to estimate the real value of this test for anxiety (Bourin and Hascoët 
2003). 
 
4.4.2 Memory and learning tasks  
 
In order to assess the cognitive effect of Myt1l knockdown in the dorsal 
hippocampus, NOD was used. This test relies on the tendency of mice to 
explore new objects over familiar ones (Dere, Huston et al. 2007). Both short 
(one hour later) and long memory (24 hours later) were measured dependent 
on the delay between presenting the first set of identical objects and the new 
one (Stefanko, Barrett et al. 2009). The results obtained in this experiment 
indicated that the mice failed to differentiate the new object from the old one 
after either a one or 24 hr-delay. Neither groups had a statistically significant 
discrimination ratio above chance (50%), suggesting that this test did not work 
in either group of mice. It is not possible to determine whether this result is 
related to the potential microlesion caused to the hippocampus by the lentiviral 
vector injection (Hammond, Tull et al. 2004, de Lima, Luft et al. 2006, Antunes 
and Biala 2012) or of it was an indicator of the failure of the NOD test for some 
other reason. One hypothesis which would explain these results would be that 
the familiar and the novel object were not different enough for the mouse to 
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discriminate between them, given the objects only differed in colour (Ennaceur 
2010). Moreover, the percentage of exploration was below 20% in all trials, 
which might be an indicator that the objects were not interesting enough to 
catch the mouse’s attention. Furthermore, the literature has provided evidence 
suggesting the susceptibility of mice to handling and the stress and anxiety 
caused by handling can have detrimental effects on the mouse’s performance 
during NOD (Dere, Huston et al. 2005). This test has the limitation of lacking a 
non-surgical group of animals and/or the handling of a naive group; without it, it 
is not possible to determine the reason for this outcome in NOD.  
 
Spatial learning and memory were analyzed using the MWM test. However, no 
significant learning was observed in either group of mice. Data from the probe 
trial were indicative of the presence of some memory for the platform location; 
the mice swam above the chance level in the target quadrant (around 30% for 
Myt1l knockdown and control) and the right quadrant where they started the test 
(below 30% for both groups) in comparison to the others. The lack of a non-
surgical group was a limitation to this study. Without this group it is not possible 
to determine whether the task did not work in these mice or, similar to the 
results obtained from the NOD test, whether the low learning ability shown in 
this test was due to a lesion affecting their learning (Moser, Moser et al. 1993, 





4.4.3 Social approaches  
 
The three chamber social approach task is a well-validated test which assesses 
differences in mouse sociability and preference for social novelty (Yang, 
Silverman et al. 2001). In this case, it was used to investigate whether Myt1l 
had a role in these behaviours. During the first trial of this test where the mice 
had the option of interacting with a novel object or a novel mouse, both the 
Myt1l knockdown and control preferred the novel mouse, showing a significant 
preference for social cues. The following trial gave the test mice the choice of 
spending time with the previously presented mouse or a novel mouse. Similarly, 
both groups spent a longer time with the novel mouse, indicating a social 
approach, a social memory, and a preference for social novelty. There were no 
significant differences in either trial between the mouse treatments suggesting 
no effect of Myt1l on these behaviours.  
 
Following this test, the mice were put through an additional test to measure 
some social behavioural patterns displayed by the mouse when encountering a 
conspecific mouse (Winslow 2001). The results from this test replicated the 
findings from the previous test, showing that the mouse exhibited social 
behaviours and little aggression. Moreover, there were no differences in social 
behaviours that could be attributed to Myt1l knockdown. An additional test was 
performed at the end of the experiment to assess the olfactory ability of the 




4.4.4 Conclusion and limitations of this study  
 
In conclusion, the behavioural outcome caused by knocking down Myt1l in the 
dorsal hippocampus in this study was a subtle anxiety-like effect that 
normalized over time. However, not only was this effect only seen in the open 
field arena, in addition it appeared to only be caused by very stressful test 
conditions without prior excessive handling. Further data corroborated that the 
effect could not be attributed to differences in locomotory activity or animal 
weight since there was an effect of treatment on these measures. In addition, 
in-vivo validation of the lentiviral vector in the overall dorsal hippocampus 
confirmed the efficiency of the shRNAmir to reduce the expression of Myt1l 
mRNA by approximately 50%. Therefore, any behavioural effects potentially 
could be attributed to this knockdown. It is important to highlight that the 
injection targeted a small portion of the dorsal hippocampus and therefore a 
subtle effect was not unexpected (Cetin, Komai et al. 2007).  
 
Although the hippocampus has been linked to mainly cognitive processes, there 
are some authors that have found a connection between this brain region and 
emotional behaviours. The hippocampus was first described by Papez (Papez 
1937) as an important participant in the “emotion circuit”. Further support came 
when MacLean’s theory included the hippocampus as part of the emotional 
brain (MacLean 1949). It was not till Gray (Gray and McNaughton 2000) in the 
first edition of his book “The Neuropsychology of Anxiety” in 1982 that the 
concept of a “behavioural inhibition system” was proposed, which is activated 
by anxiogenic situations and responds by increasing attention and awareness 
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towards the environment. Interestingly, one of the main components of this 
system is a connection between the septum and the hippocampus. Data from 
additional studies supported this hypothesis, including studies looking at the 
effect of damage to extensive areas of the hippocampus. These studies 
indicated that the rodents suffering from this damage exhibit less anxiety-like 
behaviours in comparison to control, further supporting the role of hippocampus 
in anxiety (Deacon, Bannerman et al. 2002).  
 
Although a putative role of the hippocampus in some emotional processes is 
accepted now, the link between this region and anxiety remains poorly 
understood. Some studies have divided the hippocampus into the ventral and 
dorsal regions and investigated it separately. The vast majority of results 
suggest that the dorsal hippocampus is more related to cognitive functions, 
while the ventral hippocampus is more involved in anxiety-related behaviours 
(Kjelstrup, Tuvnes et al. 2002, Bannerman, Rawlins et al. 2004, Engin and Treit 
2007, McHugh, Fillenz et al. 2011). Nonetheless, there are some studies that 
have found that lesions to the dorsal hippocampus can produce a decrease in 
anxiety-like behaviours, suggesting a weak connection between anxiogenic-like 
behaviours and this brain region (Degroot and Treit 2004, Bertoglio, Joca et al. 
2006). Moreover, it has been demonstrated that low expression of fibroblast 
growth factor 2 (FGF2) in the dorsal hippocampus results in an anxiogenic 
phenotype in rats. This study not only associated FGF2 with anxiety, but also 
demonstrated the importance of the dorsal hippocampus in this behaviour 




A second hypothesis which would explain the relationship between the 
hippocampus and anxiety infers that memory and anxiety are both part of the 
hippocampal function, but their regulation is mediated by different 
neurotransmitter systems or/and receptors (Engin and Treit 2007). Evidence 
supporting this theory along with the aforementioned theory came when a 
laboratory discovered that infusing substance P (known to be involved in 
behaviours like learning, memory, anxiety, fear and stress) into the dorsal, but 
not the ventral, hippocampus induced an anxiogenic-like reaction in rats. 
Specifically, after microdialysis, this study found that the substance P receptors 
were responsible for the effect (Carvalho, Masson et al. 2008).  
 
One of the most important limitations of this study is the site and size of the 
infection. Lentiviral vector microinjections induced a very localized gene 
modification (Cetin, Komai et al. 2007) unable to reach the whole of the dorsal 
hippocampus. Moreover, in-vivo validation demonstrated that there was only a 
50% decrease in Myt1l expression in the overall dorsal hippocampus. Perhaps 
this was not sufficient to alter behaviours in these mice. In case of the anxiety-
like behavioural pattern, it would be necessary to replicate these studies by 
tasking mice first with the anxiety tests and then with the other tests and also to 
include a non-surgical group. This would allow mice to be tested in the EPM 
and light/dark box without prior, potentially excessive, handling and test 
experience. As for the memory and learning tests, replication would require also 
an additional non-surgical group to compare and determine whether the effect 
observed was caused by a microlesion. The non-surgical group would be 
required only to determine whether the test setup worked itself with the chosen 
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mouse strain, but not as a control for Myt1l modified animals. Moreover, the 
lack of effect of this particular knockdown of Myt1l in the dorsal hippocampus 
does not necessarily mean that this gene is not involved in memory and 
learning and social approaches. It would be interesting to study the effect of 
Myt1l knockdown in a wider area of the dorsal hippocampus in addition to other 
parts of the brain related to memory, learning, anxiety and social approaches.  
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Chapter 5 : Discussion 
 
The overall aim of this thesis was to investigate the functional role of the 
transcription factor MYT1L. This gene is highly expressed in the developing 
brain, indicating a possible role in neurodevelopment. Although the expression 
of MYT1L decreases after birth, it continues to have good expression 
throughout adulthood. In addition, clinical studies have associated impairments 
in MYT1L expression with psychiatric disorders, which would imply that MYT1L 
also has a function during adult life. Despite this information, the specific role 
played by this gene has not been fully elucidated. To further expand our 
understanding of this gene, the expression of MYT1L was reduced in-vitro 
during cell differentiation and in-vivo in the adult mouse so that the underlying 
changes in gene expression and behaviour could be assessed, respectively.  
 
5.1 Myt1l shRNA remarks 
 
In order to undertake these experiments, we first had to find a silencing 
sequence that uniquely and significantly downregulated the expression of Myt1l 
in rat, mouse and human (see Chapter 2). For this purpose, the use of 
shRNAmirs over other types of silencing sequences such as siRNAs and 
shRNAs is preferred because they can produce a more efficient silencing effect 
since they can mimic the endogenous triggers of the RNAi machinery – 
microRNA (Silva, Li et al. 2005, Chang, Elledge et al. 2006, Fewell and Schmitt 
2006). Lentiviral vectors were the method of delivery for the shRNAmirs both in-
vitro and in-vivo. This was to ensure the long-term expression of the silencing 
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sequence, whether the cells are dividing or terminally differentiated, with 
minimal immune response from the host cell (Weber, Bartsch et al. 2008, 
Doherty, Schaack et al. 2011).  
 
In the search for a suitable Myt1l shRNAmir, the efficiency of three 
commercially available shRNAmirs designed to downregulate Myt1l in the rat, 
mouse and human were cloned into a lenvitviral vector. The in-vitro assessment 
was done in a neuron-related cell line derived from rat. Out of the three 
sequences, only one shRNAmir provided a significant 55% reduction of Myt1l 
expression. In order to achieve the Myt1l knockdown mouse model planned for 
Chapter 4, this sequence required further validation in a neuron-related mouse 
cell line, where it was shown to decrease Myt1l mRNA expression by a 
significant 65%. The findings obtained in this first experimental chapter 
produced the necessary tools to further investigate, in-vitro and in-vivo, the role 
of Myt1l during both neurodevelopment and adulthood. 
 
5.2 Possible downstream targets of MYT1L  
 
Rodent studies have shown that during neurodevelopment, Myt1l is highly 
expressed in the brain, implying its possible importance during this stage (Kim, 
Armstrong et al. 1997). This conjecture was supported by a study which showed 
that Myt1l was one of the three necessary transcription factors, along with Ascl1 
and Brn2, required to revert the phenotype of a mouse fibroblast and convert it 
into a functional neuron (Vierbuchen, Ostermeier et al. 2010); however, this was 
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not unexpected considering that transcription factors are involved in cell-type 
specification (Bang and Goulding 1996). At the moment, none of the current 
literature has tried to investigate the importance, at gene expression level, of 
MYT1L during the differentiation of stem cells. It was hoped that the use of stem 
cells in parallel with gene knockdown would allow the possible downstream 
targets of individual transcription factors to be determined. In doing so, the 
research could help unravel the transcriptional pathway of MYT1L.  
 
Thus, Chapter 3 was dedicated to testing the effects of the MYT1L shRNAmir 
construct in the differentiation of the human neural stem/progenitor cell line 
SPC04. Cells were transduced with MYT1L shRNA as differentiation was 
induced. In order to assess the differences in gene expression along 
differentiation, cells were harvested at two time points: two days after induction 
(pre-differentiation) and 7 days differentiation. Upon validation of a 59% 
reduction of MYT1L mRNA in SPC04 cells transduced with MYT1L shRNAmir 
at day 7 of differentiation, the gene expression of possible downstream targets 
was analyzed. Given the limitations in the quantity of RNA, the expression of 
only nine genes was assessed through qPCR assay. These genes were 
selected on the basis of being co-expressed with MYT1L when SPC04 cells 
progressed from proliferation to pre-differentiation and differentiation (3 days 
and 7 days), which our group had determined in a previous experiment (data 
unpublished). The qPCR results confirmed that BCL11B, MYT1, JPH3, SYN1 
and SNAP25 were co-expressed along with MYT1L. Furthermore, the decrease 
of MYT1L expression due to the shRNAmir resulted in the decrease of the 
expression of those five genes. Therefore, a further in-silico analysis was 
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performed which found a MYT1L binding site located in the promoter region of 
each one of the co-expressed genes used in this study, suggesting they could 
possibly be direct downstream targets of MYT1L.  
 
At the moment there is no link between neurodevelopment, MYT1L and the 
putative direct targets identified by our co-expression study. Nevertheless, it is 
important to emphasise that these genes belong to various categories related, 
to some degree, to brain development: neural cell differentiation (BCL11B and 
MYT1), neurotransmission -synaptic vesicles and neurotransmitters release- 
(SYN1 and SNAP25) and synaptic plasticity -through functional crosstalk 
between intracellular and extracellular channels to release calcium- (JPH3). 
When comparing the start of Myt1l expression in the developing rat at the 
beginning of neurogenesis, in most areas of the rat brain, both processes 
overlap. Furthermore, the peak in Myt1l expression is directly prior to birth, 
coinciding with the peak of synapse formation and cortex neurogenesis 
(Workman, Charvet et al. 2013). These facts combined with the information 
recorded about the importance of MYT1L for neuronal maturation (Vierbuchen, 
Ostermeier et al. 2010) could suggest that MYT1L is involved in neurogenesis 
and synaptogenesis in the rat and possibly in the human. 
 
5.3 Myt1l shRNAmir mouse model  
 
Further support for the importance of MYT1L comes from clinical studies. The 
incoming evidence acquired through genome mapping and gene expression 
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profiles of patients suffering from psychiatric diseases such as mental 
retardation (Gruchy, Jacquemont et al. 2007, Bonaglia, Giorda et al. 2008, 
Stevens, van Ravenswaaij-Arts et al. 2011), schizophrenia (Vrijenhoek, Buizer-
Voskamp et al. 2008, Addington and Rapoport 2009, Lee, Mattai et al. 2012, Li, 
Wang et al. 2012), autism (Garbett, Ebert et al. 2008, Meyer, Axelsen et al. 
2012) and major depression disorder (Wang, Zeng et al. 2010) has linked their 
aetiology with impairments in the sequence and expression of MYT1L.  
 
Even though all of the aforementioned diseases are the result of a complex 
combination of genes and environmental factors during early neurodevelopment 
(Van Loo and Martens 2007), it is important to remember that brain 
development continues throughout the lifespan of an organism. During 
adulthood, the brain remains plastic and can still modify its organization (Kolb, 
Gibb et al. 2003). Plasticity occurs through changes in synapses and networks 
in response to behavioural changes like memory and learning (Milner, Squire et 
al. 1998, Kandel and Pittenger 1999, Kandel 2001, Spedding, Jay et al. 2005).  
 
In order to explore the role played by Myt1l during adulthood, the behavioural 
consequences of downregulating this gene in the dorsal hippocampus of the 
adult mouse brain were investigated by bilaterally injecting the Myt1l shRNA 
into the dorsal hippocampus of mouse. This area of the brain was chosen 
because of its high expression of Myt1l in the adult mouse in comparison to 
other areas. Moreover, the previously mentioned psychiatric disorders have 
different aetiologies, but they are all related, at least in part, to 
neuropathological changes in the hippocampus (Huttenlocher 1990, Raymond, 
Chapter 5 
227 
Bauman et al. 1995, Lodge and Grace 2007, Belmaker and Agam 2008). In 
addition, the dorsal hippocampus has been linked to cognitive processes, which 
rely heavily on plasticity (Spedding, Jay et al. 2005). It is therefore reasonable 
that disruptions in Myt1l expression in this area of the adult brain could 
contribute to modifications in behaviour.   
 
Interestingly, this experiment produced a mouse with a very subtle and transient 
increase in anxiety-like behaviour that normalized within time. This effect was 
seen in terms of the time spent in the inner zone of the open field arena, where 
the Myt1l knockdown mouse spent significantly less time in the inner zone 
during the first five minutes in comparison to the control. Despite this, by the 
end of the 20-minute trial, both groups of mice were spending similar amounts 
of time in the inner arena. In this experiment, both Myt1l knockdown and control 
mice had a low baseline of exploration of the inner area and a lack of within-trial 
habituation, possibly indicating that both groups of mice found this test very 
anxiogenic. Unfortunately, no anxiety-like behaviour was triggered during EPM 
or light/dark box tests (performed approximately 7 weeks after the open field 
test). This led to the inference that the Myt1l shRNAmir mouse model elicited an 
increase in anxiety-like behaviour only in very stressful tests, without prior 
excessive handling. In terms of locomotion, no differences were found between 
the treated and control mice.  
 
Validation of the correct place of injection, as well as the spread of the virus was 
performed through immunohistochemical staining of the brain slices. The 
quantification of the knockdown efficiency in-vivo through qPCR showed a 49% 
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reduction in Myt1l expression. It is therefore likely that the effects seen in the 
Myt1l knockdown mouse model are related to the decrease in Myt1l expression 
in the dorsal hippocampus.  
 
Although the dorsal hippocampus has been mainly linked to cognitive 
processes, it was not completely unexpected to find an association between this 
brain region and anxiety. Early work from Gray and McNaughton (Gray and 
McNaughton 2000) proposed a link between anxiogenic situations and a system 
between the hippocampus and the septum. A further association between 
anxiety and the dorsal hippocampus was found in rodents with lesions in that 
area, which were found to exhibit a reduction in anxiety-like behaviours 
(Deacon, Bannerman et al. 2002, Degroot and Treit 2004, Bertoglio, Joca et al. 
2006). Another study showed that low expression of FGF2 in the dorsal 
hippocampus of the rat produced an anxiogenic phenotype (Perez, Clinton et al. 
2009, Eren-Koçak, Turner et al. 2011). Although the link between the dorsal 
hippocampus and anxiety is still poorly understood, the results obtained in this 
last experimental chapter would seem to support it. 
 
5.4 Study limitations  
 
In this thesis only one common limitation was found and it will be discussed. 
The individual limitations observed in each experimental chapter have been 




It is important to first note that although the Myt1l shRNA used for this thesis 
resulted in only a partial knockdown, the size of the reduction observed in-vitro 
(rat, mouse and human) and in-vivo (mouse) was comparable to other 
published studies (Thibault, Calvino et al. 2012, Li, Xiong et al. 2013, Shi, 
Chang et al. 2013, Zeng, Zhang et al. 2013). This limited reduction of gene 
expression can act as both an advantage and a limitation. One advantage of 
using an incomplete ablation of MYT1L instead of a complete deletion is that it 
is still unknown if the MYT1L knockout is incompatible with cell survival. 
Although it would be interesting to analyse the consequences of complete 
deletion of MYT1L in a stem cell model, it was safer in this case to only 
downregulate the gene in order to find the downstream targets of MYT1L, which 
was the aim of Chapter 3.  
 
However, in the case of Chapter 4, it was more a limitation than an advantage 
since the incomplete ablation of Myt1l expression resulted in subtle behavioural 
effects. Nonetheless, this was anticipated considering only a fraction of the 
dorsal hippocampus was infected and only about half of Myt1l mRNA was 
reduced in the region. To overcome this limitation, future experiments should 
aim for a greater reduction to verify the results obtained here. 
 
5.5 Future directions 
 
Due to unfortunate circumstances (possibly technical difficulties) the microarray 
global expression profile intended for the study described in Chapter 3 failed. I 
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strongly recommend repeating this experiment to broaden the investigation of 
the number of genes co-expressed alongside MYT1L and to possibly identify 
more downstream targets of this transcription factor. In addition, the creation of 
MYT1L antibody could provide the necessary tool to perform ChIP-sequencing 
and further validate the previous results.  
 
Additionally, it would be interesting to use immunocytochemistry to characterise 
the SPC04 cells transduced with MYT1L shRNAmir. This would show the 
differentiation potential of this cell line when MYT1L is downregulated. For this, 
cells would need to undergo staining of different markers along differentiation. 
The time frame would also need to go beyond the time point used for this study 
(7 days), until mature neurons are observed. Possible markers to use would be 
Nestin (stem cells), Glial fibrillary acidic protein (GFAP; astrocytes), 
Adenomatous polyposis coli (APC; oligodendrocytes), Neuronal Nuclei (NeuN; 
neurons) and Tau (mature neurons). Estimating and comparing the number of 
mature neurons found in SPC04 transduced with MYT1L shRNAmir and the 
control could further validate the in-vitro studies and give an idea of the 
importance of MYT1L for neuron maturation (Vierbuchen, Ostermeier et al. 
2010, Pang, Yang et al. 2011). These results would help further expand our 
knowledge of MYT1L during differentiation.  
 
Regarding the experiments described in Chapter 4, it would be advisable to 
repeat them, adding a non-surgical group of animals. This would be particularly 
important for the memory and learning paradigms to determine whether the lack 
of significant results was due to failure of the test or due to the micro-lesions in 
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the brain caused by the stereotactic surgery. In addition, all the anxiety-like 
related tests should be prioritized when retesting the knockdown mice. By 
starting with these tests, the anxiety-like behaviours might be easier to assess 
and the possible variance due to habituation to handling might be reduced. An 
alternative solution could be the use of a different mice batch for each 
paradigm; in this way it is possible to overcome the handing and testing 
sequence effects.  
 
Another possible improvement might be to increase the number of injections to 
two per hemisphere to augment the infecting area of the dorsal hippocampus 
since the knockdown efficiency was only about 49%. Although most 
experiments injecting viral vectors or plasmids into the mouse brain are 
restricted to only two injections per brain (Mao, Ge et al. 2009, van Hooijdonk, 
Ichwan et al. 2009), there are studies that have reported satisfactory results 
when increasing the volume and injections per mouse brain (Rodriguez-Lebron, 
Denovan-Wright et al. 2005). Nevertheless, this would not be without its 
hazards since more intrusion into the brain can lead to additional microlesions 
affecting the animal phenotype.  
 
An additional mouse model can be engineered through the conditional knockout 
approach, which has the advantage of selectively silencing gene expression in 
a spatio-temporal manner. In brief, this type of knockout mouse uses binary 
transcription transactivation systems that are dependent on doxycycline, 
offering the versatility to decide when the transgene would be expressed 
(Lewandoski 2001, Skarnes, Rosen et al. 2011). However, this technique had 
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carried with it the disadvantage of being time-consuming and expensive (Tong, 
Huang et al. 2011). Fortunately, the European Conditional Mouse Mutagenesis 
Program (EUCOMM) has been working on generating about 12,000 conditional 
mutations across the mouse genome and inserting them into mouse embryonic 
stem cells. This last procedure allows the generation of conditional knockout 
mouse models (The-International-Mouse-Knockout-Consortium 2007). At the 
moment, EUCOMM was able to generate both, embryonic stem cells and a 
mouse model containing a confirmed conditional knockout for Myt1l. However, 
only the embryonic stem cells are currently available for purchase, while the 
mouse remains under development 
(https://www.mousephenotype.org/data/genes/MGI:1100511). It is hoped that 
the future use of this model will help understand the cellular and behavioural 
consequences of eliminating Myt1l expression at different time points of the life 
of the mouse. 
 
Even though the study presented in this thesis failed to find an association 
between the downregulation of Myt1l in the dorsal hippocampus and cognitive 
afflictions (rather than anxiety producing ones), the decreased expression of 
this gene in other areas of the brain could have repercussions on cognition. It 
has been hypothesised that Myt1l may be involved in cognitive processes given 
the resemblance to cortical neurons produced by this transcription factor in in-
vitro experiments transforming fibroblasts (Vierbuchen, Ostermeier et al. 2010, 
Ambasudhan, Talantova et al. 2011, Pang, Yang et al. 2011). It would be 
advisable to apply either the EUCOMM Myt1l conditional knockout mouse or 
Myt1l shRNAmir model to brain regions involved in cognition, like the cortex, 
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and analyze the behavioural outcome. For instance, a reduced expression of 
MYT1L was noted in the temporal cortex of patients suffering from autism, 
which could possibly be the cause of defects in neuronal maturations and 
synapses in this area (Garbett, Ebert et al. 2008).  
 
Lastly, previous studies have suggested that MYT1L plays a role in 
synaptogenesis. I suggest that both the in-vitro and in-vivo approaches 
mentioned above would be greatly benefited by further staining of the cells or 
tissue for two purposes. Firstly, the samples could be immunostained with 
synaptic markers for excitatory synapse such as: bassoon, anti-glutamate 
receptor 2/3 (GluR2/3), Postsynaptic density protein 95 (PSD-95) and Anti-
Glutamate Receptor NMDAR1 (NR1), among others (Woolfrey, Srivastava et al. 
2009). The choice of analysing the excitatory synapses comes from the study 
showing that the majority of neurons, which matured through the addition of 
Myt1l, were excitatory and glutamatergic neurons (Vierbuchen, Ostermeier et al. 
2010). Secondly, the cells or tissue infected with the MYT1L shRNAmir could 
undergo GFP immunostaining to analyse the dendritic spines (Srivastava, 
Woolfrey et al. 2011). Notably, it has been observed that changes in the size, 
shape or number of the spines were associated to psychiatric disorders like 
schizophrenia (Glantz and Lewis 2000), major depressive disorder (Kang, Voleti 
et al. 2012), autism (Hutsler and Zhang 2010) and mental retardation 
(Kaufmann and Moser 2000), among others. This is relevant to our study, since 
the diseases mentioned before have been all linked to mutation in the MYT1L 
gene. The findings from any of the suggested studies would further increase our 





Carefully dissecting and assessing the role of individual genes in the molecular 
process could help us to ultimately understand the underlying basis of 
behavioural patterns. The validation of the MYT1L shRNAmir sequence 
presented in this thesis provided a valuable tool by which to study the function 
of MYT1L. This method of using the shRNAmir sequence in conjunction with 
lentiviral vectors to specifically knockdown MYT1L proved useful in both cell (in-
vitro) and mouse (in-vivo) models. The MYT1L shRNAmir cell model provided 
valuable information about the putative MYT1L downstream targets. As a result, 
this study has laid the foundations for determining the MYT1L pathway during 
neurogenesis. Furthermore, the animal model offered insight on a possible 
association between subtle anxiety-like behaviour and downregulation of Myt1l 
in the dorsal hippocampus. The results presented throughout this thesis 
represent the beginning of solving the puzzle of the MYT1L pathway and its role 
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